Plugin-Home DOEN 2008

5/17/2018 Plugin-Home DOEN 2008 - slidepdf.com

http://slidepdf.com/reader/full/plugin-home-doen-2008 1/65



Katalog Dalam Terbitan. Departemen Kesehatan RI

615.1

Ind Indonesia. Departemen Kesehatan. Direktorat Jenderal

p Bina Kefarmasian dan Alat Kesehatan

Daftar Obat Esensial Nasional 2008.-- Jakarta:

Departemen Kesehatan RI, 2008

1. Judul I. DRUGS



DAFTAR

OBAT

ESENSIAL

NASIONAL

2008

DEPARTEMEN KESEHATAN

REPUBLIK INDONESIA



KATA SAMBUTAN DAFTARISI

K eb ij ak an O ba t N as io na l ( 20 06 ), m e ng am a na tk an b ah wa u pa ya p en in gk ata n m ut u p el ay an an

k e se h at an , j am i na n k et er se d ia a n o b at e s en s ia l y a ng a m a n, b e rm a nf aa t s e rt a b e rm u tu d a la m j um l ah

d a n je n is y a n g c u k up , k e te r ja n g k au a n s e rt a a k s es o b a t b a g i s e lu r uh m a s y ar a ka t m e r u pa k a n t a ng g u n g

j a w ab p em e ri n ta h .

Ka ta S am but an

Da f ta r l si

D b a t e s en s ia l a d al ah o b at t er pi li h y an g p a li ng d ib u tu h ka n u n tu k p e la y an a n k e se h at an , m e n ca ku p

u p ay a d ia g no si s, p ro fi la k si s, t er ap i d a n r eh a bi li ta s i, y a ng d iu p ay a ka n t er se d ia p a da u n it p e la y an a n

k e s eh a ta n s e s ua i d e n g an f u ng s i d a n t in g k at n ya .

K e pu tu sa n M e nt er i K e se h at an R I t en ta n g D a ft ar O b at E s en si al

N a s io n a l 2 0 0 8

B ab I. P EN DA HU LU AN

P em ba ha ru an re vis i s aa t in i m eru pa ka n p en de ka ta n b aru , k are na s ela in p en am ba ha n d an

p e ng u ra n ga n p ro s es d id a hu lu i r e- ev a lu a si d a ft ar y an g s u da h a d a o l e h K o m it e N a si on a l R e vi si D D E N,

s e hi ng g a a d a o b at y a ng d ih il an g ka n k a re n a s ud a h o b so le t d a n p e na m b ah a n k a re n a p e rk e mb a ng a n

ilm u ba ru . H al in i m em butu hka n tra nsp aran si p ros es e va lu as i ya ng m em an fa atka n

b u kt i i lm i ah d a n m e m pe rt im b an g ka n f or m ul as i o b at u n tu k a n ak .

B ab I I. D afta r O ba t E se ns ia l N as io na l 2 00 8

B ab I II . D afta r O ba t T er ba ta s u n tu k P us ke sm as 2 00 8

D D E N d ie va lu a si s e ti ap 3 ( ti ga ) t ah u n s e ka li , r ev is i t e ra k hi rd il ak u ka n p a da t ah u n 2 0 05 . R e vi si D D E N

t ah u n i ni d i la k sa n ak a n o le h K o mi te N a si on a l D D E N y a ng d is ya h ka n d e ng a n S u ra t K e pu tu s an M e nt er i

Kesehatan.

L A M PI R A N -L A M PI R A N

L am pir an I

D a ft ar o ba t D O E N 2 0 05 y an g m e ng a la m i p er ub a ha n

D ih ar ap ka n d en ga n b er la ku ny a D D EN ta hu n 2 00 8 i ni , a m an at K eb ija ka n O ba t N as io na l d ap at

d it er ap k an s e ca ra l eb ih b a ik .

L a mp ir an 2

K e p ut u sa n Men te r i K e s eh a ta n R I N o . 2 3 9 /MENKES /S K / II I /2 0 0 8

t an g ga l 5 M a re t 2 0 08 t en ta n g P e mb e nt uk an K omi te N a si on al

R ev is i d an P en yu su na n D O EN ( Ko mN as R ev is i D O EN ) 2 00 8

K e pa d a s em u a p ih a k y a ng t el ah m e m be ri ka n k o nt ri bu s i d a la m p e la k sa n aa n r ev is i d a n p e ny u su n an

D D E N 2 0 08 d iu c ap k an b a ny a k t er im a ka si h.

L a mp ir an 3

P e se rt a P e mb a ha sa n T e kn is d a n R a pa t K o ns ul ta si D O E N 2 0 08

L a mp ir an 4

F o rm u l ir P e rn y at a an Ke s ed ia a n

L a mp ir an 5

F o rm u l ir P e rn y at a an Ko n ft ik K e p en ti n ga n

ra . K u s ta n ti n ah , A p t . M A p pS c.

N IP . 1 4 0 1 00 9 65

L a mp ir an 6

F o rm a t K a ji a n

Indeks

Daftar Obat E sensial Nasional2008 Daftar Dbat Esensial Nasional2008



Menimbang

Meng inga t

iii

MENTER I KESEHATAN

R E PUB L IK I N DO NE S IA

K EP UT US A N M EN TE RI K ES EH A TA N R EP UB LI K I ND ON ES IA

NOMOR 791 / MENKES / SK l V II I/ 2 0 08

TENTANG

D A FT AR O BA T E SE NS IA L N A SI ON A L 2 00 8

M E NT ER I K ES EH A TA N R EP UB LI K I ND ON E SI A

a . b ah wa d al am r an gk a m e ni ng ka tk an m u tu p ela ya na n k es eh at an d an u nt uk

m en ja min k et er se dia an o ba t y an g le bih m er at a d an te rja ng ka u o le h

m a sy a ra k at p e rl u d is u su n D a ft ar O b a t E s en s ia l N a si on a l;

b . b ah wa D a ft ar D ba t E se ns ia l N a si on al y an g d it et ap ka n d al am K ep ut us an

Me n te r i K e se h at a n N om or 4 9 7/ M e nk e s/ S Kl VI I/ 2 00 6 p e rl u d is e m pu r na k an

d a n d is e su a ik a n d e ng a n p e rk e mb a ng a n i lm u p e ng e ta h ua n d a n t ek n ol og i d i

b id an g o ba t d an k ed ok te ra n, p ol a p en ya kit , s er ta p ro gr am k es eh at an ;

c . b ah wa b er da sa rk an p er tim ba ng an s eb ag aim an a h ur uf a d an b , p er lu

d it et ap ka n k em b al i D a ft ar O b at E s en sia l N a si on al d en ga n K ep ut us an

Men t e ri K e s e ha t a n.

1 . U nd an g- Un da ng N om or 2 3 T ah un 1 99 2 t en ta ng K es eh at an ( Le mb ar an

N e g ar a T a hu n 1 9 92 N om or 1 0 0, T am ba h an L em ba r an N e g ar a N om or 3 4 95 ) ;

2 . U nd an g-U nd an g N om or 2 9 T ah un 2 00 4 te nta ng P ra ktik K ed okte ran

( Le m ba ra n N eg ar a T ah un 2 00 4 N o mo r 1 16 , T a m ba ha n L em b ar an N e ga ra

N om or 4 4 31 ) ;

3 . U nd an g- Un da ng N om or 3 2 T ah un 2 00 4 t en ta ng P em er in ta ha n D ae ra h

( Le m ba ra n N eg ar a T ah un 2 00 4 N o mo r 1 25 , T a mb ah an L em b ar an N e ga ra

N om or 4 4 37 ) e b ag a im a n a d iu b ah t e ra k hi r d e ng a n U n d an g -U n d an g N om or

3 2 T a hu n 2 00 4 t en ta ng P e me rin ta ha n D a er ah ( Le m ba ra n N e ga ra T a hu n

2008 Nomor 59 , T am bahan Lem baran Negara Nomor 4844 );

Menetapkan

Kesatu4 . P e ra tu r an P em e ri nt a h N om o r 3 2 T a hu n 1 9 96 T e na g a K e se h at a n ( L em b a ra n

N e ga ra T ah un 1 99 6 N o mo r 4 9, T a mb ah an L em b ar an N e ga ra N o mo r 3 63 7) ;

Kedua5 . P e ra tu r an P em e ri nt a h N om or 7 2 T a h u n 1 9 98 t en t an g P e n gam a na n S e d ia a n

F ar ma si d an A la t K ee ha ta n ( Le mb ar an N eg ar a T ah un 1 99 8 N om or 1 38 ,T am ba h an L em ba r an N e g ar a N om or 3 7 81 ) ;

Daftar Obat Esensial Nasional2008

MENTER I KESEHATAN

R E PUB L IK I N D ONE S I A

6 . P e ra tu ra n P e me ri nt ah N o mo r 3 8 T ah un 2 00 7 t en ta ng P e mb

P e me ri nt ah an a nt ar a P e me rin ta h, P e me ri nt ah an D a er ah

P em er in ta h D ae ra h K ab up at en /K ot a ( Le mb ar an N eg ar a

N o mo r 8 2, T a mb ah an L em b ar an N e ga ra N om o r 4 73 7) ;

7 . P er atu ra n P re id en N om or 9 T ah un 20 05 te nta ng K ed ud

F u n gs i, S u s un a n D r ga n is a si d a n T a t a K e rj a K em en t er ia n N e

Indonesia;

8 . P er at ur an P re sid en N om or 1 0 T a hu n 2 00 5 t en ta ng U nit D

T u g as E s el on I K em e n te r ia n N e g ar a ;

9 . P er at ur an M en te ri K es eh ata n N om or 0 85 /M en ke s/ Pe r/l/ 19

K ew a ji ba n M e nu lis ka n R e se p d an /a ta u M e ng gu na ka n O b

Fa s il it a s Pe l a ya nan Ke s ehat a n Peme r in t a h ;

1 0. P e ra tu ra n M e nt er i K es eh at an N o mo r 1 57 5/ M en ke s/ Pe r/ XI /2

D rg an is as i d an T at a K er ja D e pa rt em e n K es eh at an ; s eb ag

d iubah dengan Pera tu ran M enter i Kesehatan

1295 /Menkes /Per /X11 /2007 ;

1 1. K ep ut us an M e nt er i K es eh at an N o mo r 1 89 /M e nk es /S K lI II /2

K eb ij a ka n Dba t Na s io n a l;

1 2. K ep ut us an M e nt er i K es eh at an N o mo r 2 39 /M e nk es /S K lI II /2

P em be ntu ka n K om ite N as io na l R ev is i d an P en yu su na n

E s e ns ia l N a s io n al ( K omN a s R e vi si D D EN ) 2 0 08 .

MEMUTUSKAN:

K EP U TU SA N M EN TE RI K E SE HA TA N T EN TA N G D A FT AR O BA

N A SI ON A L 2 0 08 .

D a ft ar O b at E s en si al N a si on al 2 00 8 s eb ag ai ma na d im a ku d D

sebaga im ana te rcan tum da lam Lam piran Kepu

Daftar Dbat Esensial Nasional2008



Ket iga

Keempa t

Kel ima

Keenam

Ketujuh

MENTER I KESEHATAN

R E PUB L IK I N DO NE S IA

D a fta r O b at E se ns ia l N as io na l ( DD EN ) m e ru pa ka n d afta r o ba t te rp il ih y an g

p a li ng d ib u tu h ka n d a n y a ng h a ru s t er se d ia d i U n i t P e la ya n an K e se h at an s es u ai

d e n g an f u ng s i d a n t in g k a tn y a .

LAMPIRAN KEPUTUSAN MENTERI KESEHAT

NOMOR : 7911MENKES/SKNIII12008

TANGGAL: 21AGUSTUS 2008P e ne ra p an D D E N d im a ks u dk an u n tu k m e n in g ka tk a n k e te p at an , k e am a na n ,

k e ra s io n al an p e ng g un a an d a n p e ng e lo la a n o b at y a ng s e ka li gu s m e n in g ka tk a n

d a ya g u na d a n h a si l g u n a b ia ya y a ng t er se d ia s e ba g ai s a la h s a tu l an g ka h u n tu k

m e mp er lu as , m em e ra ta ka n, d an m e ni ng ka tk an m u tu p ela ya na n k es eh ata n

k e p ad a m a s y ar a ka t .DAFTAR OBAT ESENSIAL NASIONAL (DO

2008e ne ra pa n D D EN h ar us d il ak sa na ka n s ec ar a k on si ste n d an te ru s m e ne ru s d i

s em u a u n it p e la y a na n k e s eh a ta n .

D e ng an d ite ta pk an ny a K ep utu sa n in i, m a ka K ep utu sa n M en te ri K es eh at an

N o m or 4 9 7/ Me n ke s/ SK lV II /2 0 06 t en ta n g D a ft ar O b at E s en s ia l N a si on a l 2 0 05

d ic a bu t d a n d in y at ak a n t id a k b e rl ak u l ag i.

K e p u tu s a n i n i m u l a i b e rl a ku p a d a t a ng g a l d i te t ap k a n.

D i te t ap k a n d i J a k ar tap a d a t an g ga l2 1 A g us tu s 2 0 08

MENTER I K E SEHAT AN,

vDaftar Obat Esensial Nasional2008



BABI

PENDAHULUAN

BABI

K o ns ep O b at E s en s ia l d i I n d on e si a m u la i d ip e rk en a lk an d e ng a n d ik e lu a rk an n ya D a ft ar

N as io na l ( DO E N) y an g p er ta m a ta hu n 1 98 0, d an d en ga n t er bi tn ya K eb ij ak an O ba t

t ah u n 1 9 83 . D O E N d ir ev is i s e ca ra b e rk a la s et ia p 3 -4 t ah u n. D O E N y a ng t er bi t s e k ar an g

r e vi s i t a h u n 2 0 0 8 . K om it m e n p em e ri n ta h m e l ak u k an r e vi s i b e r k a la m e r up a k an p r e st a si

PENDAHULUAN

P ad a ta hun 2 007 , O rg an isa si K ese ha ta n D un ia - W o rl d H e al th O rg a ni za ti on

me l ak s a na k a n p r o gr am G o od G o ve rn a nc e o n M e di ci ne s ( G GM ) t ah a p p e rt am a d i I nd o

me l ak uk an survey t en ta n g p ro s es t ra n sp a ra n si 5 ( li m a) f un g si k ef ar m as ia n . S a la h s a

p ro s es s el ek si D O E N, y a ng d a ri s e gi p ro s es t ra n sp a ra n si d in il ai k u ra n g m e m ad a i. D

per ingatan 30th

E s s en t ia l M e d ic i ne L i st W HO d i S r i la n k a ( 2 0 07 ) , d i be r ik a n t e ka n a n k em b

t ra n sp a ra n si p ro s es s el ek si b a ik d a ri t im a h li y a ng m e la k uk a n r ev is i, p ro s es r ev is i, d a n

y a ng h a ru s s e ma k in m e n ga n da lk a n e vi de n ce b a se d m e di ci ne ( EB M ), d a n p e n ti n gn y

conf l ic t ing of in t eres tdar i p a ra a n g g ot a t im a h li .

M e n g in g a t b e b e ra p a h a l d i a t as , m a k a r e vi s i p a d a t a hu n 2 0 0 8 , t e l a h d i ri n ti s k e a ra h p e r ba

O l e h k a re n a n ya p r o se s r e vi s i k a l i i n i a g a k b e r be d a d e n g an p r os e s r e vi s i s e b e l um n y a , d a

h a l a n t a ra l a in :

1 . P e m il ih a n t im a h li m e la lu i s e le k si c u ku p k e ta t, t er m as u k p e ni la ia n t er ha d ap k e mu n

kepent ingan.

2 . S ej ak a w al p em b ah as an te la h m en ye rta ka n p ar a p e ng elo la p ro gr am y an g m e ng gu

l in g ku n ga n D e pa rt em e n K e se h at an ( bu ka n h a ny a d a la m r ap a t p le n o) . U p ay a

m er up ak an p ro se s p em b el aja ra n k em b al i k ep ad a in te rn al D ep ar te m en K es

m e m ah a m i k e mb a li k o ns e p o b at e s en s ia l.

3 . S el ai n p en da pa t d an p en ga la ma n p ar a a hli d al am ti m r ev is i, p em a nf aa ta n d ata

diutamakan.

4 . S elu ru h p ro se s p em ba ha sa n, m em be rik an p erh atia n s an ga t b es ar p ad a o ba

t er m as u k b e nt uk s e di aa n . S e pe rt i d ik et ah u i W H O t el ah p u la m e n er bi tk a n d a ft ar

u ntu k a na k, d an d ok um e n i ni m en ja di s al ah s at u a cu an . K eb er pih ak an k ep ad a

a na k, ju ga d itu nj uk ka n d en ga n d ok te r s pe sia li s a na k d al am ti m a hl i y an g b e

b a n ya k , y a it u 4 ( em p at ) o r a ng .

5 . R e vis i b er sif at m en ye lu ru h d ala m a rti m e ng ka ji s elu ru h o ba t d al am D O EN te rm

c a ta ta n y a ng s ud a h t id a k s e su a i l ag i. R e vi si s e be lu m ny a l eb ih b a ny a k h a ny a

o b at y a ng d iu s ul ka n u n tu k d it am b ah k an k e d a la m D O E N.

6 . B en tu k t ra ns pa ra ns i ju ga d itu nju kk an d en ga n a da ny a p en je la sa n t en ta ng b eb

m en ga pa s ua tu o ba t p er lu d ik elu ar ka n d an d it am b ah ka n d ar i D O EN 2 00 5, a ta

p e r ub a h a n b e n tu k s e d ia a n .




A. O b at E s en s ia l N a si on a l

O b a t e s e n s ia l a d a la h o b a t t e r pi li h y a n g p a li n g d i bu t uh k a n u n tu k p e la y a na n k e se h a ta n , m e n c ak u p

u pa ya d ia gn os is , p ro fil ak si s, te ra pi d an r eh ab ili ta si , y an g d iu pa ya ka n te rs ed ia p ad a u ni t

p e la y a na n k e s eh a ta n s e su a i d e n g an f u ng s i d a n t in g k at n ya .

3. D alam pe laksanaan rev is i, selu ruh oba t yang ada da lam

s eb el um ny a d ik aj i o le h K om it e N a sio na l R ev is i d an P en yu su na

D D EN , h al i ni m e mu ng ki nk an u ntu k m e ng el ua rk an o ba t- ob at y

s u da h t id a k e fe k ti f l ag i a ta u s u da h a d a p e ng g an ti y a ng l eb ih b a ik

c . P et un ju k T in gk at P em b uk tia n D a n R e ko m en da si

1 . K ri te ria O ba t E se ns ia l N a sio na l

a . K ri te ri a P em il ih an O b at E se ns ia l

T i ng k at p e mb u kt ia n d a n r ek o me n da s i d ia m b il d a ri U S A g e n cy f or H e al

a n d R e s e ar c h, s ebaga i be r i k ut :

P em i li h an o b a t e s e n s ia l d i da s a rk a n a t as k r it e ri a b e r ik u t :

( 1 ). M em i li k i r a si o m a n fa a t- re s ik o ( b ene fi t- r is k r a t io ) y a n g p a li n g m e n g u nt u ng k a n

pender i t a.

( 2 ). M u t u t e rj am in , t e rm a s u ks t ab i li ta s d a n b i oa v a il a bi li ta s .

( 3 ). P r a kt is d a l am p e n yi m p an a n d a n p e n g an g k ut a n.

( 4) . P ra k ti s d a la m p e ng g un a an d a n p e ny e ra h an y a ng d is e su a ik a n d e ng a n t en a ga ,

s a ra n a d a n f a si li ta s k e s eh a ta n .

( 5) . M e n gu n tu n gk a n d a la m h a l k e pa tu h an d a n p e n e ri m aa n o le h p e nd e ri ta .

( 6 ). M em i li k i r a si o m a n fa a t- b ia y a ( b ene fi t -c o s t r a ti o ) y a n g t e rt in g g i b e r da s a rk a n b i ay a

l a ng s u n g d a n t id a k l a ng s u n g.

( 7) . B il a t e rd a pa t l eb ih d a ri s a tu p il ih a n y an g m e m il ik i e fe k t er ap i y an g s e ru p a, p il ih a n

d ij at uh k an p a d a :

- O b at y a ng s if at ny a p a li ng b a ny a kd ik e ta h ui b e rd a sa rk a n d a ta i lm i ah ;

- O b at d e ng a n s if at fa rm a ko k in e ti k y a ng d ik e ta h ui p a li ng m e ng u nt un g ka n ;

- O b at y a ng s ta b il it as n ya l eb ih b a ik ;

- M ud ah d ip er ole h;

- O ba t y a ng t el ah d ik en al .

( 8 ). D b a tj a di k om b in a s i t e ta p , h a r us m em e n u hi k r it e ri a b e r ik u t:

- O b at h a ny a b e rm a n fa a t b a gi p e nd e ri ta d a la m b e nt uk k om b in a si t et ap ;

- K o m bi na si t et ap h a ru s m e nu n ju k ka n k h as ia t d a n k e am a na n y a ng l eb ih t in g gi

d a ri p ad a m a s in g - m as in g k om p on e n ;

- P er ba nd in ga n d os is k om po ne n k om b in as i t eta p m er up ak an p er ba nd in ga n

y an g te pa t u nt uk s eb ag ia n b es ar p en de ri ta y an g m e me rl uk an k om b in as i

t ersebut ;

- K om b in as i te ta p h ar us m e ni ng ka tk an r as io m a nfa at- bia ya (benef i t - cos t

rat io);

- U ntu k a nti bio ti ka k om b in as i t et ap h ar us d ap at m e nc eg ah a ta u m en gu ra ng i

t e rj a di n ya r e si s te n s i d a n e f ek m e r ug i ka n l a in n y a.

T I N G KA T P EM B UK T IA N ( S TA T EME N TS O F E V I D E N CE )

l a F a kt a d i p er ol eh d a ri m e ta a n al i s is u ji k l in ik a c ak d e ng a n k on tr ol .

I b F a kt a d i p er ol eh d a ri s e ku ra n g- ku ra n gn y a s a tu u ji k l in ik a ca k d e ng a

I ia F a kt a d i p er ol eh d a ri s e ku ra n g- ku ra n gn y a s a tu s tu d i d e n g an k on tr o

y a n g d i ra n c an g d e n ga n b a ik .

l ib F a kt a d ip e ro le h d a ri s e ku ra n g- ku ra n gn ya s at u s tu d i q u as i- ek sp e

l a in y a n g d i ra n c an g d e n g an b a ik .

I II F a kt a d ip e ro le h d a ri s tu d i d e sk ri pt if y a ng d ir an c an g d e ng a n b a ik

k om p a ra t if , s tu d i k o re l as i , d a n s tu d i k a s us .

I V F a kt a y a ng d ip e ro le h d a ri l ap o ra n a ta u o p in i K o m it e A h li d a n / a ta

k l in i kd a ri p a k ar y an g d i se g a n i.

2 . P en era pa n K on se p O ba t E se ns ia l

O b at e se n si al a d al ah o b at p a li ng m e nd a sa r y an g d ib u tu h ka n o le h p e la y an a

J ik a d ala m p ela ya na n k es eh ata n d ip er lu ka n o ba t d i lu ar D D EN , d ap at d

F o rm u la ri um ( R S) a ta u D a ft ar ob a tt er ba ta s l ai n ( D a ft ar D ba t P K D, D P H D A s

P en er ap an K on se p D ba t E se ns ia l d ila ku ka n m e la lu i D a fta r O ba t E se ns

P ed om an P en go ba ta n, F orm ula riu m R um ah S a kit , D afta r o ba t te rb a

I nf or m at or iu m O b at N a si on a ll nd o ne s ia y a ng m e ru p ak a n k om p o ne n s al in

m e n c ap a i p e n in g k at a n k e te r se d ia a n d a n s u p la i o b a t s e r ta k e ra s io n a la n p e n g

b . K ri te ri a P en am ba ha n d an P en gu ra ng ana . D af ta r O ba t E se ns ia l N as io na l

1 . D a la m h al p en am b ah an o ba t b ar u p er lu d ip er ti mb an gk an u ntu k m e ng ha pu s

o ba t d en ga n i nd ik as i y an g s am a y an g t id ak l ag i m e ru pa ka n p ili ha n, k ec ua li

a d a a l as a n k u a t u n tu k m em p e rt a ha n k an n y a .

2 . O ba t p ro gra m d iu su lk an o le h p en ge lo la p ro gra m d an a ka n d in ila i s es ua i

k ri te ri a u m um D D E N.

D a ft ar D b at E s en s ia l N a si on a l ( D DE N ) m e ru p ak a n d a ft ar b e ri si ka n o b

p al in g d ib utu hk an d an d iu pa ya ka n te rs ed ia d i u ni t p ela ya na n k es e

d en ga n f un gs i d an ti ng ka tn ya . D D EN m er up ak an s ta n d ar n as io na l

pe l a y anan keseha tan .

2Daftar Obat E sensial Nasional2008 Daftar Dbat Esensial Nasional2008



P en er ap an D DE N d im ak su dk an u ntu k m en in gk at ka n k ete pa ta n, k ea ma na n,

k e ra s io n al an p e ng g un a an d a n p e ng e lo la a n o b at y a ng s e ka li gu s m e n in g ka tk a n d a ya

g un a d an h asil g un a bia ya y an g te rs ed ia s eba ga i sa la h sa tu la ng ka h u ntu k

m em p er lu a s, m em e ra ta k an d a n m e n in g ka t ka n m u tu p e la y an a n k e se h at an k e pa d a

m a sy ar ak a! . P e ne ra pa n D D EN h ar us d il ak sa na ka n s ec ar a k on si st en d an t er us

mene rus d i s emua un it p e la y a nan k e s eha t a n.

B e n tu k s e di aa n , k e ku a ta n s e di aa n d a n b e sa r k e ma s an y a ng t er ca n tu m d a la m D D EN

a d al ah m e n gi ka !. B e sa r k e m as a n u n tu k m a si ng -ma s in g u n it p e la y an a n k e se h at a n

d id as ar ka n p ad a e fis ie ns i p en ga da an d an d is tr ib us in ya d ik ait ka n d en ga n

penggunaan.

d af ta r o ba t e se ns ia l k hu su s u nt uk ilm u K eb id an an d an P en ya kit

P e ny us un an F o rm u la riu m S p es ia li st ik m e li ba tk an b aik a so si as i p

s p e si a li s t e r ka i t maupun mas in g -masi n g s u b s pe s ia l is a s in y a . D engan

s e rt a p e ra n a k ti f p a ra s p es ia li s d ih a ra p ka n p a ra s p es ia li s t er se b ut m e

s eh in g g a penggunaan oba t r a s io n a l d a p a t d i t e r a pk a n dengan ba i k.

e. I n f o rm a t o r ium Oba t Nas i o na ll ndone s ia

b . P ed om an P en go ba ta n

I nf or ma to ri um O b at N a si on al I nd on es ia b er is i i nf or ma si o ba t y an g

d is a ji ka n s e ca r a r in g ka s d a n s a ng a t r e le v an d e ng a n k e bu t uh a n d o kt e r,

t en a ga k e se h at an l ai nn y a. I nf or m a to r iu m Ob a t N a si on a l I nd o ne s ia d

D e pa rt em e n K es eh at an u nt uk m e nj am in o by ek tiv it as , k el en gk ap am e n ye s at ka n . I nf o rm a si o b at y a ng d is a ji ka n m e li pu ti i nd ik a si , e fe k s a

c a ra p e ng g un a an d a n i nf or m a si l ai n y a ng p e nt in g b a gi p e nd e ri ta . P e

I nf o rm a to r iu m Ob a t N a si on a ll nd o ne s ia d il ak u ka n b e rd a sa r ka n b u kt i y

s e ca r a i lm i ah y a ng b e rk a it a n d e ng a n k em an fa a at an d a n p e n g g un a an o b

P e do m an P e ng ob at an d is us un s ec ar a s is te m at ik u nt uk m e mb an tu d ok te r d al am

m e n eg a kk a n d ia g no s is d a n p e ng o ba ta n y a ng o p ti m al u n tu k s u at u p e ny a ki t t e rt en t u.

P e d om a n P e n go b at an d is u su n u n tu k s e ti ap t in g ka t u n it p e la y an a n k e se h at a n, s e pe r ti

P e do m an P e ng ob at an D a sa r d i P u sk es ma s d an P e do m an D ia gn os is d an T er ap i d i

R um ah S a ki !. P e d om a n P e n go b at an m em ua t i nf o rm a si p e ny a ki t, t e ru ta m a p e ny a ki t

y a ng um um t e rj ad i d a n k e lu h an - ke lu h an n ya s e rt a i nf or m a si t en t an g o b at ny a m e li pu ti

k e k ua t a n , d o s is d a n l amapengoba t an .

3. P e ng el ol aa n d a n P e n g gu n aa n O b at

U n tu k m e n in g ka t ka n p e ng g un a an o b at y a ng r a si on a l, p e ng g un a an o b at e s en

p e la y an a n k e se h at a n s e la in h a ru s d is e su a ik a n d e ng a n p e dom a n p e ng o ba t

d i te t a pk a n , j u g a s a ngat b e r k ai ta n d engan penge lo l aa n oba !.C. F o rm u la r ium Rum a h S a k it

F or mu la riu m R um ah S ak it m er up ak an d aft ar o ba t y an g d is ep ak ati b es er ta

i nf om a sin ya y an g h ar us d it er ap ka n d i R u ma h S a ki !. F o rm u la ri um R u ma h S a ki t

d is us un o le h P a ni ti a F ar m as i d an T e ra pi ( P FT ) I K o mi te F a rm a si d an T er ap i ( KF T )

R um ah S a k it b e rd a sa r ka n D D EN d a n d is e m pu r na k an d e ng a n m em pe r ti m ba n gk a n

o ba t l ai n y an g t er bu kt i s ec ar a i lm ia h d ib ut uh ka n u nt uk p el ay an an d i R u ma h S a ki tt er se bu !. P e ny us un an F o rm u la ri um R u ma h S a ki t ju ga m e ng ac u p ad a p ed om a n

p en go ba ta n y an g b er la ku . P en er ap an F or mu la riu m R um ah S ak it h ar us s ela lu

d ip an ta u. H a sil p em a nt au an d ip ak ai u nt uk p el ak sa na an e va lu as i d an r ev is i a ga r

s e su a i d e n g a n p e rk e mb a ng a n i lm u p e ng e ta h ua n d a n t e k no lo g i k e do k te r an .

P e n ge lo la a n o b at y a ng e fe k ti f d ip e rl uk a n u n tu k m e n ja m in k e te r se d ia a n o b a

d an ju mla h ya ng te pa t d an m em en uh i sta nd ar m utu. A sp ek ya ng p

penge lo l a an oba t me l ip u t i a n t ar a l a in :

P em ba ta sa n ju mla h d an m ac am o ba t b er da sa rk an D af ta r D

m e n gg u na k an n am a g e n e ri k, d e ng a n p e re n ca n aa n y a ng t ep a !.P e n ga d aa n d a la m j um l ah b e sa r (bu lk purchas ing).

Pembe li a n y a ng t r an s p a ra n dan k ompe ti ti f .

S i s tem aud it d a n pe l ap o ra n da r i k i n e rj a p e nge lo l a an .

d . F o rm u la ri um S p es ia li st ik

P e ne ra pa n P e ra tu ra n P e me ri nt ah N o mo r 3 8 t ah un 2 00 7 t en ta ng P e mb

P em er in ta h an a n ta r a P em er in t ah , P em er in t ah a n D a e ra h P r o pi ns i, d a

D a e ra h K a bu p at e n/ K ot a m em b aw a i m pl ik a si t er h ad a p o r ga n is a si k e se h at a

k ab up at en m a up un k ot a. D e mi ki an p ul a h aln ya d en ga n o rg an is as i p en g

m a s in g -m a s in g d a er a h k a bu p at e n I k o ta m em pu n ya i s tr u kt ur o r ga n is a si

s en di ri d al am p en ge lo la an o ba !. D im a na h al i ni m e mb uk a b er ba ga i p

p erb ed aa n y an g s an ga t m en da sa r d i m asin g-m asin g K ab up ate n/K

me l a ks a na kan penge lo l a an oba !.

F o rm u la r iu m S p e si al is ti k m e r up a ka n s u at u b u ku y a ng b e ri si i nf or m as i l en g ka p o b at -

o b at y a ng p a li ng d ib u tu h ka n o le h d o kt er s p es ia li s b id a ng t e rt en tu , u n tu k p e ng e lo la a n

pa s ie n d engan i n d ik a s i p e n y ak i t t e rt e n tu .

F o rmu la r ium Spe s ia l is t ik d i su s u n un t uk men i ng k a tk a n k e ta a t an pa ra d o k te r s p e si a li s

R u ma h S a ki t t er ha da p F or m ula ri um R u ma h S a ki t y an g s el am a i ni m a si h s an ga t

r e nd a h. B i da n g s p es ia li sa s i t er te n tu b is a s a ja m em pu n ya i b a ny a k s u bs p es ia li sa s i,

m i sa ln y a b id a ng s p es ia li sa s i I lm u K e bi da n an d a n P e n ya k it K a nd u ng a n, m e r up a ka n

b i d an g s pe si a li s as i y a n g mempun ya i b a n y ak s u b spe s ia l is a s i, s e h in g g a dapa t d i su s u n

S i kl us d is tr ib u si o b at d im u la i p a da s a at p r od u k o b at k e lu a r d a ri p a br ik a t au d

b e ra k hi r p a da s a at l ap o ra n k o ns um si o b at d is e ra h ka n k e pa d a u n it p e ng a da

o ba t y an g e fe kt if h ar us m e mil ik i d es ai n s is te m d an m a na je m en y an g b ai k




a nt ar a l ai n: m e nj ag a s up la i o ba t t et ap k on st an , m e m pe rt ah an ka n m u tu o b at y an g b a ik

s ela m a p ro se s d is tr ib u si , m e m in im a lk an o b at y an g t id a k t er pa ka i k ar en a r us ak a ta u

k a da lu a rs a d e n ga n p e re n c an a a n y a ng t e pa t s e su a i k e bu t uh a n m a s in g -m a s in g d a e ra h ,

m e m il ik i c at at an p e ny im p an a n y an g a ku ra t, r as io n al is as i d ep o o b at d an p e mb e ri an

i nf o rm a s i u n tu k m em p e rk ir a ka n k e bu t uh a n o b a !.

6 . P em an ta ua n d an E va lu asi

P em an ta ua n d an e va lu as i d ila ku ka n u nt uk m en un ja ng k eb er ha sila n

D OE N m ela lu i m ekan ism e pe mantau an da n eva lua si ke luaran

p en er ap an D O EN y an g s ek alig us d ap at m en gid en tif ik as i p er ma sa la h

d a n s tr a te g i p e n an g g ul an g a n y a ng e f ek t if .

H al in i d ap at d ic ap ai m ela lu i k oo rd in asi, s up erv is i, p em an ta ua n

p en er ap an D O EN o le h D ep ar te me n K es eh at an . P em an ta ua n d an e va

d i la k sa n a ka n s e ca r a b e rj en ja n g s e su a i d e n ga n f u ng s i d a n t in g ka t ny a .

D e ng a n a d an ya d es en tr al is as i d ih a ra p ka n k ab u pa te n /k ot a m a up u n p ro vi ns i d a pa t

m en cu ku pi k eb ut uh an o ba tn ya m a sin g- ma sin g. P em e rin ta h p us at d ala m h al in i

D e p ar te m e n K e s eh a ta n h a n ya memback-up ma n a ka la k a b up a te n /k o ta m a u p un p r ov in s i

t id a k d a pa t m e m en u hi k eb u tu h an n ya . D O E N m e ru pa ka n d a sa r u nt uk p e re n ca n aa n d an

p e n ga d a an o b a t b a ik d i d a e ra h ( k ab u p at e n I kota I p ro v in s i ) d a n t in g k a t p u s a !.7 . R ev is i DO EN

U n tu k p e n ge lo la a n d a n p e n gg u n aa n o b a t k h u s u s ( s pe s ia li st ik ) d a la m m e n g at a si k e ad a a n

t er te nt u, p e me ri nt ah c .q . D ir ek to ra t J en d er al B in a K e fa rm a si an d a n A la t K e se ha ta n ,

D e pa rt em e n K e se h at an R I d ap a t m e m as uk an ny a m e la lu i j al ur k hu su s ( sp e ci al a c ce s

scheme) sesua i den gan Keputusa n M enter i K esehatan Nom or :

1379 .A /Menkes /SK /X I / 2002 .

D O EN p er lu d ir ev is i d an d is em pu rn ak an s ec ar a b er ka la . R ev is i t id ak

m e ny es ua ik an d en g an k em a ju a n i lm u p e ng e ta h ua n , t et ap i ju g a u nt u

d a la m p en g gu n aa n d a n p e ny er ah an y an g d is es ua ik an d e ng a n t en a ga k

s a ra n a p e la y an a n k e se h a ta n y a ng a d a .

4 . K om un ik as i, In fo rm as i d an E du ka si ( KI E)

P en ye mp ur na an D O EN d ila ku ka n s ec ar a te ru s m en er us d en ga n u su la

u n it p e la ya na n k es eh a ta n , p e nd id ik an , d a n p e ne lit ia n k es eh a ta n, b a

m au pu n s wa st a, d is am p aik an k ep ad a D ir ek to ra t J en de ra l B in a K ef

K e se ha ta n , D e pa rt em e n K e se ha ta n R e pu bl ik I nd on e si a. R e vi si D O E N

s e ca r a p e ri od ik s e ti ap 3 ( ti ga ) t a hu n .I E m e ng en a i o b at e se n si al m e ru p ak an s ua tu p ra sy ar at u n tu k m e nd o ro n g p e ng g un a an

o b a t d a n p e n ul is a n r e se p y a ng r a si o na l o l e h t e n a g a k e se h a ta n .

K IE k ep a da t en ag a k es eh a ta n d an m a sy ar ak at d a la m r an gk a p en in gk at an p e ng g un a an

o b a t y a n g r a si o na l p e rl u d i t in g ka t ka n d a n d il a ks a na k a n s e ca r a t e ru s -m e n e ru s m e la lu i j a l ur

berikut:

a . I ns ta ns i P e m e rin ta h I Swas ta

b . O r g an is a si P r o fe s i y a n g t e r ka i t

c . K u ri ku l um p e n di d ik a n t e na g a k e se h a ta n

d . J al ur la in y an g m e m u n gk in ka n

8 . Jag a M utu

J ag a m utu o ba t m en ye lu ru h y an g m elip uti ta ha p p en ge mb an ga n

P e m bu a ta n O b at y an g B a ik ( CP O B ), m o ni to ri ng m u tu o b at p ad a r an ta i

p e ng g u na a n ny a , m e r up a ka n e l em e n p e n ti ng d a la m p e n er a pa n k o ns e p o b a t e

9 . R e si st en si A n ti bi ot ik

S e ti a p o b a t y a n g t e rc a n tu m d a la m DOEN h a ru s d is e rt a i d e n ga n i nf o rm a s i y a n g a k u r a t d a n

o b ye k ti f s e hi ng g a d a p at d i m en g e rt i o le h t e na g a k e se h a ta n . I n fo r m as i t e rs e bu t m e li pu t i

i nd ik a si , k o nt ra i nd ik a si , d o si s, c a ra p e n gg u n aa n , p e ri ng a ta n p e rh a ti an , e f ek s a m p in g ,

i n te r a k si o b a t d a n ben t uk s e d ia a n .

R e si st en si a n ti bi ot ik m a ki n m e ni ng ka t t er ut am a p a da a nt ib io ti k e se ns ia l

y an g r el at if m u ra h h a rg a ny a. K e ad a an i ni d in il ai s an ga t m e m ba h ay ak an ,

a kh ir ny a d u ni a k es eh at an a ka n k eh ila n ga n a n ti bi ot ik y an g m a si h p ek a

u nt uk m e m er an g i p en ya ki t- pe n ya ki t i nf ek si y an g b ar u m u nc ul (emerg

mu n cu l k e m ba li ( reemerging) . P e ny eb a bn ya k ar en a p en g gu n aa n a n ti bi o

r a s io n a l , b a i k o l e h t e n aga k e s ehat a n maupun pende r it a .5 . P en elit ia n d an P en ge mb an ga n

P e ne li ti an d a n p e ng e mb an g an d ila ku ka n u n tu k m e nu n ja n g p ro se s p e ny us un an d an

p en ye m pu rn aa n D O EN . P en elit ia n d an p en ge mb an ga n t er se bu t d ila ks an ak an

s eja la n d en ga n p er ke m ba ng an ilm u p en ge ta hu an d an te kn olo gi k es eh ata n d ala m

b id an g k ed ok te ra n, f ar ma si, e pid em io lo gi, d an p en did ik an . H as il p en elitia n d an

pengem bangan d igu nakan sebaga i m asu kan da lam proses re vis i d an

p e n yem p u rn a an D OEN s e ca r a b e rk a la .

U n t u km enga t as i ma s a l ah r e s is t e n si a n t ib i o ti k d i p e rl u k an upa y a -u p a y a :

a . M e ny el en g ga ra ka n s ur ve ila n s p o la r es is te n si m ik ro ba s eh in gg a d

re s is t e n b a k t er i t e r ha d ap an t ib i o ti k .

b . M e n y el en g g ar a ka n s u rv e il a ns p o la p e n gg u n aa n a n ti bi ot ik .

P e n ye le n g ga r a s u rv e il an s p o la p e ng g u na a n a n ti bi ot ik a d a la h i ns ti tu s i

r u m ah s a ki t, P u s ke s m as , D i na s K e s eh a ta n s e rt a i ns t it u si k e se h a ta n , p

pene l i t ian l a i n .




c . M en ge nd alik an p en gg un aa n a nt ib io tik o le h p et ug as k es eh at an d en ga n c ar a

m em b er la k uk a n k e bi ja k an p e nu li sa n r e se p a n ti bi ot ik s e ca r a b e rt a ha p s e su a i d e ng a n

k eadaan pende ri ta d a n pen y ak i t y a n g d i de r it a n ya , d e ngan p i li h an mu l a i d a r i a n t ib i ot ik

l in i p e r t ama , k e d ua, k e ti g a d an an t ib i o ti k y a n g s angat d i b at a si p e n ggunaanny a .

B . T er min olo gi

1 . ls i dan Form at DOEN

a . D O E N R u ma h S a ki t s am a d en ga n D O E N u nt uk s el ur uh u ni t p el ay an

b . S a tu je ni s o ba t d a p at d ip er gu na ka n d al am b eb er ap a b en tu k s ed ia an d

s e di aa n d a pa t t er d ir i d a ri b e be r ap a j en is k e ku a ta n .

c . D a la m DOEN , o b at d ik e lo m p ok k an b e rd a sa r ka n k e la s , s u b k el as d a n k

s u b- su b ke la s t er a pi . D a la m s e ti ap s u bk e la s a t au s u b- s ub k el as t er a pi

b e rd a sa r ka n a b ja d n am a o b a! .

d . M e ny el en gg ar ak an k om u nik as i, i nf or m as i d an e du ka si k ep ad a s em u a p ih ak y an g

m e n gg u na k an a n ti bi ot ik b a ik p e tu g as k e se h at an m a u pu n p e nd e ri ta a ta u m a sy a ra k at

lu as te nta ng c ar a m en gg un ak an a ntib io tik s ec ar a r as io na l d an b ah ay a y an g

d i ti mbu lk a n a k ib a t p e nggunaan an t ib i o ti k y a n g t i d a k r a s io n a l.

1 0. O b at Su m ba ng an

2. Ta ta Nama

S u mb an ga n a ta u d on as i o ba t d ar i s ua tu n eg ar a, l em b ag a s wa st a i nt er na si on al a ta u

l em b a ga d o no r i nt er n as io n al d a pa t m e n un ja n g p e la y an a n k e se h at a n m a s ya r ak a t s u at u

n eg ar a y an g m em bu tu hk an . D ala m p ela ks an aa nn ya , d on as i o ba t h ar us m em en uh i

p e rs y ar a ta n s e pe r ti y a ng t e rc a nt um d a la m P e d om a n WHO u n tu k S um ba n ga n Ob a t (WHO

G u id el in es f or D r ug D o na ti on 1 99 9) . P e la ya na n k es eh at an y an g d ig un ak an h ar us

m e me nu hi p ed om a ni st an da r y an g b er la ku . P e do m an t er se bu t m e nc ak up k et en tu an -

k et en tu an t en ta ng p em il ih an o ba t, m u tu o ba t d an m a sa b er la ku o ba t, p en ge m as an d an

pembe ri a n l a b el , i n fo rma s i d a n pengel o la a n .

a . N a ma o ba t d it uli sk an s es ua i d en ga n F ar m ak op e I nd on es ia e di si t er ak

a da d ala m F a rm a ko pe I nd on es ia m a ka d ig un ak an I n te r n at i on a l N

Name s ( IN N ) n am a g e ne r ik y a ng d it er b it ka n WHO .

b . O b at y an g s ud ah l az im d ig un ak an d an t id ak m e mp un ya i n am a I NN (

d e ng a n n am a l az im , m i sa ln y a : g a r a m o r al i! .

c. O ba t ko mb in asi ya ng tid ak m em pu nya i n am a IN N (g en erik) d ib er

d is e pa k at i s e ba g ai n a m a g e ne r ik u n tu k k om bi na s i d a n d it ul is ka n m

k omp o ne n z a t b e r k ha s ia tn y a d is e rt a i k e ku a ta n m a s in g -m a s in g k om po

d . U n tu k b eb er ap a h al y an g d ia ng ga p p er lu n am a s in on im , d it ul is ka n d

kurung .

Em p a t p r i ns ip u t am a o b at d o n a si a d a la h :

a . D o n as i o b a t h a ru s m em b er ik a n m a n fa a t m a ks im a l b a gi n e ga r a p e ne r im a .

b . M em a ham i k e bu tu h an d a nm e n g h orm at i o t or it a s n e ga r a p e ne r im a .

c . T id a k m e n gg u na k an s ta n da r ga n da b a gi m u tu o b at y a ng d id o na s ik a n.

d . A d a ny a k om un ik a si y a ng e f ek ti f a n t a ra n e ga r a d o no r d a n p e n e ri m a.

3 . P en ge rtia n d an S in gk ata n

a . P en ge rtia n

( 1) B en tu k s ed ia an

O b at s um b an ga n y an g d it er im a s eb aik ny a s es ua i d en ga n D O E N. A g ar p en ye di aa n o ba t

d a n p e rb e ka la n k e se h at a n d a pa t m em b an tu p e la k sa n aa n k e se h at an , m a ka j en is o b at d a n

pe rb ek a la n k e s eha t an ha ru s s e s u a i d e n gan po la p e n y ak i t d i I n d o ne s ia .

B e nt uk s ed ia an a da la h b en tu k o ba t s es ua i p ro se s p em b ua ta n

da lam ben tu k s e pe rt i y a n g a k an d i gu n a k an , m i s a ln y a : t a b l et s a lu t

i n tr a v ena dan s ebaga i n ya .

U n tu k o b at y a ng b e lu m t e rd a ft ar d i I n do n es ia m a ka p em as u ka n o b at b a nt u an h a ru s m e la lu i

m e k an is m e m em as u ka n ny a m e la lu i j al ur k h us u s ( s pe c ia l a c ce s s c he m e ) s e s ua i d e n gan

pe ra tu r a n y a ng be r la k u .

( 2) K ek ua ta n s ed ia an

K e ku a ta n s e di aa n a d al ah k a da r z a t b e rk h as ia t d a la m s e di aa n o

k ek ua ta n s ed ia an d al am b en tu k g ar am a ta u e st er ny a, m a ka g ar

t er s eb u t d ic a nt um k an d a la m t a nd a k u ru n g, m i sa ln y a: e ta m b ut ol

( h id r ok lo r id a ). S e d an g ka n u n tu k k e ku a ta n k a nd u ng a n z a t b e rk h

m a ka n am a g ar am a ta u e st er y an g d it ul is d al am t an da k ur un g a

d e ng a n k a ta s e ba g ai , m i sa ln y a: k lo r ok u in t ab le t 1 5 0 m g ( se b ag a i

( 3) K em as an

K em a sa n a da la h w a da h t er ke ci l y an g b er hu bu ng an l an gs un g




( 4) B es a rk em a sa n larinfus la ru tan infus

OAT oba t antituberku lo sis

serb se rbuk

serbak tif se rbuk ak tif

serb in j se rbuk in je ks i

s e rb i n j i . v . s e r buk i n je k s i i n tr a v ena

serb k ering se rbuk kering

s ir sirup

s irkering sirup k ering

sup supos itoria

susp suspens i

tab tab let

tab k unyah tab let kunyahtabsa lu t tab let s a lu t

ta b s a lu t e n te rik ta ble t s alu t e n te rik

tab s cored tab let dengan tanda belah

ta b s ub lin gu al ta ble t s ub lin gu al

tab v ag ina tab let v aginal

tts tete s

ttsma ta tete sm ata

tts te linga tete s t e linga

C. P r o se s P e m ba h a ru a n R e vi s i

B e sa r k em a sa n a d al ah j um la h s at ua n s ed ia an a ta u k em a sa n t er ke ci l d al am s at u

k em as a n s ta n d ar , m i sa l ny a k o ta k 1 0 0 v i a l.

b. Lain-lain

( 1) P e nu li sa n i nf or ma si p ad a k ol om r es tr ik si d im a ks ud ka n u nt uk o ba t- ob a t d e ng a n

p em a ka i an s e ba g a i b e ri ku t :

( a ). d i pe r lu k an p em a nt a ua n t e rh a da p k em un g k in a n t im b u ln y a e fe k sam p in g

( b) . p e mb at as an i nd ik as i

( c ). t e rb a ta s u n tu k k a su s -k a su s t er te n tu

( d ). d i pe r lu k an m o n it or in g k e ta t at a u p e rt im b a n ga n m e d is

( e ). d i pe r lu k an p e rh a ti an t e rh a d ap s i fa tl ca r a k e rj a o b a t

( f) , d ip e rl uk an c ar a a ta u p e rl ak ua n k hu su s

( g ). d i pe r lu k an f a si li ta s t e rt e nt u

( h) . d ik om b in as ik an d e ng a n o b at l ai n

( i) . d i d a e r ah - da e ra h t er te n tu ( d ae r ah e n d em i s)

0). p em a ka ia n s e su a i p r og r am d ib i da n g k e se h a ta n .

( 2) P en uli sa n i st il ah te kn is a ta u k ata -k at a b ah as a a sin g d ig un ak an h ur uf m ir in g.

( 3) D a ft ar o b at n a si on a l m e ru p ak an d af ta r o b at y an g d ig u na ka n u nt uk r um a h s ak i! .

( 4) P e ma pa ra n D O EN u n tu k P u sk es m as d a la m k er ta s b e rw a rn a r ne ra h.

c. Singkatan

arnp arnpul

btl bo to l

b ls blis te r

ih inha las i

in j in je ks ii nj d lr n r nin ya k i nje ks i d a la rn r ni ny ak

in ji.a . in je ks i i n traarteri

in j in f iltr in je ks i in filtras i

in j i.k . in je ks i i n tra ku tan

in j i.rn. in je ks i in tra rnuskula r

inj i . v . in jeks i int ravena

inj p . v . in jeks i paraver tebral

in js .k . in je ks i s ubkutan

kapl kaplet

kaps kapsul

k tk kotak

k tg kantong

lar larutan

larre kta l larutan rek ta l

P e rn b ah a sa n b u ka n h a ny a d ar i u s u la n y an g r na su k, t et ap i r ne n gk aj i s el ur uh o b at

2 0 05 . H a l i ni d il ak uk an r ne n gi ng a t p e rk er nb an g an i lr nu k ed o kt er an y an g b el ur

d i d a l a rn n ya . H a l i n i t e rl ih a t d a ri b e rb a g ai p e rn b a ta s a n y a ng b e rl a ku 1 0 ( se p u lu h ) t a

s e ka r an g i n i s u da h b u k an l a gi p e rn b a ta s a n, c o nt o hn y a p e n gg u n aa n o b a t k a n k e r.

T ir n a hl i d a n k on su lt an b e ke rj a b e rs ar na d al ar n p er nb a ha sa n y an g d ib ag i d al ar n

p e rn ba h as an b e rd a sa rk an k el as t er ap i. K o ns ul ta n t er ut ar na y an g b e rt an g gu n g j a

EBM , t el ah b ek er ja s es ua i d e ng a n k or np e te ns i. S e la in i nf or rn a si d a ri k on su lt an

s e kr e ta r ia t r n en d u ku n g d e n ga n i nf o rr n as i d a ri C o c h ra n e r e vi e w d a n W H O Library .

rnesk i infor rnas i EB M b e lu r n s e p en u h ny a b e rl ak u , n a rn u n p e rn b a ha s an t id a k l a gi h

p e rn b u kt ia n t in g ka t k e -4 , p e n da p a t a h li s e rn a ta .

P e rn a h ar n an k o n se p DO E N , r n ul a i d i s os ia l is a si k an k e rn b al i. R u p an y a p e rn a h ar n an

e se n si al r nu la i l un tu r d an p e nj el as an t en ta n g h a l i ni s an g at d ih ar ga i. B e be ra pa

r n un c ul u n tu k r n er n pe r rn u d ah p e n ge r ti an a t au k o ns e p o b a t e s en s ia l . O b a t e s en s ia

b u k an l a ng i t- Ia n g it , d i te r je r na h ka n d a ri : E s se n ti al M e di ci ne i s a f lo o r n o t a ceilin

9 4 6) . O b at e se n si al a d al ah k eb u tu ha n r ni ni rn a l d a la rn p e la ya n an k es eh a ta n . S u a

e se n si al j ik a a nd a t id a k d a pa t b e rb u at t an p a o b at t er se b ut ( Yo u c an 't d o w it ho

p er na ha rn an in i, p er so al an y an g r nu nc ul k er nu dia n y ait u rn as al ah p er be da an

p e ng e rt ia n o ba t p ro g ra rn . P er be da a n p e rs ep si o ba t e se ns ia l d an o b at p ro g ra rn a

p a da p ro se s p e ng a da a n o b at , b ai k d a ri p ro gr ar n d an r na u pu n o le h P e la ya n an K e

( P KD ) . U n tu k r n en g a ta s i h a l i n i t e la h d i se p a ka ti , a k an d i la k uk a n s o si a li sa s i d a n p

k h u su s d a ri D e p ar te r ne n K e se h a ta n t e rk a it d e n ga n o b a t e s e n si al d a n o b a t p r o g ra r n




D a la m p r os e s r e vi si , s e j ak a w a l t e la h d ir e nc a na k an a k an m em be r ik a n p e rh a ti an p a d a o b a t u n t u k

a n ak . K e bi ja k an i ni b u ka n d im a ks u dk a n s em at a-m at a a g ar s e la r as d e ng a n k e bi ja k an g lo b al ,

n a m un I n do n es ia y a ng k o ns is te n m em p er ju a ng k an p e nu r un a n a n gk a k ema t ia n b a yi d a n a n ak ,

m e mb ut uh ka n p en ek an an h al in i. K et er li ba ta n 4 o ra ng d ok te r s pe sia li s a na k, m e mb er ik an

k o nt ri bu s i c u ku p u n tu k h a l i n i . D em i ki an p u la k e te r li ba ta n s ta f D ir e kt or a t B i na K e se h at a n A n a k,

d an d ir ek to ra t la in , s an ga t in te ns if . P e na m ba ha n b eb er ap a o ba t u nt uk a na k d en ga n b en tu k

s e d ia a n k hu su s ana k , s e p e r t i k a r bamaz epi n d i se d i ak a n da l am ben tu k s i ro p .

( 2) . K ea ng go ta an K om Na s D OE N b er sif at te ta p s am pa i te rb en tu k

r ev is i D O E N b er ik ut ny a. K om N as D O E N d is ah ka n m e la lu i S K M

menc ant umk an t u g as - tu g a s ny a .

( 3 ). N am a a n gg o ta t im a h li d a n k o ns u lt an y a ng t er p il ih d is u su n s e su

t an pa g el ar , h an ya d ib ed ak an d ok te r, d ok te r u m um , d ok te r

apo teker .

( 4) . T id ak s em ua k ela s t er ap i m em bu tu hk an a hli y an g h ar us te rc

K om N as D O E N.

( 5) . J ik a d ip er lu ka n, d ap at d iu nd an g s eo ra ng a hli d i b id an gn ya u

n a ra s um b e r y a ng m em be r ik a n p a nd a ng a nn y a d a la m p r os e s r e v

te rm asuk da lam tim ah li dan konsu ltan serta tidak iku t

p e n gambi la n k e pu tu s a n .

( 6) . T ug as t im a hl i d a n k on su lt an t er ca nt um d al am S K s eb ag ai b er ik u

(a ). T im a hli b ertu gas m ela ku ka n e va lu asi o ba t d ala m D OE

m e n il ai u s ul an o b at y a ng a k an d im a s uk ka n d a n/ at a u d ik e lu

d al am D O E N 2 00 8.

( b ). K o ns u lt a n b e rt ug a s m em be r ik a n m a su k an t ek n is I i lm i a h y a

t im ah li .

(c) . T im ah li dan konsu ltan bersam a-sam a m em berikan

teknis I i lm i ah k e pa d a D e p ar te m e n K e se h at an m e la lu i D i re k

B in a K ef ar m as ia n d an A la t K es eh at an d ala m p en er ap an

n as io na l s er ta m e mb an tu D ir ek to ra t B in a P e ng gu na an O

d a la m p e ne r ap a n k e bi ja k an D OEN .

( 7) . P e ng el ola p ro gr am a da la h w a ki l d ar i d ir ek to ra t d i li ng ku ng an

K e se h at a n y a ng m em p un y ai p r og r am p e ng o ba ta n I pengadaan o

( 8) . P e la ks an a a da la h D ir ek to ra t B in a P e ng gu na an O b at R as io n

J e nd e ra l B i na K e fa r ma s ia n d a n A l a t K e se h at an D e p ar te m e n K e

P a da p em b ah as an t er ak hir y ait u R ap at P le no u nt uk p en ge sa ha n, t ela h d is ep ak at i 7 8 o ba t

d ih ap us d ar i D O E N 2 00 5 d an 4 8 d i ta m ba h k e d a la m D O E N 2 00 8. P e ru ba ha n f or m ul as i ( be nt uk

s ed ia an , k ek ua ta n d an k em a sa n) t er ja di p ad a 2 1 o ba !. T e rd ap at 3 3 o ba t y an g d ib er i c at at an

p e rl u d ia d ak a n o le h p em er in ta h m e la lu i c a ra - ca r a y a ng s e su a i d e ng a n k e bi ja k an y a ng b e rl ak u .

S e h in g ga j um l ah t o ta l o b a t y a n g a d a d a l am DOEN 2 0 08 a d al ah 3 2 3 i t em o b a! .

1 . P ro se s re vis i

P r o se s r e vi si d im u la i d e ng a n m e n gi ri m ka n s u ra t k e pa d a i ns ti tu s i p e la y an a n k e se h at an

( ru m ah s ak it t ip e A , B , C , p us ke sm a s) p em e ri nt ah m a up un b eb er ap a s wa st a t er pil ih ,

p em e ga ng p ro gr am p en go ba ta n d i l in gk un ga n D e pa rt em e n K e se ha ta n d an o rg an is as i

p r of e si . S e te la h 3 b u la n p e ng ir im a n , d a ri s e ju m la h 1 1 4 i n s ta n si y a ng d ib e ri ka n s u ra t, 2 5

i ns ta ns i m e mb er ik an j aw ab an . D a ri ja w ab an t er se bu t 3 m e mb er ik an ja w ab an t id ak a da

u su la n, 2 2 j aw a ba n u nt uk m e na m ba hk an , d an t id ak a da u su la n u nt uk m e ng ha pu s o ba t

d a ri D OEN . M e s ki pu n d a la m s u ra t p e rm i nt a an s u da h d ib e ri ta h uk a n b a hw a p e ng u su la n

h ar us m em be rik an d ata p en du ku ng d an k eg un aa n, n am un h an ya 1 0 u su la n y an g

m em b er ik a n d a ta p e nd u ku n g. S e la in u s ul an d a ri i ns ta n si , t im a h li d a n k o ns u lt an , d a pa t

membe r ik a n u s u la n d engan da t a p endu k ung.

T a ta c ar a i ni m e ru pa ka n a cu an d al am p el ak sa na an r ev is i D O E N p ad a t ah un 2 00 8 y an gs a ng a t d ip e rl uk a n d a la m t e rw u ju d ny a p r os e s t ra n sp a ra n si d a n a k un ta b il ti as . A c ua n i ni

b e ri si k e pa n it ia a n, p e ne t ap a n k ri te r ia p r os e s r e kr u it m en a n gg o ta t im a h li r e vi si D OEN ,

tugas dan kew ajiban anggota tim ah li revis i D OE N, proses revis i, jenis dan

p e ny e le n gg a ra a n r a pa t p e m ba h as a n d a n c a r a p e n y eb a rl ua s an D OEN .

b . P ro se s p em il ih an a ng go ta T im A h li d an K on su lt an

2 . K ep an it ia an

( 1) . P e rs ya ra ta n a ng go ta T im A h li d an K on su lt an :

( a ). M em il ik i i nt eg r it as d a n s ta n da r p r of e si on a l t in g gi .

( b) . A ng go ta tim a hli d an k on su lt an a da la h k lin ik us d ar i b e

s p es ia li sa s i, f ar m ak o lo g i ( kl in ik ) , d o kt er g ig i, a p ot ek e r, d

puskesmas .

( c) . D em i m em pe ro le h t im a hli y an g p ro fe sio na l d an t id ak b

yang bersangku tan supaya tidak m ew akili asos r

d ep ar te me n/ ba gia n d i r um ah s ak it , a ta u ja ba ta n la in y

men imbu l ka n k on fl ik .

( d ). M e n ya ta k an k e se d ia a n s e ca r a t er tu li s.

( e ). B e r se d ia m e n an d at an g an i f o rm u li r b e rk a it an d e ng a n k o nf li k

N am un , o ra ng y ang m em ilik i k on flik ke pe ntin ga n

d ip e rt im b a ng k an o le h t im m e n ja d i a n gg o ta t im a h li , b il a d i n il

d a p a t men ja g a i n te g r it a sn y a .

a . O rg an is as i

( 1 ). S t ru k tu r o r ga n is a si b e rb e nt uk K om it e N a si on a l D a ft a r O b a t E s en s ia l ( K omN a s

D OEN ), t er d ir i d a r i :

( a) . T im a hl i

( b ). K o ns u lt an

( c) . P e ng elo la P ro gr am d an

( d ). S e k re ta r ia t P e la k sa n a




( 2 ). P r o se s r e kr u tm e n a n gg o ta T im A h li d a n K o n s ul ta

( a) . S ek re ta ria t m en ya mp aik an p er min ta an k es ed ia an t er tu lis d ar i y an g

b e rs a ng k ut an d is e rt ai p e rm o h on a n i ji n k e pa d a a ta s an , y a ng d il ak u ka n 1

( sa t u) b u la n s e be lu m r a pa t p e rd a na r e vi si D OEN .

( b ). Y a ng b e rs a ng k ut a n m e n ya ta k an k e se d ia a n t er tu li s 1 ( s at u ) m i n g gu s e te la h

m e nd ap at s ur at p er m in ta an t er se bu t d ia ta s, y an g d is er ta i p er ny at aa n

ten tang kon f l ik kepent i ngannya .

( c ). S u r at pe rmi nt aa n k e se d ia a n b e ri si :

U r a ia n t u g as t im ah l i.

J a dwa l p embaha s an ma t e ri y a n g ha ru s d i h a d ir i y a n g be r sa n g k ut a n .

T a ta e a ra r e vi si D OEN .

T at a e ar a p em b ah as an t ek ni s ( pe ny ia pa n d ra ft r ev is

pleno.

P e se rt a r ap at : t im a hl i, k on su lt an , p en ge lo la p ro gr a

k e gi at an r e vi si D OEN .

( b ). R a p at -r a pa t p e m ba h as a n t ek n is

M e r up a ka n r a pa t- ra p at p e m ba h as a n m a te r i r e vi si .

M e mb ah as u su la n p en am b ah an /p en gu ra ng an o ba t

u n it p e la y an a n k e se h at an ( k om p il as i u s u la n d a ri b e

p e la y an a n k e se h at a n d a n D OEN 2 0 05 d is e di ak a n o le

M e ne er ma ti s ee ar a k hu su s o ba t y an g d iu su lk an d i lu

e s en s ia l W HO y a ng h a ru s d ip e rt im b a ng k an s e ea r a s eU s ula n m em as uk ka n s up le me n m ak an an k e d ala m

akan d iper t imbangkan.

A pa bila tim a hli t id ak d ap at m en ga mb il k ep ut us an

m a sa la h , m a ka d a pa t m e n gu n da n g n a ra s um b e r d i l ua

P e se r ta r a pa t :

o T im a hli

o Konsu ltan

o P e ng el ol a p ro gr am D e pa rt em e n K es eh at an t er ka

o N ar as um be r t er ka il.

H a si l r a pa t p e m ba h as a n t ek n is a d al ah d r af t r e vi si D OE

3. C a ra r ev is i DO EN

a . P en gu su la n

P ro se s r ev is i d ia w al i d en ga n p en gi ri ma n s ur at p er mi nt aa n u s ul an t er tu lis k ep ad a

u nit p ela ya na n k es eh ata n ( RS P en did ik an , R S K hu su s, R S P ro pin si, R S T NI-

P O LR I, R S S w as ta t er pil ih , R S K ab up at en t er pil ih , P u sk es ma s R a wa t I na p) , D i n as

K e se h at a n P r op in s i y a ng m e w ak il i, p u sk e sm a s d a n p e ng e lo la p r og r am ( d ir e kt or a t

t er k ai t d i l in g ku n ga n D e p ke s ). S u r at p e rm i nt aa n d ik ir im o le h p e la k sa n a 3 ( ti ga ) b u la n

s e be lum ra pa t p e r d a na .

b . K om p il as i u s ula n

P e la ks an a m e la ku ka n k om p il as i u su la n y an g m a su k d an d ik elo m po kk an s es ua i

d en ga n k ela s t er ap i. D il ak uk an d al am w a kt u 1 ( sa tu ) b ul an s et el ah t an gg al b at as

u s u la n mas u k .

e . M at er i r ev is i

M a t er i r e vi si a d al ah m a tr ik s y a ng m e n ya n di ng k an D OEN WHO e d is i t e ra k hi r, D OEN

t er d ah u lu d a n u s ul an h a si l k o m p il as i. M a t er i r e vi si a k an d is e ra h ka n k e pa d a t im a h li 1

( s a tu ) m i n g gu s ebe lum ra pa t p embaha s an t e k ni s .

( c) . R a pa t P le no

Be r f un g s i u n t uk men y epa k a ti , menge sah k an dan men

d r af t r e vi si D OEN .

P i mp in a n s id a ng a d al ah k e tu a t im a h li .

P e ng es ah an d ra ft D O E N m e nj ad i D O E N r ev is i b ar u,

D irje n B in a K efar ma sia n d an A la t K ese ha ta n

K e se h at an a ta u y a ng m e w ak il i.

H as il p en ge sa ha n r ap at p le no tid ak d ap at d iu ba h

redaksional .

P e se r ta r a pa t p le n o s e la in m e r ek a y a ng b e rf un g si s e ba

k e pu tu s an d i i ns ti tu s i m a si ng -ma s in g j ug a d ih a ra p ka n

d a la m p e ny e ba r lu a sa n D OEN .

Pe s e rt a r a p a t p l e n o ada la h

o P es er ta r ap at p er da na

o P e se rt a r ap at p em b ah as an t ek ni s

o K om ite m ed ik R S p en did ika n, R um ah S ak it T

Sw a st a t er p il ih d a n r u m a h s a ki t l a in y a ng m em b er i

o F ak ulta s K ed ok te ra n

o F aku lta s F a rm asi

d . K ri te ria p em b ah as an

U su la n y an g a ka n d ib ah as h an ya la h u su la n y an g d is er ta i a la sa n d an b uk ti i lm ia h

(ev idence) y a ng l e ng k ap .

e . C ar a p e m ba ha sa n m a te ri r ev is i

( 1 ). R e vi si d a pa t b e ru p a s em ua a ta u s a la h s a tu p r os e s b e ri ku t

( a ). H a n ya m e n gk a ji u s ul an y a ng m a s uk . M e n ol ak d an m e n er im a u s u la n

(b ). M en gka ji se lu ru h D OE N d an u su lan ya ng m asu k. M en gh ap us d an

m e n am b a hk a n o b at e s en s ia l b a ik d a ri u s u la n a t a u d a ri a n g g o ta t im a h li d a n

konsul tan.

( 2 ). J e ni s r a pa t p e m b a ha s an

( a ). R a p at P e rd a na b e ri si t en ta n g :

Pen j el a sa n t e n ta n g penger t ia n o ba t e s e n s i al ( b a ta s a n , k r it e r ia , j um la h

oba t e s e n s i al y a n g i d e al d a l am DOEN dan l a in - la i n ).

I m pl em e n ta s i D OEN ( ka it an d e ng a n o b at p r og r am , a e ua n p e ng a da a n

o b at P K D , D PHO - A SKES d a n l a in - la in ) .




o S ek ola h T in gg i K ep er aw ata n

o D in as K e se ha ta n P r op in si y an g m e mb er ik an u su la n r ev is i

o O r g an is a si p r of e si ( IB I , I D I, P PN I , I S F I, I ka t an a h li /s p es ia li s)

o In du str i f ar ma si ( BU M N d an G P F ar ma si)

m er up ak an o ba t t er pilih p ad a p as ie n s an ga t g aw at , s eb ag ai

h ip n ot ik a , p r a a n e s te s i. S e m e nt a ra i tu e n fl ur a n e a ir a n i h, b t l 2 5 0

d ar i d af ta r d en ga n a la sa n k ur an g m en gu ntu ng ka n jik a d ib a

p en gg u na an i so fl ur an d an h al ot an . S e da ng ka n t hi op en ta l s er

mg / amp , meng i ng a t k e t er s e d ia a n d i p a s a ra n , d i ke l u ar k a n da r i d a f t

4 . P en je la sa n P er ub ah an O ba t 5 . A n ti ep il ep si - A nt ik on vu ls i

U s u la n p e nam b ah a n b e nt u k s ir o p d a n t a bl et k u ny a h s e di aa n u n tu k p a si en

S e h in g g a d a la m DOEN i ni t e r ea n tu m f en it o in s ir u p 5 0 m g /5 m l , k a rb a m az e pi n

b tl 1 20 m l, t ab k un ya h 1 00 m g . F e n ob ar bi ta l t ab 5 0 m g d it am b ah ka n d al am

sangat d i per l ukan .

P e ru ba h an o ba t d a la m D O E N 2 00 8 b ai k n am a g en er ik a ta u f or m ul as in ya , b er da sa rk an

k e la s t e ra p i a d a la h s e ba g a i b e ri ku t :

1 . A n al ge si k, A n ti pi re ti k, A n ti in fl am a si N o ns te ro id , A n ti pi ra i

1 . 1. A n a lg e si k N a rk o ti k

S u fe n ta ni l i nj d al am b en tu k s it ra t 5 0 m e g/ ml , d ik el ua rk an d a ri d af ta r, k ar en a

k e l an g k aan k e t er s e d ia a n d i p a s a ra n .

6 . A nt iin fe ks i

D a la m b eb er ap a k al i r ev is i, s ela lu m a su k u s ul an u nt uk m e ma su kk an

n am un b ar u p ad a r ev is i k ali in i K om N as D O EN , m em be ri t em pa t k ep

d en ga n p em ba ta sa n k hu su s p en gg un aa n y aitu p ad a p ro fila ks is b ed ah

S ef az olin m er up ak an o ba t t er pilih s eb ag ai p ro fila ks is b ed ah u nt u

t er ja di ny a i nf ek si l uk a o pe ra si . H a l y an g s am a t er ja di p ad a s ef tr ia ks on

y an g m er up ak an o ba t p ilih an u nt uk m en in gitis d an d ig un ak an u ntu k

b er at y an g r es is te n d en ga n k lo ra mfe nik ol. P en un da an m as uk ny a

s ef al os po ri n i ni , l eb ih d is eb ab ka n t er ja di ny a p er ke m ba n ga n r es is te ns

y a ng s a ng a t p e sa t , k h us u sn y a d i R S .

1 .2 . A n al ge si k N o n N a rk ot ik

M e t am p ir o n i nj i .m . 2 5 0 m g /m l d ik e lu a rk a n d e n ga n a la s an k e am a n an , d im a n a

b e nt uk i nj ek si d ap at m e ny eb ab ka n s yo k a na fil ak ti k. S e me nt ar a i tu u s ul an

m enam bahkan ke topro fen sup 100 m g dan parase tam ol sup 12 0 m g,

2 40 m g d a pa t d it er im a , m e ng in ga t k et op ro fe n s up d ig u na ka n u nt uk p as ie n

p as ea o pe ra si y an g b elu m b is a m en er im a p em be ria n o ba t s ee ar a o ra l d an

t id ak m e ng ir it as i l am b un g. S e da n gk an p ar as et am o l s up d ib u tu hk an u nt uk

k as us k ej an g d em a m, p as ea o pe ra si p a da a na k, s es ua i d e ng an t at al ak sa na

k es eh ata n p ad a a na k. K ete rs ed ia an d an p en ga da an p ar as eta mo l s up

d ib a ta s i h a ny a s am pa i t in g ka t r u m ah s a ki t k a bu p at e n.

T im a hli s ep ak at u ntu k m en er im a u su la n p en am ba ha n v an ko mis in in j 5

m e n ga t as i i nf e ks i MR SA (me t h ic i li n r e s is t a n t S. aureus) , s u at u i nf e ks i n o

s er iu s. A m fo te ri si n* ) i nj . i . v . , v ia l 5 0 m g d iu su lk an d an d ite rim a m as uk

k a re n a m e r up a ka n s a tu - sa t un y a o b at a n ti fu n gi s is te m ik , t e ru t am a u n tu k m e

j am u r d i p a ru -p a ru . D a la m d a ft ar d ib e ri t an da * ) y an g b e ra rt i " me m bu tu h

k h u s us da l am penggunaann ya " .

1 . 3 . An t ip i ra i

K olk his in ta b 5 00 m eg , s eja k a wa l s ud ah t er ea ntu m d ala m D O EN . N am un

d en g an m u ne ul ny a b an ya k o ba t N S A ID , d in il ai e fi ka sin ya t id ak j au h b er be da

d en ga n N S AID y an g la in , s ed an gk an k ea ma na nn ya ju st ru le bih r en da h

d ib a n di ng N SA ID . M a k a k o lk h is in d ik e lu a rk a n d a ri D OEN . W HO M o de l L is t 2 0 07

p u n t id a k m e n ea n tu m k an k o lk h is in l ag i.

U nt uk k elo mp ok a nt ia mu ba d ita mb ah ka n d ilo ks an id f ur oa t t ab 5 00 m

p er lu ny a p en g ob at an k is ta y an g t id ak m e nu n ju kk an g e ja la . D a la m h

d it am b ah ka n a rt es un a t i nj i .v /i .m 6 0 m g /m l y an g e fi ka si ny a d in il ai e b ih

a r te m e th e r i nj , m e s k ip u n d a ri s e gi p e m ak a ia n a r te m e th e r l eb ih p r ak ti s t er u

P u sk es m as . P a da k el om p ok a n ti vi ru s p ro te as e i nh ib it or d it am b ah ka n t

k ar en a s an ga t d ib ut uh ka n u ntu k H IV /A ID S , w ala u h ar ga ny a m ah al. D

a ntitu be rku lo sis , s ela in d ise dia ka n b eb er ap a o ba t d ala m b en

d ie a nt u mk a n b e b er a pa k om bi na s i u n tu k k e pe n ti ng a n p r og r am . N am u n, d a la

s ed ia a n d is er ah ka n k ep ad a k eb u tu ha n p ro gr am , a pa ka h b er be nt uk F D

combinat ion) a ta u k om b ip ak . S e di aa n t un gg al m a si h d ip er ta ha nk an u n

d a la m p e la y an a n k e se h a ta n y a ng b e lu m m e la k sa n ak a n p r og r am d i r e ct ob s e

shor t course (DOTS ) .

2 . A ne st etik

2 .1 . A n es te tik L ok al

D i us u lk a n l id o ka in i nj ek s i 5% + g lu ko sa 7 ,5 % , a m p 2 m l, u nt uk m a su k d al am

D O EN , k hu su sn ya u nt uk a ne ste si s pin al, te ru ta ma d i d ae ra h y an g s uk ar

m e n da p a tk a n b u pi va k ai n. S e la in i tu , e f ek t ok s ik t e rh a d ap j an t un g l eb ih k e ci l.

L id ok ain in j 1 % ( HC I) + ep ine frin 1 : 20 0.000 ke masan 20 dan 30 m l

d ik e lu a rk a n d a ri D OEN , k a re n a k em as a n d in il ai t e rl al u b e sa r , s e hi ng g a a k an

m em p erm u da h k o nt am i na s i j ik a d ig u na k an b e ru la n g.

2 .2 . A ne st et ik U m um D an O ks ig en

U s ula n is oflu ra n e air an ih la r. 3 - 3 ,5 % , b tl 2 50 m l d it er im a d ala m D O EN

k ar en a m e m il ik i k el eb ih an t er ha da p ja n tu ng d a n d ig u na ka n u nt uk k ea d aa n

p a si en t er te n tu . S e la in i tu m id az ola m i nj i . v . 1 mg /m l da n in j i . v . 5 m g /m l,

8 . A n ti ne op la st ik , I mm u no su pr es an d an T e ra p i P a l ia ti f

K lo rm e ti n d a n l ev am is ol d ik el ua rk an d a ri D O E N, k ar en a t id ak l ag i d ig un

a nt ik an ke r m e ng in ga t e fi ka si d an k ea m an an ny a. O le h t im a hl i d iu su lk an




p e na m b ah a n d a un o ru b is in H C I s e rb u k i nj 5 0 m g , k l o ra m bu s il t ab le t 2 m g d a n m e lf al an t ab

2 m g . D a un o ru b is in m e ru p ak a n p e ng o ba ta n u ta m a p a d a L e uk em i a L im fo s it ik A k ut y a ng

b a ny a k d it em u ka n p a da a n ak -a n ak . K lo ra m b us il h a rg a ny a m u ra h , t e rd a ft ar d i I nd o ne s ia

d an s es ua i d en ga n W H O M od el L is t. M e lfa la n m e ru pa ka n o ba t m u ra h d an s an ga t

d i pe r lu k a n d a lam p e n go b a ta n mu l ti p le m ye l oma .

P a da s u bk e la s t er ap i a n ti ps ik os is d iu su lk a n p e na m ba h an m e ti lf en id a t r as e

bentuk r e gu la r r e le a se da n e x te n de d r e le a se , u n tu k m e n ga ta si A t

H ype r a ct iv e D i so rd e r ( AD H D ). M e sk i b u kt i (ev i dence) b e lu m s ep e nu h ny a

n a mu n s el am a i ni m e ru p ak an o b at t er pi li h u n tu k A D H D. P e na m ba h an k lo z

k a re n a m e ru p ak a n o b at t er pi li h u n tu k y an g s u da h r es is te n t er ha d ap a n ti ps ik

i ni e fe k ti f n a mu n p e rl u d iw a sp a da i t er ja d in y a a g ra n ul os it os is . P e ng u ku ra n

s e c ar a b e r ka l a s e b ai k ny a d i la k u ka n .4 . O ba tG ig i D an M ulu t

D a r i k e l a s t e ra p i i n i c u k up b a n ya k o b a t y a n g d i ni la i s u d ah o b s ol e t, b a h ka n p e n g gu n a a nn y a

s u da h t id a k d ia ja rk a n l ag i d i F a ku lt as K e do k te ra n G ig i, s ep e rt i p re p ar at s u lf a cones da n

p a st a i od o fo rm . A d a p u la y a ng m e ni m bu lk a n m a sa la h p e nc e ma ra n l in g ku n ga n , s ep e rt i

p en gg un aa n a ma lg am , o le h k are na itu d is ep ak ati b ah wa a ma lg am d ig an ti d en ga n

kompos i t .

2 8 . O b a t T e l in g a , H i d u n g d a n T e n g g o ro k a n.

P e ru b ah a n b e rm a kn a t er ja d i j ug a p a da o b at t et es t el in g a, h id u ng d a n t en g

p er tim b an ga n p ar a a hl i b ah w a p en go ba ta n i nf ek si te li ng a ti da k p er lu

a n ti bi ot ik m a up u n k or ti ko s te ro id . S e la in i tu s e di aa n a n ti bi ot ik d a la m b e nt u

a t au t e li n g a t id a k t e rc a n tum d a lam WHO M o d el L is t.1 7 . O b a tK a r di o va s ku l er

P ad a k ela s te ra pi in i d ila ku ka n b eb era pa p eru ba ha n te mp at s ub ke la s te ra pi a ta u

d i ke l ua r ka n k a re n a t id a k l a gi d i pr o d uk s i d a n t id a k t e rs e d ia d i p a s a r a n s e p er ti p r ok a in am i d,

r e se r pi n , k u in i di n . P a d a s u b ke l as t e ra p i a n ti a ri tm i a d i tam b a h ka n am i od a ro n d a n d i g ok s in .

D a la m s ub k el as a n ti hi pe rt en s i d it am b a hk a n i nj ek si n a tr iu m n it ro p ru si d, y a ng e fi ka s in ya

s a n ga t b a ik u n tu k p em b e da h a n d e n g an t e kn i k h i po t en s i d a n s e p ti k s y ok .

D . P en ye rb ar lu as an D OE N 2 00 8

D a la m r an gk a p en er ap an k on se p o ba t e se ns ia l, m ak a D O EN 2 00 8 h ar us d is e

s a ra n a p e la y an a n k e se h at an d i s e lu ru h I nd o ne s ia . P e ny e ba rl ua s an d a pa t b e ru p

b uk u y an g d ik ir im ka n k e s ar an a p el ay an an k es eh at an a ta u d ip ub li ka sik an

elek t ronik .1 8 . O b at To p ik al

D a ri k e la s t er ap i i ni b a ny a k o b at y a ng d il ke lu a rk a n t er ut am a k a re n a s u da h o b so le t a n ta ra

l ain g en ti an v io le t, s al ep l ev er tr an . B eb er ap a c air an s ep er ti l oti o k um m er fe ld i, j ik a

d i pe r lu k a n, d a p at d im a s u kk a n d a lam f o rm u l ar ium r um a h s a k i! .

T a m ba h an b a ru y a ng d it er im a d a la m D O E N a d al ah p e rm e tr in s eb a ga i a n ti sk a bi es y a ng

k u ra n g t ok si k b a gi a n ak , m e ng g an ti ka n g a me k sa n . P e na m b ah a n l ai n a d al ah l iq u or v e il li

y a it u o b a t s e d e r ha n a y a n g e f ek t if m e n g a ta s i d e rm a t it is b a s ah .

2 0 . L ar ut an E le kt ro li t d a n N u tr is i

G ar am o ra li t k em a sa n 1 00 0 m l d ik elu ar ka n d ar i D O EN , k ar en a k em a sa n t er la lu b es ar ,

k u ra n g e fi si en d a la m p e ny im p a na n d a n t id a k l ag i m e n ja m in k e se g ar an l ar ut an . D e ng a n

d e m ik ia n h a ny a t er se d ia k em a sa n 2 0 0 m l .

D a la m h a l c a ir an n u tr is i p a re n te ra l y a it u l ar ut an n u tr is i I V, s e m ua d ik e lu a rk a n d a ri D O E N.

K o m Na s D O E N, t er ut am a t im a h li d a n k o ns u lt an , s a ng a t m e ny a da ri p e nt in g ny a s e di aa n i ni ,

a k an t et ap i k o mp o si si s ed ia a n y a ng a d a d i p a sa ra n b e rv a ri as i, d e ng a n k e bu tu h an y a ng

m u n gk in b e rb e da . U n tu k i tu d iu s ul ka n a g ar k e bu tu h an a k an s ed ia a n i ni d it am p u ng d a la m

f o rm u l ar ium r um ah s a k i! .

U n tu k k ep e nt in g an a n ak d a n n e on a tu s d a la m k e la s t er ap i i ni d it am b ah k an l ar ut an n u tr is i :

g lukosa4% + N aC I 0 , 1 8% i n fu s , d a n n a tr ium b i ka r b on a t i n j 1 , 4% i s ot o ni k.

2 3 . P s ik o fa rm a ka

A lp ra zo la m d ik el ua rk an k ar en a d in il ai ti da k e se ns ia l d an c en de ru ng m e ni mb ulk an

o ve r u se d d an k et er ga ntu ng an . D al am s ub ke la s te ra pi a nti de pr es i d an a nt im a ni a,

d iu su lk an p e na m ba h an f lu o ks et in , s e rt ra li n d a n p a ro k se ti n. F lu o ks e ti n k a p/ ta b 1 0 m g

d a n k ap /t ab 2 0 m g , d i te ri ma u n tu k p il ih a n g o lo n ga n S S R I.

1 8Daftar Obat E sensial Nasional2008 Daftar Dbat Esensial Nasional2008



BABII

DAFTAR OBAT ESENSIAL NASIONAL 2

KELAS TERAP I ,

N A M A G E NE RI K

FORMULASI( Be n tu k S e d ia a n ,

K e ku a ta n , d a n K em a sa n )

RESTR

1 . A N AL GE SI K, A N TI PI RE TI K, A N TI IN F LA M AS I N ON S TE RO ID , A N TI PI RA I

1.1 A NALGES IK N ARK OTIK

BABII fentani l

DAFTAR OBAT ESENSIAL NASIONAL 2008 kodein

inj i . m . l i . v . 0,05 m g / m l ( se ba ga i P e ng gu na an p e

s it ra t) , k tk 5 a mp @ 2 m l

ta b 1 0 m g , b tl 2 5 0 t ab

m orfin in j i.m .ls .k.li.v . 10 m g / m l

(HCl/sul fat),

k tk 10 a mp @ 1 m l

t a b 1 0 mg (HC l/ s u lf a t) ,

pe tid in in j i.m .ls .k.li.v . lambat 50 m g / m l

( HC I) , k tk 1 0 a m p @ 2 m l

sufen tan il in j 5 m c g / m l (sebaga i s i t ra t ) ,

k tk 5 via l @ 1 0 m l

1 .2 A N A LG E SI K N O N -N A R KO T IK

a sa m a se ti ls ali si la t ( as et os al) t ab 1 00 m g , k t k 1 0 b l s @ 1 0 t a b

t ab 5 00 m g , k t k 1 0 b l s @ 1 0t ab

fen ilbu tason tab sa lu t 200 mg,

b tl 1 0 0 / 1 0 0 0 t a b

P em ak aia n d

k ea da an a ku

m akan dan ha

m ing gu , ke mu

d il an ju t ka n d e n

y a ng l eb ih a m a

ibupro fen tab 200 mg, btl 100 tab

t ab 4 00 m g , b t l 1 0 0 t ab

ke topro fen sup 100 m g D igunakan u ntu

p a s c a ope ras i




KELAS TERAP I,FORMULASI

(Ben tuk Sed iaan , RESTRIKSINAMA G ENERI K

Kekua t an , d a n Kema sa n )

metamp iron tab 500 m g , bt l 1000 t ab P em aka ian supaya diba tasi

un tuk m engurang i e fe k

s am p i ng a g ra n u lo s it o si s.

na trium dik lo fenak tab 2 5 m g, k tk 1 0 str@ 10 tab

ta b 5 0 m g, ktk 1 0 s tr@ 1 0 t ab

pa rasetam ol tab 1 00 m g , bt l 1000 tab

ta b 5 00 m g , b t l 1 0 00 t ab

s ir 1 2 0 m g / 5 m l, b tl 6 0 m l

s up 1 20 m g

s up 2 40 m g

1 . 3 . ANT I P IRA I

alopurino l tab 100 mg , bt l 1 0 0 / 1 0 0 0 tab - M enghamba t p roduks i

a s am u ra t ( 35 % p e nd e ri ta )

- T id ak d ib erika n s ew ak tu

s e ra n g an a k u t

probenes id tab 500 mg , bt l 1 0 0 / 1 0 0 0 tab - M em pe rc ep at e ks kre si

a sa m u ra t d i g in ja l, te rja di

p ad a 6 5% pe nd erita .

- D os is 2 X Y, t a bl e t d e n ga n

b a n ya k m i n um .

- T id ak d ib er ik an sewaktu

s e ra n g an a k u l.

2 . A N E S TE T IK

2 .1 A NE ST ET IK L OK AL

bupivaka in in j p . v . 0 , 50% ( HC I) ,

k tk 5 via l @ 20 m l Khusus untuk ana lgesia

i n j 0 , 5% ( HC I) + g lu ko sa 7 ,5 %, sp in al.

k tk 5 am p @ 4 m l

etil klorida sem p rot, btl 100 m l Kem asan ha rus k edap u da ra.

lidokain in j in f iltr 1% (HCI),

k tk 1 00 am p @ 2 m l

inj p . v . 2% ( HC I) ,

k tk 1 00 a mp @ 2 ml

j el i 2 % , tu be 1 0 9

s em p ro t 4 %, b tl 5 0 m l

i nj 5 % + g lu ko s a 7 ,5 % , K hu su s u ntu k a na lg esia

amp2 m l spinal .

2 2Daftar Obat Esensial Nasional2008

RESTRFORMULASI

KELAS TERAP I, (Bentuk Sed iaan ,N AMA G E NERI K

~ ~ K ~ e ~ k ~ u a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a ~ n

2 .2 A NE ST ET IK U M UM d an O KS IG EN

halotan cairan ih , btl 5 0 / 2 5 0 ml

isoflu ran cairan i h , btl 250 m l

ke tam in in j i . v . 10 m g / m l ( s eb a g ai H C I) ,

k tk 1 0 v ia l @ 2 0 m l

inj i . v . 50 m g / m l ( s eb a g ai H C I) ,

k tk 1 0 v ia l @ 2 0 m l

inj i . v . 1 m g / m l

inj i . v . 5 m g / m l

i h, g a s d a la m t ab u ng

U n tu k p e ng g un aidazolam

n i t rogen ok s i da

oksigen ih , gas dalam tabung

p ropofo l in j 10% , ktk 5 am p @20 m l

tiopenta l serb in j i . v . 50 0 m g / a m p

( g ar am N a ) ( u nt u k d i la r ut ka n

d im 2 0 m l a ir i nj ek si ),

k tk 2 5 a mp

2 .3 P RO SE DU R P RE O PE RA TIF , O BA T u nt uk

a trop in in j 1 m g / m l (sulfat),

k tk 50 amp @ 1 m l

d ia zepam tab 5 m g , bt l 1000 tab

i nj 5 m g / m l , k tk 10 0 a mp @ 2 m l

m o rf in in j i.m .ls .k .li.v . 10 m g / m l

(HCl/sulfat),

k tk 10 a mp @ 1 m l

3 . A N TI AL ER G I d an O B AT u n tu kA N A FI LA K S IS

deksam e tason in j 5 m g / m l ( s ebaga i na t ri um

fo sfa t) , k tk 1 00 a mp @ 1 m l

d ifenhidram in in j i.m .10 m g / m l (HCI ) ,

k tk 10 0 a mp @ 1 m l




KELAS TERAP I,

N A M A G E NE RI K

FORMULASI

( B en t uk S e d ia a n ,

K e ku a ta n , d a n K e ma s an )

RESTRIKSI

ep i nef r in ( ad rena l in )

klorfeniramin

i n j s . k. li .m . 0 , 1% ( s eb a g ai

HCI/bitartrat),

ktk 1 00 am p @ 1 m l

ta b 4 m g (m al ea t) , b tl 1 00 0 ta b

i n j 5 m g /m l ( m al e at ),

ktk 1 00 am p @ 1 m l

- T er pi li h u ntu k a na fil ak sis

- D os is 0 ,3 m g - 0 ,5 m g, b is a

diu lang

4. A N TI DO T d an O BA T L AI N u n tu k K ER A CU N AN

4.1 KHUSUS

atropin

deferoksamin

k a l si um f o li na t

( I euk ov o ri n , Ca l

k a l si um g l uk ona t

me t il t i on i n k l o ri da

( b i ru me t i len )

nalokson

na t ri um b i k a rbona t

na t ri um t i os u l fa t

p r o tam i n s u l fa t

24

i n j i . m .l i. v. ls .k 1 m g /m l ( su l fa t ),

ktk 1 0 am p @ 2 m l

s e rb i n j 5 0 0 m g /m l ( m e si la t ),

ktk 1 0 v ia l @ 1 0 m l

ta b 1 m g, b tl 1 00 ta b

ta b 1 5 m g , b tl 1 0 t ab

in j 3 m g/m l, k tk 1 0 a mp @ 1 m l

i n j 1 0 0 m g /m l ,

k tk 2 4 a m p @ 10 ml

inj i . v . 1 0 m g /m l ( se b ag a i

d ih id ra t) , k tk 1 0 a m p @ 1 0 m l

i n j 0 , 0 2 m g /m l ( H CI ),

ktk 1 0 a mp @ 2 m l

i n j 0 , 4 m g /m l ( H CI ),

ktk 5 am p @ 2 m l

ta b 5 00 m g, b tl 1 00 0 ta b

inj i . v . 2 5% , k tk 1 0 a mp @ 10 m l

i nj i .m .1 0 m g /m l,

ktk 1 0 v ia l @ 5 m l

Dalam label perlu

d ic an tu mk an p er in ga ta n

"h an ya se ba ga i a ntid ot"

( dos is bes a r ).


RESTRFORMULASI

KELAS TERAP I , ( Be n tu k S e d ia a n ,N A M A G E NE RI K

~ ~K~e~k~ua~t~an~,~d~an~K~em~a~s~a

4.2 UMUM

apom orfin in j s.k. 5 mg /m l (H CI),

k tk 10 a m p @ 1 m l

karbon a ktif serb a k tif, k tg 0,5 k g

m agnes ium su lfa t serb, k tg 30 9

5. ANTI EP IL EP S I - A N TI KON V ULS I

d iazepam in j i . m . l i . v . 5 m g /m l ,

k tk 10 0 a mp @ 2 m l

la r r e kta l4 m g/m l, t ub e 2 ,5 m l

fenito in kaps 30 mg (ga ram N a ),

b tl 2 5 0 k ap s

k ap s 1 00 m g ( ga ra m N a) ,

b tl 2 5 0 k ap s

i nj 5 0 m g /m l ( ga ra m N a ),

k tk 10 a m p @ 2 m l

s ir 5 0 m g/5 m l, b tl 1 20 m l

fenobarbita l tab 30 m g , btl 1000 tab

ta b 5 0 m g, b tl 1 00 0 ta b

ta b 1 00 m g, b tl 1 00 0 ta b

i nj i .m 5 0 m g /m l,ktk 1 00 a mp @ 2 m l

inj i . v . 5 0 m g /m l ( se ba g ai g ar am

N a), k tk 100 am p @ 2 m l

karbamazepin tab 2 00 m g, b tl 1 00 /1000 tab

ta b k un ya h 1 00 m g

s ir 1 00 m g/5 m l, b tl 1 20 m l

m agnes ium su lfa t in j i . v . 2 0% , a mp 2 5 m l

inj i . v . 4 0% , a mp 2 5 m l

ta b 2 50 m g ( ga ra m N a) ,

b tl 5 0 t ab

ta b 5 00 m g ( ga ra m N a) ,

b tl 5 0 t ab

s ir 2 50 m g/5 m l ( g ar am N a) ,

b tl 1 20 m l

valproat




RESTRIKSIFORMULASI



KELAS TERAP I,

N A MA G E NE RI K

6 . A N T II N FE K S I

6 .1 A N T E L M IN T IK

6 . 1. 1 A n t e lm i n ti k I n te s ti n a l

a lben dazo l tab 4 00 mg, ktk 5 str @ 6 tab Un t u k s t ro n g il 0 id e s .

D os is un tuk anak 20

mg/kgBB

m ebendazo l tab 1 00 m g, b tl 100 tab

s ir 1 00 mg/5 m l, b tl 3 0 m l

p iran te l tab scored 250 m g (se baga i

p a mo a t) , b tl 2 50 t ab s co re d

s us p 1 25 mg/5 m l ( s e b aga i

p am oa t) , b tl 3 0 m l

praziku an te l tab s cored 300 m g,

btl 100/ 1000 t ab s co r ed

6 . 1. 2 A n t i fi la r i a

d ie tilka rbamaz in tab scored 100 mg (sitra t), D ised iakan untuk dae rah-

b tl 1 000 tab daerah endem is fila r ias is.

6 . 1. 3 A n t i si s to s om a

praziku an te l tab 600m g,b tl100 tab - H anya untuk daera hSu l awe si T e ngah .

- Kh usus d i Ka lim antan

S e la t an u n tu k p e ng o ba t an

F a sc i% p si s b u sk i.

6 .2 A N T IB A K T E R I

6 .2 .1 B e ta l ak ta m

am oksis ilin tr ih id ra t tab scored 500 mg,

k tk 1 0 s tr @ 1 0 t ab sco re d

s ir k er in g 1 25 mg/5 m l, b tl 6 0 m l

s e rb i nj i .m . li .v . 2 5 0 m g / vi al

( se ba g aig a ra m N a ),

k tk 1 0 v ia l

ampisi l in

s e rb in j i .m . li .v . 5 0 0 m g /v ia l

( se ba g ai ga ra m N a ),

k tk 1 0 v ia l

2 6Daftar Dbat Esensial Nasional2008

FORMULASIKELAS TERAP I, ( Be n tu k S e d ia a n ,N A M A G E NE RI K

~ ~ K ~ e ~ k u ~ a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a = n

s e rb i nj i .m . li .v . 2 5 0 m g /v ia l

( s eb a ga i g a ra m N a ) ,

k tk 1 0 v ia l


( s eb a ga i g a ra m N a ),

k tk 1 0 v ia l

i nj i .m . 1 ,2 j ut a U l /m l ,

k tk 2 5 v ia l @ 4 ml

i nj i .m . 2 ,4 j ut a U l /m l ,

k tk 2 5 v ia l @ 1 0 m l

ampisi l in

benza t i n benz i l pen is i l in

benz i l pen is i l in k r i s ta l

dik loksasi l in

f e n o ks ime ti l p e n is i li n( p e n is i li n V )

proka in benz i l pen is i l in

sefazol in

seftriakson

RESTR

i n j i .m . l i. v . 1 0 j u ta U l /v i a l,

k tk 2 5 v ia l

k ap s 2 50 m g ( se ba ga i g ar am

N a ), k tk 2 5 s tr @ 4 k ap s

t ab s co re d 5 00 m g ( se ba ga i

g ar am N a )

s i r 6 2 , 5 mg/5 m l ( s e b aga i

g ar am N a) , b tl 6 0 m l


( s eb a ga i g a ra m N a ) ( u nt u k

d il ar u tk a n d a la m 5 m l ai r

i nj ek s i) , k tk 2 0 v ia l

t ab 5 00 m g ( se ba g ai g ar am K ),b t l 1 0 0 0 t ab

t ab 2 50 m g ( se ba g ai g ar am K ),

k tk 1 0 s t r @ 1 0 t a b

s ir k e ri ng 2 5 0 mg/5 ml

( se ba ga i g a ra m K ), b tl 6 0 m l

s e rb i nj i .m . 3 j ut a U l /v ia l,

k tk 1 0 0 v ia l

s e rb i nj i .m . 1 j u t a U l / vi al ,

k tk 1 0 0 v ia l

s er b in j 1 9 1 v ia l, k tk 2 v ia l D ig un ak an p ad

bedah untuk

t er ja d in y a i nf ek i

s er b in j 1 9 1 v ia l, k tk 2 v ia l






(Ben tuk Sed iaan , RESTRIKSI (Bentuk Sed iaan , RESTRNAMA GENERIK NAMA GENERIK

Kekuatan, dan Kemasan) Kekuatan , dan Kemasan)

6 .2 .2 A n ti b ak t er i L a in t r im e top rim tab scored 2 00 m g,

b tl 1 0 0 t a b s co re d6 . 2 .2 . 1 T e t ra s i k li n

doks is ik lin kaps 100 m g(sebagai h ik lat lH C I), D a pa t d ig u na ka n p a d a p a s ie n 6 . 2. 2 .4 M a k ro li dk tk 1 0 s tr@ 1 0 k ap s d e n ga n g a g a l g i nj a l

e ritrom is in kaps 2 50 m g (sebaga i s tea rat),

in j i . v . 2 5 0 m g /3 m l ( H CI ),b tl 1 0 0 k a ps

oksitetrasiklins ir 2 0 0 m g /5 m l ( se b ag a i e ti l

k tk 1 0 am p @ 3 m ls u ks in a t) , b tl 6 0 m l

in j i . v . 5 0 m g /m l ( H CI ),k tk 1 0 v ia l @ 1 0 m l

k lindam is in in j 1 50 m g/m l (sebaga i fo s fat), K husus un tuk in

k a ps 2 5 0 m g ( HC I) ,k tk 1 00 a mp @ 2 m l

tetrasiklin

b tl 1 0 00 k a ps

6 . 2 .2 . 5 Am i nog l ik o s i daa ps 5 00 m g ( HC I) ,

k tk 1 0 s tr@ 1 0 k ap sgentam is in in j 1 0 m g /m l ( sebagai su lfat),

k tk 1 00 a mp @ 2 m l

6 . 2 .2 . 2 K l o ram fe n i k o l i n j 4 0 m g / m l ( s eb a g a i s u lf a t) ,

k lo ram fen iko l kaps 2 50 m g , b tl 1 000 k aps k tk 1 0 a mp @ 2 m l

s u sp 1 2 5 m g /5 m l ( se b ag a i

p a lm i ta t) , b tl 6 0 m l 6 . 2. 2 .6 K u i no l ons e rb i nj i . v . 1 0 0 m g /m l

s ip rof lo ksas in tab s cored 500 m g ( sebaga i HC I), T id ak s eb ag ai( s eb a g ai N a s u ks i na t ),

k tk 1 0 bls @ 10 t ab sco red un tuk infeks ik tk 1 0 v ia l @ 1 0 m l

posit if .

6 . 2 .2 . 3 Su l f a -T r im et o p r imvankom is in se rb i n j 500 m g /v ia l, k tk 1 via l L ife s av in g

kotrim oksazo l D OEN I tab , k tk 1 0 s tr@ 10 t ab MRSA

( de w as a ) k o mb in a si :

s u lf am e to k sa zo l4 0 0 m g 6 .2 .2 .7 P en g gu n a an K h u su s

t r im e top rim 80 m gm e tron idazo l tab 2 50 m g , b t l 100 /1 000 tab

ta b 5 00 m g , b t l 1 0 0/1 00 0 t abko trim oksazo l D OEN II tab , bt l 1 00 t ab

s up 5 00 m g, k tk 6 s up( p e di a tr ik ) k om b in a s i :

l ar i nf us 5 m g /m l, b tl 1 00 m ls u lf am e to k sa zo l1 0 0 m g

trim e top rim 20 m gsu lfa sa la z in tab 500 m g , bt l 500 tab P em aka ia n k

co l i t is u l ce ra li vakotrim oksazo l D OEN III in j i . v . , k tk 5 a mp @ 5 m l, P erlu p ertim ba ng an y an g

kom b inas i: k tk 5 v ia l @ 10 ml ba ik , hanya un tuk kondis i

6 .3 A N TI IN F EK S I K H U SU Sulfam e toksazol 80 m g/m l da ru ra t.

trim etop rim 16 mg /m l6 . 3 .1 An t i le pra

sulfad ia z in tab 500 m g , bt l 100 tab dapson tab scored 100 m g,

b tl 1 0 00 t ab s co re d

8Daftar Dbat Esensial Nasional2008 Daftar Obat Esensial Nasional 2008



FORMULASIKELAS TERAP I, ( B e n t u k S e d i a a n ,N A M A G E NE RI K

~ ~ K ~ e ~ k ~ u a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a ~ n . ) ~ ~

k ap s d al am m in ya k 1 00 m g ,

b tl 1 0 0 k a ps

FORMULASIKELAS TERAP I, ( B e n t u k S e d i a a n ,N A M A G E NE RI K

~ ~ K ~ e ~ k u ~ a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a ~ n ) ~

RESTRESTRIKSI

Kombinas i :

ri fampisin

isoniazid

pirazinamid

e tambuto l

k lofazimin, micron i zed

k ap l1 50 m g; 4 5 0 m g

ta b 7 5 m g; 3 00 m g

ta b 4 0 0 m g; 5 00 m g

ta b 2 7 5 m g; 2 50 m g; 5 00 m g

B entuk sed i

p en gg un aa n s

p ro gr am T B p arifamp isin kaps 300 mg,

k tk 1 0 s tr @ 1 0 k ap s

P e ng gu na an t er ba ta s u nt uk

l e pr a d an t u b er k u lo s is

6 .3 .3 A n ti se p ti k S a lu ra n K e m ih

kotrimoksazo l DOE N I tab , ktk 10 s tr @ 10 t ab

( d ew a sa ) k o mb in a si :

s u lf am e to k sa z ol 40 0 m g

tr im etoprim 80 m g

6 . 3 .2 A n t i tu b e r ku l o s is

etambuto l tab 250 m g (HCI), b tl 100 tab

t ab 5 00 m g ( HC I) , b tl 1 00 t ab

ison iazid tab 100 mg, btl 1000 tab

t ab 3 00 m g , b t l 1 0 0 0 t a b

me t e n am i n mande la t

( h e ks am in mande la t )

t ab s a lu t e n te r ik 5 0 0 m g ,

b tl 10 0 / 1 0 0 0 t a biraz inam id tab 500 m g, btl 1 00 tab Khusus u ntuk R STP

( R S T u b er k ul os a P a r u) .

n itro fu ran to in tab scored 100 m g,

b t l 1 0 0 t ab s co r edifamp isin tab scored 300 mg,

k tk 1 0 s tr @ 1 0 t ab

t ab 4 50 m g, k tk 1 0 s tr @ 1 0 t ab

t ab 6 00 m g, k tk 1 0 s tr @ 1 0 t ab

H a ny a u nt uk t ub er ku lo sis

d a n l e p ra .

trimetoprim tab scored 2 00 mg,

b t l 1 0 0 t ab s co r ed

6 .4 A N T IF U N G Istrep tom isin serb in j 1000 m g l v i a l (sebaga i

s u lf at ), k tk 1 0 0 v i a l 6 . 4. 1 A n t i fu n g i, s i st e m ik

amfoteris in *) i n j. i . v. , v i a l 5 0 m g / 1 0 m l,

v ia l @ 1 0 m l

*) Penggunaan

k eah li a n k h u

Kombinas i :

ri fampisin

isoniazid

k ap l1 50 m g; 7 5 m g

t ab 1 50 m g; 5 0 m g

Bentuk sed iaan dan

p en gg un aa n s es ua i d en ga n

p r og r am T B p a ru n a s io n a lgriseofulv in, micron i zed t ab s co re d 2 50 m g ,

b t l 1 0 0 t ab s co r ed

Kombinas i :

ri fampisin

isoniazid

e tambuto l

k ap l1 50 m g

t ab 1 50 m g

t ab 4 00 m g

Bentuk sed iaan dan


p ro gr am T B p ar u nas iona l

ketokonazo l tab 200 m g, btl 100 tab I n di ka s i d ib a ta s

k an did ia sis

k ro nis y an g t i

t er ha da p n is ta t

o ba t la in , in f

s is te m ik ( ka

p a ra ko ks i -

dan la i n -l a i n ) .

Kombinas i :

ri fampisin

isoniazid

pirazinamid

k ap l1 50 m g; 7 5 m g ; 4 5 0 m g

tab 7 5 m g; 5 0 m g ; 3 00 m g

t ab 4 00 m g; 1 50 m g; 5 00 m g

Bentuk sed iaan dan


p r og r am T B p a ru n a s io n a l

n ista tin tab sa lu t 500 .000 U l/tab

b tl 10 0 / 1 0 0 0 t a b

s us p 1 00 .0 00 U l/ ml, b ot ol 12 m l

3 0Daftar Dbat E sensial Nasional2008 Daftar Obat E sensial Nasional 2008



KELAS TERAP I,N A M A G E NE RI K

FORMULASI



RESTRIKSI

6 . 4 .2 An t i fung i , t o p ik a l

A n t if un g i D OEN

kombinas i :

a sa m b en zo a t 6 %

a sa m s al is il at 3 %

mikonazo l

na t r i um t i osu lfa t

nistatin

6 .5 AN T IP RO T O ZO A

s ale p , p ot 3 0 9

s er b 2 % ( ni tr at ), k tg 2 0 9

k ri m 2 % ( ni tr at ), t ub e 1 0 9

c air an 2 5% , b tl 3 0 m l

t a b v a gi na 1 0 0 .0 0 0 U I /t a b,

k tk 1 0 s tr @ 1 0 t ab

6 .5 . 1 A n t iam u b a d a n A n t ig i ar d ia s is

d iloksan id tab 500 mg (fu roa t)

met ron idazo l

6 . 5 .2 An t ima la r i a

t ab 2 50 m g , b t l 1 0 0 t ab

t ab 5 00 m g , b t l 1 0 0 t ab

6 .5 . 2. 1 U n tu k P e n ce g a ha n

klo roku in tab 1 50 mg (sebaga i fosfa t),

b tl 1 0 00 t a b

6 .5 . 2. 2 U n tu k P e n g ob a ta n

A n t im a la r ia D OEN

kombinas i :

p ir im eta min 2 5 m g

s ulf ad ok sin 5 00 m g

artemether

ar tesuna t

3 2

t ab , b tl 5 0 0 t ab

i nj 8 0 m g /m l ,

ktk 6 am p @ 1 m l

inj i . v . l i . m . 6 0 m g /m l

ktk 8 via l @ 1 m l

U nt uk d ae ra h- da er ah y an g

t er d ap a t r e si st e ns i t e rh a d ap

k lo ro ku in y an g d it et ap ka n

o leh D inas K eseha tan

Kabupaten .


RESTRFORMULASI

KELAS TERAP I, ( Be n tu k S e d ia a n ,N A M A G E NE RI K

~ ~ K ~ e ~ k u ~ a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a =

kombinas i :

a rte su na t ta b 5 0 m g

a m od ia ku in t ab 2 00 m g

klorokuin

kuinin

pr imaku in

6 .6 A N T IV IR U S

6 . 6 .1 An t i h e rpes

asik lovir

6.6.2. Ant iret rovira l

k tk , 2 b ls @ 1 2 t a b ( ko m bi pa k)

k tk , 3 b ls @ 8 ta b

t a b 1 5 0 m g ( s eb a g ai f os fa t ),

b t l 1 0 0 0 t ab

s ir 5 0 m g /5 m l, b tl 6 0 m l

t a b 2 2 2 m g ( b is u lf a t) ,

b t l 1 0 0 0 t abinj i . v . 2 5% ( s eb a ga i H C I) ,

k tk 1 00 a mp @ 2 m l

t a b 1 5 m g ( s eb a ga i f o sf a t) ,

b t l 1 0 0 0 t ab

t ab s co re d 2 00 m g

t ab s co re d 4 00 m g

6 . 6. 2 .1 . N u c le o s id e R e v er s e T r an s c ri p ta s e I n hi b it o r ( N R TI )

lam ivud in ( 3 TC ) tab 150 mg

stavudin

zidovudin

t ab 3 0 m g , b tl 6 0 ta b

t ab 4 0 m g, b tl 6 0 ta b

t ab 3 00 m g, b tl 6 0 t ab

t ab 1 0 0 m g , b tl 1 00 t ab

s ir 5 0 m g /5 m l, b tl 1 0 m l

l a r i n f u s i . v . 2 00 m g/1 0 m l

6 . 6. 2 .2 N o n N u c le o s id e R e v er s e T r an s c ri p ta s e I n h ib i to r ( N N RT I)

efavirens tab 200 mg, b tl 90 tab

t ab 6 00 m g, b tl 3 0 t ab

nevirapin

6 . 6. 2 .3 P r o te a se I n h ib i to r

lopinavir

ta b 2 00 m g, 6 b ls @ 1 0 ta b

tab

H a n ya u n tu k

gawat .

Daftar Obat Esensial Nasional 2008





(Ben tuk Sed iaan , RESTRIKSI (Bentuk Sed iaan , RESTRNAMA G ENERI K

Kekua t an , d a n Kema sa n )N AMA G E NERI K

Kekua ta n , d a n Kemas a n )

7 . A N TI M IGREN daktinom is in in j i . v . 0 , 5 mg / v ia l ,

7 . 1 P RO F IL AKS ISk tk 1 v ia l 0 , 5 m g

dihidroergo tam in tab 2,5 mg (sebagai m es ilat), daunorubis in serb in j 20 m g /v ia l (HCI),

k tk 1 0 s tr@ 1 0 t ab ktk 1 v ia l @ 4 m l

prop ranolo l tab scored 40 m g (H CI)dokso rubisin serb in j i . v . 1 0 m g /v ia l ( H CI ),

b tl 1 0 0 t a b s co re dk tk 1 v ia l @ 5 m l

7 .2 S ER A NG A N A K UT s er b i nj i . v . 5 0 m g /v ia l ( H CI ),

ergo tam in tab 1 m g ( tartrat), btl 100 tabktk 1 v ia l @ 2 5 m l

komb inasi: tab, ktk 30/100 tabe toposid in j 20 mg /m l, k tk 10 am p @ 5 ml

ergotam in 1 mgk ap s 1 00 m g, b tl 1 0 k a ps

ka fein 50 mg fluo rouras il in j i . v . 5 0 m g /m l ,

k tk 10 am p @ 5 m l

8 . A N TI NE OP LA S TI K, I MU N OS UP R ES A N d an O BA T u n tu k T ER AP I P A LI AT IF

k als iu m fo lin at (Ie uko vo rin , ta b 1 5 m g , b tl 1 0 ta b8 .1 H O RM O N D A N A N TI HO R M ON Ca l in j 3 m g/m l, k tk 5 a mp @ 1 /1 0 m l

m ed ro ksi p ro ge ste ro n a se ta t ta b 2 5 0 m g, b tl 5 0 ta b

i nj 2 00 m g/m l, k tk 1 v ia l 2 , 5 m l k lorambus il tab 2 mg

tam oksifen tab 20 m g (sebagai s itrat), m elfa lan tab 2 mg Ha rus disimp

b tl 3 0 t ab 2-8°C.

tes tos te ron kaps l unak 4 0 m g (undekanoat),

m erkaptopurin tab 5 0 m g , b tl 25 tab

k tk 5 s tr @ 4 k ap s lu na km eto treksa t tab 2 ,5 m g ( sebagai garam Na),

b tl 1 00 t ab

8 .2 . I M UN O S UP R E SA N s er b i nj 5 0 m g /v ia l ( se b ag a i

azatioprin tab 50 mg, btl 100 tabg ar am N a) , k tk 1 v ia l

s e rb i n j i . v .l i. m .l i. t. 5 m g /v i al

s ik lo sporin kaps l unak 2 5 m g, btl 50 k aps( se b ag a i g ar am N a ), k tk 1 v ia l

in j 5 0 m g/m l, k tk 1 0 a mp @ 5 m lp roka rbaz in kaps 5 0 m g (sebagai HCI),

8 . 3 S I TO T O KS IKb tl 1 00 k ap s

asparaginase serb in j 1 0.000 U I/v ia l, ktk 1 v ia ls iklofo sfam id tab s a lut 5 0 m g, b tl 28 tab

s er b i nj i . v . 2 0 0 m g /v ia l, k tk 1 v ia l

b leom is in serb i n j 15 mg/amp (sebagai s er b i nj i . v . 5 0 0 m g /v ia l, k tk 1 v ia l

H CI), k tk 1 a mp s er b i nj i . v . 1000 mg / v ia l ,

busu lfan tab salut 2 mg, btl 100 tabk tk 1 v ia l

dakarbaz in serb in j 1 00 m g /via l, k tk 1 v ia ls isp lat in serb i n j 10 mg /v ia l, k tk 1 0 via l

s er b i nj 5 0 m g /v ia l, k tk 1 0 0 v i a l




FORMULASIKELAS TERAP I, ( Be n tu k S ed ia a n , RESTRIKSI

~ _ _ N _ A _ M _ A _ G _ E N _ E _ R _ I _ K ~ K ~ e ~ k ~ u ~ a t = a n ~ , ~ d = a n ~ K e ~ m ~ a = s ~ a n ) , ~

s e rb i n j i .m . li .v . ls . k 1 0 0 m g l v i a l ,

k tk 5 v ia l

s i tarabin

v inb lastin serb in j 10 m g l v i a l (sul fat),

k tk 1 v ia l

v inkr is tin serb in j i . v . 1 m g l v i a l (sul fat),

k tk 1 v ia l

8 .4 T E RA P I P A LI AT IF , O B A T u n tu k

morfin tab 10 mg (su lfa t), b tl 30 tab

- T idak bo leh d iberikan

seeara in t ra teka l

H a ru s d is im p an p ad a s uh u

2-8 °C

S e su ai p ro gr am p er aw a ta n

pa l ia t if r umah s a k it

A n ti pa r ki ns o n OOEN

kombinasi :

b en se ra zid 2 5 m g

le vo do pa 1 00 m g

t ab , b tl 1 00 t ab

9. ANT I PARK I NSON

triheksifen id il tab 2 m g (HCI), b tl 250 t ab

1 0 . D A RA H , O B AT y an g M E M PE N G AR U HI

1 0 .1 AN T IANEM I

asam fo la t tab 1 mg, btl 1000 tab

t ab 5 m g , b t l 1 0 0 0 t a b

t ab s al ut 3 00 m g , b t l 1 0 0 0 t a b

s ir , b t l 6 0 m l

t t s, b t l

i n j 5 0 0 m e g / m l ,

k tk 1 00 a m p @ 1 ml

b e si ( II ) s u l fa t 7 H 2 0

sianokobalamin

( v it am in B1 2 )

1 0 .2 K O A GU L A SI , O B A T y a n g M E M P EN G A RU H I

f ito me na dio n (vita min K 1) ta b s alut 1 0 m g, b tl 1 00 0 t ab

i nj 1 0 m g / m l , k tk 1 00 a m p @ 1 ml

i nj i .m 2 m g / m l , am p 1 m l

3 6

- O os is u nt uk b ay i b ar u la hir

1 mg

- O os is u nt uk b ay i p re ma tu r

0 ,5 m g


FORMULASIKELAS TERAP I , ( Be n tu k S ed ia a n , RESTR

~ _ _ N _ A _ M _ A _ G _ E N _ E _ R _ I _ K ~ K ~ e = k = u = a t = a n ~ , ~ d = a n ~ K e = m ~ a = s ~ a n ) ~

i n j i . v .l s .k . 5 0 0 0 U l /m l ,

k tk 1 v ia l 5 m l

h e pa r in , N a

p ro tam i n s u lf a t

warfarin

i nj 1 0 m g / m l , k tk 1 0 v i a l @ 5 m l P em aka ian te r

tertentu).

t ab 2 m g ( ga ra m N a /K ),

b tl 1 0 0 t a b

1 1. P RO DU K D A RA H d an P EN G G AN TI P LA S MA

1 1.1 P R OD U K D A RA H

f a k to r V I I I ( k o ns e n tr a t )

f a k to r I X k omp le k s

f r a ks i p r o te i n p l asma

s e rb i nj 2 5 0 U l lv ia l +

p el ar ut 1 0 m l , k tk 1 v ia l

U n tu k h a em o fi li


p el ar ut 2 5 m l, k tk 1 v ia l


p el ar ut 1 0 m l , k tk 1 v ia l

U n tu k h a em o fi li

H ar us d ip ro du

benar

h y d ro x y e t hy l s ta r ch

1 1.2 P EN G GA N TI P LA S MA d an P LA S MA E KS P AN D ER

P e n gg a nt i p la s ma OOEN

kombinasi :

p o l ig e l in ( e k iv a le n d engan

0 ,63 9 n itro ge n) 1 7,5 9

n atriu m klo rid a 4 ,2 5 9

ka lium k lo rida 0 ,19 9

k a ls i um ( t e ri k at p a d a

po lipep tida 0 ,125 9

a i r s t e ri l b e b a s p i ro g e n

sampa i 500 m l

l ar i nf us 6 % , b tl 5 00 m l

l ar i nf us 1 0% , b tl 5 0 0 m l

la r in fus, b tl 500 m l - Pemaka ian

(kasus te r ten

- P er lu s ar an a

khusus .

- V ar ia si k om b

y an g b er ed a

dapa t d i gu n a k





KELAS TERAP I ,FORMULASI

(Ben tuk Sed iaan , RESTRIKSI (Bentuk Sed iaan , RESTRNAMA G ENERI K

K e ku a ta n, d an K ema sa n )N AMA G E NERI K

Kekua ta n , d a n Kemas a n )

1 2 . D I AGNO S TI K 1 2 .1 . 6 U r og r af i

1 2. 1 B A HA N K O NT RA S R A DI OL OG I iopam idol in j 0,612 g / m l ,

ktk 10 am p @ 20 m l

12 . 1 .1 Ang iog ra f i i n j 0 , 7 55 g / m l ,

meglum in am idotrizoat in j 6 5%, ktk 1 v ia l 50 mlktk 10 am p @ 20 ml

meglumin natrium inj i . v . 7 6% , k tk 1 a m p 20 m l

12 . 1 .2 B i l ig r a fi amidotrizoat

natrium iopodat kaps 500 m g, b tl 6 kaps1 2. 2 T ES F U NG SI

12 . 1 .3 H i s t erosalp ingog r a fi 1 2 .2 . 1 G i n ja l

meglum in natrium inj 76%, ktk 1 amp 20 m lnatrium aminohipurat in j i . v . 20 0 m g / m l ,

amidotrizoatktk 1 a mp 10 m l

1 2 .2 .2 H a ti

1 2 . 1 .4 M ie log r a fi natrium bromsulftale in in j i . v . 5% , k tk 1 a mp 3 m l

iofendilat in j mengandung 30,5% iodium,

ktk 1 a mp 3 m l 12 . 2 .3 L a i n - la i n

fluoresein tts m ata 1% (garam Na), b tl 5 mlioheksol in j 240 m g I/m l, ktk 1 via l 1 0 ml tts m ata 2 % (g ar am N a) , b t l 5 m l

i nj 3 00 m g I/m l, k tk 1 v ia l 1 0 m l in j 1 0% , ktk 1 a m p 5 m li nj 3 50 m g I/m l, k tk 1 v ia l 2 0 m l in j 2 0% , ktk 1 a m p 5 m l

iopam idol in j 0,408 g / m l , 1 2. 3 T ES K U LIT

ktk 10 am p @ 10 mltuberkulin prote in in j i .k . 1 :10, k tk 1 v ia l 2 ml

i n j 0 , 612 g / m l , p u r if i ed de r iv a t iv ektk 10 am p @ 20 ml

1 3. A N TI SE P TI K d a n D IS IN F EK T AN1 2 .1 .5 S a lu ra n C e rn a

B ah an ko ntras m ed ia D OE N g ra nu l, ktg , d en ga n la r a sa m 1 3 .1 AN T IS E P T IK

kombinasi: sitrat a nhidrat 10% hidrogen peroksida cairan konsentrat, btl 1 000 m l D isimpan dn at ri um b ik ar bo na t 1 ,2 5 9 dengan sumsimetikon 0 ,0 42 9 k ed ap u da ra

da r i c ahaya .barium sulfat serb, k tg 200 9 - U ntu k d ie nc e

s us p 2 ,2 %, b tl 2501450 ml 3% .s us p 5 5% , b tl 2 I klorheksidin lar 5 ,0% (glukonat), bt12,51 Untuk diencerkans us p 6 5% , b tl 5 00 m l

meglum in natrium lar 59,7% , btl 1 20 ml

amidotrizoat polikresulen (kondensasi cairan, btl 10 m l I 5 0 m l

me t akr es ol s u l fona t &

metanal )




RESTRIKSI RESTRFORMULASI


~ ~ K ~ e ~ k ~ u a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a = n

1 4.2 G IG I d an M U LU T, B A HA N u nt uk

FORMULASIKELAS TERAP I, ( B en t uk S e d ia a n ,N A M A G E NE RI K

~ ~ K ~ e ~ k ~ u a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a = n ) ~ ~

la r 1 0% , b tl 1 00 0 m lo v id o n i o di d a

1 3 .2 D I SI N F EK T AN

etanol70%

b a h an t um pa t an s em e nt a ra

l ar , b t l 1 0 0 m l 11000 ml g la ss i on o me r A R T

(A t rauma t ic Res t or a t iv e

Treatment )a ls ium h ipok lo rit serb , ktg 20 9 P rogram sam ijaga D it jen

P2-PL.

k r es o l t e rs a p on i fi ka s i 5 0%

(I isol)

g u tt a p e rc h a p o in tsc ai ra n , b tl 1 0 00 m l

pa raform a ldeh ida tab 1 g , b tl 1 00 t ab

la r 5 % , b tl 1 00 0 m l

k om p os i t r e si n

p a st a p e ng is i s al ur an a ka r

s p o ns g e la t in

senyaw a k lo r serb (un tuk la rO ,1% ), b tl 1 00 9

s u rg i ca l g i ng g iv a l p a c k se t

l ar d a n s er b, b tl 1 00 9

s er b, b tl 1 0 9

l ar , b tl 6 9 ( 4, 8 m l)

c oc oa b ut te r 5 9

k tk 1 2 0 b a ta n g

se t

p a s ta , b t l

cubic les 1 x 1x 1 c m , k lg 5 0 b u ti r

1 4. G IG I d an M UL UT , O BA T d an B AH AN u nt uk1 5 . D IURET IK

1 4. 1 G IG I d an M U LU T, O BA T u nt uk f urosemida

A n es te ti k l ok a l g i g i D O E N

kombinas i :

l id ok ai n H C I 2 %

epinefrin 1 : 8 0.000

i n j , k t k 20/50/100 am p @ 2 m l

hidrok lor l iaz id

e t i l k l o ri da mani t o ls em p ro t 0 ,0 5- 0,2 m l, b tl 1 00 m l K em as an h aru s ke dap

udara

eugeno l spi ronolak tona ir an , b tl 1 0 m l

fluor tab 0 ,5 m g , bt l 100 tab

ta b 4 0 m g , b tl 2 5 0 ta b

in j i . v . l i . m . 10 m g / m l ,

k tk 2 5 a mp @ 2 m l

ta b 2 5 m g , b t l 1 0 00 ta b

l ar i nfu s 2 0% , b tl 5 0 0 m l

ta b 2 5 m g, k tk 1 0 s tr@ 1 0 t ab

t ab 1 0 0 m g , k tk 1 0 s tr @ 10 ta b

ka ls ium h id roks ida pasta , k tk 2 t ube1 6. 1 H O R M ON A N TI D/ uR E TI K

1 6. H OR M ON , O BA T E ND OK R IN L AI N d an K O NT RA S EP TI K

k l or fe n o l k am fe r m e n to l

(CHKM )

c ai ra n , b tl 1 0 m l desmopres in

vasopres in

k lo rheks id in la r 0,2% ( glu kona t)

lid oka in in j 2% (HC I), ktk 100 am p @ 2 m l

p as ta 5 % ( HC I) , t ub e 1 0 9

s em p ro t 1 5% ( HC I) , b t l 6 0 m l

1 6 .2 AN T ID I A B ET E S

1 6 .2 . 1 A n t id i ab e te s , O r al

gl ibenk lamida

na trium h ipok lo rit cairan konsentrat 5% , b tl 1 0 m l U ntuk d ience rkan.

nistat in glipizids us p 1 00 .0 00 U l/ ml, b tl 1 2 m l


s emp r o t

i n j i . m .l s. k . 2 0 I U /m l ,

k tk 1 0 a mp @ 1 m l

ta b 2 ,5 m g, b tl 1 00 t ab

ta b 5 m g , b tl 1 00 ta b

ta b 5 m g, k tk 5 b ls @ 2 0 t ab



RESTR IKS IFORMULAS I

K E LA S T E RA P I, ( B e n t u k S e d i a a n ,N A MA G E NE R IK

~ ~ K ~ e ~ k ~ u a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a = s a ~ n ) ~ ~

ta b 5 00 m g , b tl 1 00 ta bet f ormin

1 6 .2 . 2 A n ti di ab e te s , P a re n te r al

insul in in t ermediate i nj 1 00 U l/m l, k tk 1 v ia l 1 0 m l

insul in regular

insul in regular : insul in

in t ermediate ( 30 : 7 0 )

i nj 1 00 U l/m l, k tk 1 v ia l 1 0 m l

i nj 1 00 U l/m l, k tk 1 v ia l 1 0 m l

1 6.3 H O RM O N K EL AM IN d an O BA T y an g M EM P EN G AR UH I F ER T IL IT A S

16 . 3 .1 A n d r o ge n

t es tos teron

1 6 .3 . 2 E s tr o ge n

es t rogen t e r kon j ugas i

et in i les t radio l

16 . 3 .3 P r o g e st o g e n

h i d r oks i p r oges te r on

noret is t eron

16 .3 .4 Kon t rasept i k

1 6 .3 .4 .1 K o nt ra se p ti k, O ra l

kombinas i :

l ev on or ge st re l 1 50 m e g

e tin ile stra dio l 3 0 m eg

i nj d a la m m in y ak 2 0 0 m g / m l

( en a nt at ), k tk 1 v ia l 1 m l

ta b 0 ,6 25 m g , k tk , s tr 2 8 ta b

ta b 0 ,0 5 m g, b tl 1 00 ta b

ta b 0 ,5 m g , b t l 1 0 0 t a b

i nj i .m . 1 2 5 m g / m l , k tk 1 a mp 2 m l

ta b 5 m g, b tl 3 0 ta b

S es ua i d en ga n P ro gr am K B

N a si on al y an g d ik oo rd in ir

BKKBN .

pil

1 6 .3 . 4. 2 K o n tr a se p ti k , P a r en t er a l

m ed ro ks i p ro ge ste ro n a se ta t in j d ep o 1 50 m g

Goppe rT

1 6 .3 .4 .3 K o nt ra se p ti k, A K D R ( I UD )

se t 1 buah

42Daftar Dbat Esensia l Nasional2008

RESTRFORMULAS I

K E LA S T E RA P I, ( B e n t u k S e d i a a n ,N A MA G E NE R IK

~ ~ K ~ e ~ k u ~ a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a = s a ~ n ) ~

16 . 3 .4 . 4 Kon t r a sep t i k, lmp lan

levono rges tre l im p lan 2 rods ( 3-4 t ahun )

l a ru t an l u go l

1 6. 4 H O R MO N T IR O ID d an A N T IT I RO I D

b tl 3 0 m l

na t r ium t i ro k s i n

propi l t iouras i l

16 . 5 KORT I KOSTERO I D

deksametason

hidrokor t ison

prednison

t ab 0 ,1 m g , b t l 5 0 ta b

t ab s co re d 1 00 m g , b tl 1 00 0 ta b

t ab 0 ,5 m g , b t l 1 0 00 ta b

i nj 5 m g / m l ( s ebaga i na t r ium

fo sfa t) , k tk 1 00 a mp @ 1 m l

t ab 1 0 m g ,

s e rb i nj 1 0 0 m g l v i a l ( N a suk s ina t )

k tk 1 00 v ia l @ 2 m l

t ab 5 m g , b tl 1 00 0 t ab

D ala m p em a

d i la r u tk a n d u lu

1 7 . K A R D IO VA S KU LE R , O BA T

1 7 . 1 A N T I ANG I N A

atenolo l

d i lt ia z em H e l

i s os o rb i d d i n it r a t

n i t rogl iser in

1 7 . 2 A N T I AR I TM IA

amiodaron

digoks in

ta b 5 0 m g, k tk 1 0 s tr@ 1 0 t ab

ta b 3 0 m g, k tk 1 0 s tr@ 1 0 t ab

t ab s u bl in g ua l 5 m g ,b tl 6 0 t ab

t ab s u bl in g ua l 0 ,5 m g ,

btl 100/ 1000 tab

t ab 2 00 m g, k tk 3 0 ta b

i n j 1 5 0 m g / 3 m l,

k tk 6 am p @ 3 m l

t ab 0 ,0 62 5 m g ; b tl 1 00 ta b

t ab 0 ,2 5 m g ; b t l 1 0 0 t a b

in j 0 ,2 5 m g /m l; ktk 1 am p @ 2 m l

T ab let 0 ,0 62

pediat r ik

Daf tar Oba t Esens ia l Nas io na l 2 00 8



RESTRIKSIFORMULASI

KELAS TERAP I, ( B en t uk S e d ia a n ,N A M A G E NE RI K

~ ~ K ~ e ~ k ~ u a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a = s a ~ n ) ~ ~

k ap s 1 0 0 m g ( fo s fa t) , b tl 1 0 0 k ap sisopi ramida

ep i ne fr i n ( ad r ena l in )

l idokain

propranolo l

verapami l

1 7 .3 AN T IH I P ER T E NS I

atenolo l

h idrok lorot iaz ida

kaptopr i l

k lonid in *)

l isinopril

met i ldopa

na t r ium n i tr op r us i d *)

ni f edip in

i n j 0 , 1% ( se b a g ai b i ta r tr a t) ,

ktk 1 00 am p @ 1 m l

inj i . v . 2% ( H e l) ,

ktk 1 00 am p @ 2 m l

ta b 1 0 m g ( He l) , b tl 1 00 ta b

inj i . v . 1 m g / m l (Hel ) ,ktk 1 0 a mp @ 1 ml

ta b 4 0 m g ( He l) , b tl 3 0 t ab

i n j 2 , 5 m g / m l (Hel ) ,


ta b 5 0 m g, b tl 5 0 t a b

ta b 2 5 m g, b tl 1 00 ta b

t ab s co re d 1 2 ,5 m g ,

k tk 1 0 s tr @ 6 t ab s co re d

ta b s co re d 2 5 m g ,

ktk 1 0 s tr @ 6 I 1 0 t ab s c o re d

i n j i . m . 0 , 15 m g / m l (Hel ) ,

ktk 1 a mp 1 m l

ta b 5 m g, k tk 3 s tr@ 1 0 t ab

ta b 1 0 m g , k tk 3 s tr@ 1 0 t ab

ta b 2 0 m g, k tk 3 s tr @ 1 0 t ab

ta b s al ut 2 50 m g,

b tl 10 0 / 1 0 0 0 t ab

i n j , v i a l

ta b 1 0 m g

1 7 .4 A N T IA G R EG A S I P L AT E LE T

a sa m a se til sa lis il at ( as eto sa l) ta b 8 0 m g, k tk 1 0 b l s @ 1 0 t ab

44

Un tuk in traka rdia l a tau

resus i t as i

Un t uk a r i tm i a s up r av en t r ik u l e r.

- T ida k bo leh digu nakan

u n tu k w a n i t a h am il .

- D ap at ti mb ul e fe k s am p i ng

batuk .

D ig u na k an u n tu k h ip e rt en si

berat

D i be r ik a n s e ti a p 4 j am .


RESTRFORMULASI


~ ~ K ~ e ~ k u ~ a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a = s a ~ n )

1 7 .5 T ROMBO L IT I K

s t reptok inase

1 7.6 G A GA L J AN T U NG , O BAT

digoks in

furosemida

kaptopr i l

1 7.7 S YO K , O B AT u n tu k

1 7 .7 . 1 S y o k K a r di og e n ik

dobutamin

dopamin

ep i ne fr i n ( ad r ena l i n)

1 7 .7 .2 S y ok k a re n a a n es te si

efedr in

norepinef r in

17 . 8 ANT I H I P ERL IP I DEMIA

s imvastat in

i n j 7 5 0 .0 0 0 U l lv ia l

i n j 1 , 5 j u ta U l lv i al

t ab 0 ,0 62 5 m g, b tl 1 00 ta b

t ab 0 ,2 5 m g , b tl 1 0 0 / 1 0 0 tab

i n j 0 , 25 m g / m l , k tk 1 a mp 2 m l

ta b 4 0 m g, k tk 2 0 s tr @ 1 0 ta b

i n j i . v' /i .m . 1 0 m g / m l ,



k tk 1 0 s tr @ 10 t ab s co re d

t ab s co re d 2 5 m g,

k tk 1 0 s tr @ 1 0 t a b s c or ed

i n j 5 0 m g / m l ; v ia l 5 m l

i n j 2 5 m g / m l ; am p 1 0 m l

i n j 4 0 m g / m l (Hel ) ,

k tk 5 a mp @ 5 m l

inj i . v . 0 ,1 % ( se ba ga i H el l

b it ar tr at) , k tk 1 00 a mp @ 1 m l

i n j 5 0 m g / m l ( l+Cl) ,

k tk 10 0 a mp @ 1 m l

i n j 4 m g / m l ; am p 2 m l

t ab s co re d 1 0 m g ,

k tk 3 0 t ab s co re d

P em akaian

( k as us t e rt en tu

P e rl u s ar an a

khusus.

Tablet 0,0625

pediat r ik

- T id ak b ole h

u n tu k w a n it a

D a pa t t im b ul

batuk .

S ebaga i lo n

vasop ressor .





FORMULASI( B en t uk S e d ia a n ,


RESTRIKSI

1 8 .1 AN T IAKNE

1 8. K U Ll T, O BA T T OP IK A L u n tu k

a s am r e ti n oa t

1 8 .2 AN T IB AK T ER I

A n t ib a k te r i D O E N

kombinas i :

bas itras in 500 U I/g

p o li m ik si n B 1 0 .0 0 0 U I/ g

pe r ak s u l fad i a z in

1 8 .3 AN T IF U NG I

A n t if u ng i D O E N

kombinas i :

a sa m b en zo at 6 %


mikonazol

na t ri um t i os u l fa t

k ri m 0 ,0 5% , tu be 2 0 9

s ale p, tu be 5 9

k ri m 1 % , p o t 5 0 0 9

s ale p, p ot 3 0 9

s e rb 2 % ( ni tr at ), k tg 2 0 9

k ri m 2 % ( ni tr at ), t ub e 1 0 9

1 8 .4 AN T II N F LAMAS I d a n AN T IP RU R IT IK

c air an 2 5% , b tl 3 0 m l

be t ame t as on

hidrokor l ison

s a le p 0 , 1% ( s ebaga i v a l e ra t ) ,

tu be 5 9

k r im 0 , 1% ( s eb a g ai v a le r a t) ,

tu be 5 9

k ri m 2 ,5 % ( as e ta t) , t ub e 5 9

l i quo r v e i ll i ( s o lu t io s a l ic y l ic larutan

a c id 0 ,1 % ) k o mb in a si :

a s am s al is il at 0 ,1 %

bo raks 0 ,5 %

g lise rin 10 %

permet r in

1 8 .5 AN T IS KAB IE S d a n AN T IP E D IK U L O SI S

k ri m 5 % , t u be

46

H a ny a u n tu k l uk a b a ka r y a ng

luas .

U ntuk keadaan aku t dan

kronis .

D i b ua t s e g ar


RESTRFORMULASI


~ ~ K ~ e ~ k u ~ a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a = n )

s al ep , p ot 3 0 9a le p 2 -4 , k o mb in as i :

a sa m s alis ila t 2 %

b el er an g e nd ap 4 %

1 8 .6 KAU S TI K

pe rak nitra t la r 20% , bt l 1 0 ml U n tu k le si h

as am sa l is i l a t

1 8 .7 K E RA T OL IT IK d a n K E RA T OP L AS TI K

c o a l t a r

podof i l in

urea

1 8 .8 L A IN - LA I N

bedak s a l is i l

l iq u o r c a rb o n is d e te r g en s

l i quo r f abe r i

salep 2% , po t 30 9

salep 5% , po t 30 9

s ale p 1 0% , p ot 3 0 9

la r 5 % , b tl 1 00 m l

t in g tu r 2 5 %, b tl 30 m l P e rlu pengaw a

karena:

- H aru s d ia plik

dok ter

- 1 -4 j am s ete la

h a ru s d ib e rs

t idak ada

ter t inggal .

- P en ggu na an

pe neb alan

karena

m en im bu lka n

ak i ba t abs o r p

- T i da k b o le h d

w an i ta h am il

t eratogenik .

- T id ak b ol eh d

o l e h p a s ie n

- T id ak b ol eh d

k rim 1 0 % , t ub e 4 0 9

s er b 2 %, k tk 1 00 9

s us p 2 %, b tl 3 0 m l

s us p 5 %, b tl 3 0 m l

l iquor




FORMULASIKELAS TERAP I , ( Be n tu k S e d ia a n , RESTRN A M A G E NE RI K


la r i n fus , b tl 5 00 m l U n tuk pra o pe ra

FORMULASIKELAS TERAP I,N A M A G E NE RI K

RESTRIKSIBe nt u k S e d ia a n ,


L a r ut a n n u tr is i O O E N

kombinas i :

g lu kosa 5 %

n a tr iu m k lo ri da 0 ,2 2 5 %

1 9 . L ARUTAN D IA L IS I S P ERI TO NEA L

dia lisa pe ritonea l O OEN la r i nfu s , 24 bt l @ 1000 m l

hem od ia lisa O OEN la r, btl 1 g a lon

L a r ut a n n u tr is i , k om b in a s i :

g lu kosa 4 %

n at riu m k lo ri da 0 ,1 8 %

l ar i nf us , b tl 5 0 0 m l2 0. L AR UT AN E LE KT RO Ll T, N U TR IS I d an L AI N - LA IN

2 0.1 O RA L

Garam o ra lit se rb , 1 00 ktg,

ti ap k tg u nt uk 2 00 m l a i r

O im i nu m s ed ik it d e mi s e di ki t

2 -3 t eg u k u n tu k m e ng h in d ar i

muntah

m an ito l la r in fus 20% , btl 500 mlkombinas i :

n atriu m k lo rid a 0 ,5 2 9

kalium k lo rida 0 ,30 9

t r ina t r ium s i tr a t

d ih id ra t 0 ,58 9

g lu ko sa a nh id ra t 2 ,7 0 9

na trium b ikarbonat in j i . v . 8 ,4 %, b tl 2 5 m l

i n j 1 , 4% i s ot o ni k, b t l

P e r lu d i la k u ka n

g a s d a r ah .

na trium k lo rida la r in fus 0 ,9% , b t l 500 m l

la r i nfu s 3 %, b tl 5 0 0 m l

in j 1 5 % , v i al 5 0 m l

P e r lu d i la k u ka n

k a d ar n a tr ium .

ka lium k lorida tab s iap l aru t 300 m g ,

tu be k ed ap 1 0 t a b

- S eb el um d ig un ak an ta bl et

d i la r u tk a n d a lam a i r

- O is im pan d ala m w ada h

k e d ap u d a ra .

ringe r la k ta t la r in fus , b tl 500 m l

2 0.3 L AIN - L AIN

a i r u n tu k i n je k s ia trium b ika rbona t tab 5 00 m g, b tl 1 000 t ab

k tk , a m p / vi al @ 1 0 m l /2 0 m l

2 0 .2 P A R EN T ER A L

c a i ran i n tr a l ip i d2 1. M ATA , O BA T u nt uk

l ar i nf us 1 0 %, b tl 1 0 0/ 50 0 m l

l ar i nf us 2 0 %, b tl 1 0 0/ 50 0 m l

P em aka ia n te rb atas

( k as us t e r ten t u ) .P e rl u s a ra n a d a n k e ah li an

k husus .

2 1 .1 . A N E ST E TI K L O KA Lbupivakain in j 0 ,5% (H e l),

k tk 5 a mp @ 2 0 m l

te tra ka in tts mata 0 ,5% ( H e l), bt l 5 m la rr ow g lu ko s a a n a

( O G a n a )

l ar i nf us , b tl 5 0 0 m l

2 1 .2 AN T IM I KRO BA

amfoter is ind a rr o w g l uk o s a ha l f s t re ng t h l a r i n f u s, b t l

s al ep m at a 3 % , t ub e 3 ,5 9

deks trose la r in fu s 5 %, btl 500 m l

gen tam is in salep m ata 0 ,3% , tube 3 ,5 9

tts m at a 0 ,3 % , b tl 5 m lglu kosa la r in fu s 5% , bt l 500 ml

l ar i nfu s 1 0% , b tl 5 0 0 m l

la r i nfu s 4 0 %, b tl 2 5 m l

in j i . v . 1 m e k/m l, k tk 1 a m p 1 0 m l

idoksu rid in tts mata 0 ,1 % , bt l 5 m l

s al ep m at a 0 ,5 % , tu be 4 9a l i um k l o ri da

ka ls ium g lukonat in j i . v . 1 0% , k tk 2 4 a m p@ 1 0 m l oks ite tra s ik lin salep m ata 1% ( H e l), tube 3,5g






(Ben tuk Sed iaan , RESTRIKSI (Bentuk Sed iaan , RESTRNAMA G E NERI K

Kekua t an , d a n Kema sa n )N AMA G E NERI K

K e ku a ta n , d an K ema sa n )

su lfa se tam ida tts m ata 15% (natrium ), b tl 5 m l 2 2. O KS IT OS IK d an R EL AK SA N U TE RU S

2 2 .1 O KS IT O S IK2 1 .3 AN T II N F LAMAS I

be tam e tason tts m a ta 1 mg /m l ( na trium ) ,m e tilergom e trin tab s alu t 0 ,1 25 m g ( ma lea t),

b tl 1 0 0 t a bb tl 5 m l i n j 0 , 2 0 0 m g / m l,

k tk 1 00 a m p @ 1 ml

2 1 .4 M I D R IA T IKoks ito s in in j 10 UI/m l, ktk 100 am p @ 1 ml

a trop in tts ma ta 0 ,5% ( su lfa t), b t l 5 m l

t ts m a ta 1 % ( su lf at ), b tl 5 m l2 2.2 R EL AK SA N U TE RU S

hom a tropin tts m a ta 2 % ( sebaga i H B r), m agnes ium su lfa t in j 20% , k tk 1 0 v ia l @ 2 0 m l

b t l 1 5m l i nj 4 0 % , k tk 1 0 v ia l @ 2 0 m l

2 1.5 M IO TI K D AN A N T I G LA UK OMA2 3 . P S IKO FARMAKA

ase tazo lam ida tab 2 50 m g , b t l 100 tab

s e rb i n j i . m /i .v . 5 0 0 m g / vi a l

( se b ag a i g a ra m N a ),

k tk 1 0 v i a l + 1 0 a m p a ir

un t uk i n j e ks i @ 5 ml

2 3 .1 A N TI AN S IE T AS d a n A N T II NS O M NI A

d iazepam tab 2 m g , bt l 1 000 tab

ta b 5 m g , b tl 1 00 0 t ab

i nj i .m . 5 m g /m l ,

k tk 1 00 a m p @ 2 ml

p ilo ka rp in tts m a ta 2 % ( HC I/n itra t), bt l 5 m l

t ts m a ta 4 % ( HC I/ ni tr at ), b tl 5 m l2 3 .2 A N TI DE P RE S I d a n A N T IM A N IA

am itript ilin tab sa lu t 25 m g (H C I),

k tk 1 0 b l s @ 1 0 t abt im o lo l tts ma ta 0 ,25% ( m alea t), b tl 5 m l

t ts m a ta 0 ,5 % ( m al ea t) , b tl 5 m lfluokse t in kap /tab 1 0 mg , ktk 30 tab

k ap /ta b 2 0 m g , k tk 3 0 ta b

2 1 .6 L A IN - LA I N

kombinas i :

h idroks ipropi l

m etilse lu lo sa 5 m g

deks tran (70 ) 1 m g

g lise rin 2 m g

benzalkonium

klo rida 0 ,01 % b /v

lar 2% , bt l 5 m l U n tuk kasus dry eyes

syndrome

l it ium ka rbona t tab 2 00 m g , ktk 1 0 str @ 10 tab B i I a m e m

d il ak u ka n m o

oba! . S a fe t y w i

mm o l e k /I

2 3 .3 A N TI Oa S ES I K O M PU L SI

k lom ip ram in tab 2 5 m g (H C I), b tl 1 000 t ab

na trium krom og lika t tts m ata 2% , b tl 1 5 ml23 . 4 ANT I P S IKOS I S

flu fenaz in tab 2,5 m g (H CI), bt l 100 tab

i n j i . m .2 5 m g / m l ( d e ka n o at ),

k tk 1 0 v ia l @ 1 ml

5 0Daftar Dbat Esensial Nasional2008 Daftar Obat Esensial Nasional 2008



FORMULASIKELAS TERAP I, ( B en t uk S e d ia a n ,N A M A G E NE RI K

~ ~ K ~ e ~ k ~ u a ~ t ~ a n ~ , ~ d ~ a ~ n ~ K ~ e ~ m ~ a ~ s a ~ n . ) ~ ~

ta b 0 ,5 m g, b tl 1 0 0 / 1 0 0 0 tab

ta b 1 ,5 m g, b tl 10 0 / 1 0 0 0 t ab

ta b 2 m g, k tk 1 00 ta b

ta b 5 m g, b tl 1 0 0 / 1 0 0 0 tab

t ts 2 m g / m l , b tl 1 5 m l / 1 0 0 ml

inj i . r n , 2 m g / m l ( l+Cl)

k tk 5 amp @ 1 m l

inj i . r n , 5 m g / m l ( l+Cl)

k tk 5 amp @ 1 m l

i n j 5 0 m g / m l ( s ebagai dek anoa t)

k tk 5 amp @ 1 m l ( long

ac t ing)

FORMULASIKELAS TERAP I , ( Be n tu k S e d ia a n ,N A M A G E NE RI K


s er b i nj i .v / i .m, 10 0 m g l v i a l

( k lo r id a ), k tk 1 0 v ia l

RESTRIKS I RESTR

halope ridol S ebaga i a lternatif

k lorpromazin.

suksin ilko lin P em aka ian

( k as us t e r ten t

P e rl u s ar an a

khusus,

2 4.2 M IA ST EN IA G RA VIS , O BA T u ntu k

neost igmin *) i n j 0 , 5 m g / m l (metilsulfat),

k tk 5 0 am p @ 1 m l

t ab 6 0 m g ( br om id a ),k tk 1 0 s t r/b ls @ 1 0 t a b

*) M eru pa ka n

k ed u a s e te la h

pi r idos t igmin

2 5. S AL UR AN C ER NA , O BA T, u ntu k

k lorp rom azin tab sa lut 2 5 m g (He l),

b tl 1 0 00 t ab

t ab s al ut 1 0 0 m g ( H el ),

b tl 1 0 00 t ab

inj i . r n , 25 m g / m l ( l+Cl) ,

k tk 1 00 am p @ 1 m l

2 5 .1 A N TA S ID A d a n A N TI UL K US

An tas ida DOEN I tab k unyah , b tl 1 000 t ab

kombinas i :

a luminium

h id ro ks id a 2 0 0 m g

magnes ium

h id ro ks id a 2 0 0 m glozapin *) ta b 2 5 m g, k tk 5 0 t a b

ta b 5 0 m g, k tk 5 0 t a b

- S eb aik ny a d ila ku ka n c ek

le uk os it s ec ara b erk ala

(hat i -hat i agranulos i t os is )

- M eru pa ka n o ba t te rp ilih

d a lam p e n go b a ta n p s ik o s is

yang sudah res is ten

t er h ad a p a n ti p si ko t ik l a in

A n tas ida DOEN II susp , b tl 60 m l

kombinas i :

a luminium

h i dr o ks i da 2 0 0 m g / 5 ml

magnes iumh i dr o ks i da 2 0 0 m g / 5 ml

rispe ridon tab 1 mg , ktk 5 s tr@ 10 tab

ta b 2 m g, k tk 5 s tr@ 1 0 t ab ranitid in tab 150 mg , ktk 3 s tr@ 10 tab

2 3. 5 . A D HD , O BA T u nt uk

( d l ) me t i lf en ida t *)

2 5 .2 AN T IE ME T IK

dimenhidr inatab r e gu la r r e l e as e 1 0 m g ,

k tk 3 0 t ab

tab e x te n d ed r e le a se 2 0 m g,

k tk 3 0 t ab

P e rl u k ea h li an k hu s us d a la m

penggunaannya .ta b 5 0 m g, b tl 1 00 0 ta b P enggunaan

sebelum m a

m e nd a pa tk an

y an g l eb ih b a ik

2 4 . R E LA K SA N O TO T P ER IF ER d an P EN G HA M BA T K O L IN E S T ER A S Ek lorp rom azin tab s alut 2 5 m g (He l),

b tl 1 0 00 t ab

i n j i . rn . 2 5 m g / m l (Hel ) ,

k tk 1 00 am p @ 1 m l

i nj i .m 5 m g / m l (Hel ) ,

k tk 1 00 am p @ 2 m l

2 4 .1 P E NG H A MB A T N E UR O M US K UL E R

a tra ku rium in j 25 m g 1 2 ,5 m l, a m p 2 ,5 m l

rokuronium in j i.v 10 m g / m l ; v ia l 5 m l






NAMA G E NERI K(Bentuk Sed iaan , RESTRIKSI (Bentuk Sed iaan , RESTR



metok lopram id tab 10 m g ( sebagai H CI), 2 5 .7 A N TI IN F LA M A SI , O B AT u n tu k

b tl 1 0 0 t ab

i nj 5 m g /m l ( se b ag a i H C I) ,su lfasa la zin tab 500 m g, k tk 1 0 str@ 10 tab


s ir 5 m g/5 m l, b tl 5 0 m l 2 6. S AL UR AN N AP AS , O BA T u nt uk

t ts 0 ,1 m g /t ts , b tl 1 0 m l2 6 .1 AN T IA SMA

2 5 .3 AN T IH EMO RO ID am inof ilin tab sco red 2 00 mg ,

An tihem oro id DOEN sup, k tk 1 00 s up

b tl 1 0 00 t ab s co re d

kombinas i :i nj 2 4 m g /m l,

b is mu t s ub ga la t 1 50 m gktk 1 00 am p @ 10 m l

h ek sa klo ro fe n 2 ,5 m g

lidokain 1 0 m gbudesonid ae roso l 100 m eg/pu ff,

seng oks ida 120 m gk an is te r 1 5 m l

su p ad 2 9a e ro s o l 2 0 0 m e g /p u ff ,

k an is te r 1 5 m l

2 5 .4 AN T IS P ASMOD I K deksame tason tab 0 ,5 m g , b t l 1 000 t ab

atropin tab 1 mg (sulfat), k lg 100 tabinj i . v . 5 m g /m l ( se b ag a i n a tr iu m

i n j i . m .l i. v. /s .k . 0 , 25 m g / m lfo sf at) , k tk 1 00 a mp @ 1 m l

( su lfa t) , k tk 1 00 a m p @ 1 m le fedrin tab 25 mg (HCI), btl 1000 tab

i n j i . m .l i. v. ls .k . 1 m g /m l ( su l fa t ),

k tk 50 am p @ 1 m lepinefrin (ad renalin ) in j 0 ,1 % ( s ebaga i HC I /b i ta r t ra t ) ,

eks tra k be ladon tab 10 m g , b tl 1 00/1000 tabk tk 1 00 am p @ 1 m l

sa lbutam ol tab 2 m g (sebaga i sulfat),

2 5. 5 D lA RE , O BA T u ntu k b t l 1 0 0 / 1 00 0 t a b

Garam ora lit se rb, 1 00 ktg, D im inum sed ik it d em i s ed ik itt ab 4 m g ( se b ag a i s ul fa t) ,

kom binas i: tia p k tg u ntuk 2 00 m l air 2-3 teguk un tuk m engh inda rib t l 1 0 0 / 1 00 0 t a b

na t r ium k l o ri da 0 ,52 9 muntahl ar i h 0 , 5 % , 10 ml Inhala si un tuk

k a l ium k l o ri da 0 ,3 0 9i h /a e ro s o l 1 0 0 m e g /d o s is intermitten

t r in a t ri um s i tr a t( s eb a g ai s u I fa t ) , s e ra n g an a k ut

dih idrat 0 ,58 9t ab u n g 2 0 0 /4 0 0 d o s is

g lu ko sa a n hi dr at 2 ,7 0 9i n j 5 0 m e g /m l ( s eb a g ai s u lf a t) ,

k tk 1 00 am p @ 1 m l

2 5 .6 KA T ARTI Kl a r r e s p ir a to r u n tu k n e b ul iz e r

bisakodil sup 5 m g, k tk 6 sup

2 ,5 m g /2 , 5m l N aC I,

k tk 4 x 5 n e b ul e s

s up 1 0 m g, k tk 6 su p

glise rin eairan , bt l 100 m l2 6 .2 AN T IT U S IF

deks trom eto rfan tab 15 m g (H Br), b tl 1 000 t ab

s ir 1 0 m g /5 m l ( H Br ), b tl 6 0 m l





FORMULASI



RESTRIKSI

kodein

2 6 .3 E K S PE K TO R A N

g l i se r i l g ua i a k ol a t

o b at b a tu k h it am ( OB H )

t a b 1 0 m g ( H CI /f o sf a t) ,

b tl 2 5 0 t ab

s ir 2 5 m g/5 m l, b tl 6 0 m l

ta b 1 00 m g, b tl 1 00 0 ta b

e a ir an , b tl 2 0 0 m l

e a ir an k on se n tr at , b tl 1 00 0 m l

2 7 . S IS TE M I MU N , O BA T y an g M E MP EN G A RU HI

2 7 .1 S E R UM d a n I M UN O G LO B U LI N

h um a n te ta nu s im u no gl ob ul in in j i .m . 5 0 0 U I, v ia l

s e ru m a n ti b is a u la r

A .B .U . I ( k h us u s u la r d a ri

l u ar P a p u a)

A . B. U .I I ( k hu s u s u l ar d a ri

P apua )

s e r um an t id i ft e r i ( AD .S )

s e r um an t ir ab i es

s e rum a n ti te t an u s ( A .T . S)

s e r um imunog lobu l in

5 6

inj i . m . l i . v . , k tk 1 0 v ia l @ 5 m l

i n j i . m . 1 0 .0 0 0 U I /v i al ,


i n j i . m . 2 0 .0 0 0 U I /v i al ,

ktk 1 0 v ia l @ 1 0 m l

i n j i . m . 1 0 0 U I /m l ,

ktk 1 0 v ia l @ 2 0 m l

U n tu k p e ne e ga h an :

i n j i . m . 1 5 0 0 U I /am p .


U n tu k p e ng o ba ta n :

inj i . m . l i .v . 1 0 . 0 0 0 UI / amp,

ktk 1 0 a mp @ 2 m l.

inj i . m . l i . v 20 . 000 U I / vi a l ,


in j i .m ., k tk 1 0 v i al @ 1 0 m l

D is im p an p a d a s uh u 2 -8 0 C.

- K hu su s d ae ra h t er te nt u .

- D is im pa n p ad a s uh u 2 _80 C.

D is im p an p a d a s uh u 2 _ 80 C.

- D igunakan un tuk

pengobatan pos t -exposure

d i d a e ra h r a bi e s.

- D is im pa n p ad a s uh u 2 -8 0 C.




FORMULASIKELAS TERAP I , ( Be n tu k S e d ia a n , RESTRN A M A G E NE RI K


2 7 .2 V A K SI N

vaks in B .C.G . in j i.k ., k tk 5 am p @ 2 m l Ha rus dis im pan

inj i.k ., k tk 5 am p @ 4 m l dibaw ah 50 C

vaks in eam pak in j s .k , D is im pan p ada

k tk 1 0 v ia l ( 10 d os is ) @ 5 m l

v a ks in j e ra p d i ft e ri

t etanus(DT)

i nj i .m ., k tk 1 0 v ia l @ 5 m l

v ak sin h ep atitis B re ko mb in an in j 2 0 m e g/m l, k tk 1 v ia l 0 ,5 ; 1 m l D is im pa n p ad a

D is im p an p a da

v a ks in j e ra p d i ft e ri t e ta n u s

p e rt us i s ( D T P )

i nj i .m ., k tk 1 0 v ia l @ 5 m l

v a ks in j e ra p t e ta n u s ( t e t anus i nj i .m ., k tk 1 v i al 5 m l

a d s or b ed t o xo i d)

vaks in po lio tts , k tk v ia l 1 0/20 d os is

v ak si n r ab ie s , u n tu k m a nu s ia s e rb i nj s .k .l i. k. ,

k tk 7 v ia l @ 1 d o si s +

7 a mp p ela ru t @ 2 m l

Booster :

k tk 5 a mp @ 1 d o sis +

5 a mp p ela ru t @ 4 m l

D is im p an p a da

D is im p an p a da

D is im p an p a da

- D is im pa n p ad

- D igunakan

pengobatan

da n pos t -exp

d a e ra h r a bi e s.

h idrogen peroksida eairan konsen tra t, b tl 1 000 m l

2 8. T EL IN G A, H ID UN G d an TE NG G OR OK AN , O BA T u nt uk

karbog liserin tts te linga 10 % , btl 5 m l

lid okain eairan s em p rot 4 % (HC I),

b tl 5 0 m l

t ts h id u ng 0 ,0 2 5% ( HC I) ,

b t l 1 5m l

t ts h id u ng 0 ,0 5 0 % ( HC I) ,

b tl 1 0 m l

oks imetazol in

- D is impan d

dengan sum

k ed ap u da ra

d a ri e a h a ya .

- U ntu k d ie ne e

3% .





(Ben tuk Sed iaan ,N AMA G E NERI K

K e ku a ta n, d an K ema sa n )

2 9 . V IT A MI N d a n M IN E RA L

a sam askorb at (v ita min e ) ta b 5 0 m g, b tl 1 00 0 t ab

e rg ok als ife ro l (v ita min 0 3) k ap s 5 0.0 00 U I, b tl 1 00 k ap s

s us p 1 0. 00 0 U l/m l, b tl 6 0 m l

iodium kaps lunak 200 m g,

b tl 1 5 00 k a ps l un a k

ka ls ium glukona t in j 100 m g / m l ,

k tk 2 4 a m p @ 1 0 m l

ka ls ium lak tat (kalk) tab 5 00 m g, b tl 1 000 tab

n iko tinam id tab 100 m g

p iridoks in (v itam in B 6) tab 10 m g (H el), b tl 1 000 tab

ta b 2 5 m g (H el ), b tl 1 00 0 ta b

re tino l (v itam in A ) tab 5 000 IU , b o to l1 000 tab

k ap s l un a k 5 0 .0 0 0 U I,

b tl 5 0 k ap s l un ak

k ap s l un a k 1 0 0. 00 0 U I,

b tl 5 0 k ap s lu na k

k ap s l un a k 2 0 0. 00 0 U I ( se b ag a i

p a lm i ta t ), b tl 5 0 k a p s l u na k

t iam in (v itam in B1 ) tab 5 0 m g (H el), b tl 1 000 tab

v itam in B k omp leks tab, b tl 1 000 t ab

5 8

RESTRIKSI

P em a ka i an t er a pe u ti k p a d a

hipokalsemia

BAB III

DAFTAR OBAT TERBATAS

UNTUK PUSKESMAS 2008




BAB III

DAFTAR OBAT TERBATAS

UNTUK PUSKESMAS 2008




1 . A N A LG E SI K, A N TI PI RE TI K, A N TI IN F LA M A SI N O NS TE RO ID , A N TI PI RA I

pet id in

1 .1 A N A LG E SI K N A R KO T IK

inj i . m / s . k / i . v l am b at 5 0 m g / m l(H CI), k tk 1 0 a mp @ 2 m l

1 .2 A N A LG E SI K N O N -N A R KO T IK

asam ase t il s a li s il a t

(asetosal )

ibuprofen

metampiron

na t r ium d i k lo f enak

parasetamol

1 . 3 . ANT I P I RA I

alopur inol

probenes id

5 9

ta b 1 00 m g , k tk 1 0 b l s @ 1 0 ta b

ta b 5 00 m g , k tk 1 0 b l s @ 1 0 ta b

ta b 2 00 m g , b tl 1 00 ta b

ta b 4 0 0 m g , b tl 1 00 ta b

ta b 5 00 m g , b tl 1 00 0 ta b

ta b 2 5 m g, k tk 1 0 s tr@ 1 0 t ab

ta b 5 0 m g, k tk 1 0 s tr@ 1 0 t ab

ta b 1 00 m g , b tl 1 00 0 ta b

ta b 5 00 m g , b tl 1 00 0 ta bs ir 1 2 0 m g / 5 m l, b tl 6 0 m l

ta b 1 00 m g , b tl 100/ 1000 tab

ta b 5 00 m g , b tl 100/ 1000 tab




RESTRIKSI

2 . A N E S TE TI K

2 .1 A NE ST ET IK L OK AL

e til klorida sem pro t, b tl 100 m l

P em akaian hanya d iP u s ke sm a s P e r aw a t an

lidoka in in j in filtr 1 % (HC I),

k tk 1 00 a mp @ 2 m l

inj p. v 2% ( HC I) ,

k tk 1 00 a mp @ 2 ml

je li 2 % , t u be 1 0 9s em pr ot 4 %, b tl 5 0 m l

2 .2 A NE ST ET IK U M UM d an O KS IG EN

ke tam in in j i.v 10 m g / m l ( s eb a g a i H C I ),

k tk 1 0 v ia l @ 2 0 m l

inj i.v 50 m g / m l ( s eb a g a i H C I ),

k tk 1 0 v ia l @ 2 0 m l

i h, g a s d a la m t ab u ngP em ak aia n s up ay a d ib ata si

u n tu k m e n g u ra n g i e f ek s am p i n g

agranulos i t os is .

oks igen

t iopental se rb in j i.v 50 0 m g / a m p

( g a ram N a ) ( u nt u k d i la r u tk a n

d a la m 2 0 m l a ir i nj ek si ),

k tk 2 5 a m p

2 .3 P RO SE DU R P RE O PE RA TIF , O BA T u ntu k

a trop in in j 1 m g / m l (sulfat),

k tk 5 0 a mp @ 1 m l

- M engham ba t produk s i

a s am u ra t ( 35 % p e nd e ri ta )

- T id ak d ib erikan se wa ktu

s e ra n g a n a k u t

d iazepam tab 5 mg, btl 1000 tab

i nj 5 m g / m l , k tk 10 0 a mp @ 2 m l

m o rf in in j i . m / s . k f i . v 10 m g / m l

( HC l/s ulf at ), k tk 1 0 a m p @ 1 m l

- M em perce pa t e kskre si

a sa m u ra t d i g in ja l te rja di

p a d a 6 5% p e n d er it a

- O os is 2 X Y, t a bl e t d e n g an

b a n ya k m i n um .

- T id ak d ibe rikan se wa ktu

s e ra n g a n a k u l.

3 . A N TI AL ER G I d an O BA T u n tu kA N A FI LA K SI S

deksam etason in j 5 m g / m l ( s ebaga i na t r ium

f os fa t) , k tk 1 00 a m p @ 1 m l

d ifenhid ram in in j i.m 1 0 m g / m l (HCI ) ,

k tk 1 00 a mp @ 1 m l

Daftar Obat Esensial Nasional 2008Daftar Dbat Esensial Nasional2008

RESTR

K e m as an h a ru s

P em akaian

P u s ke sm a s P e

Pem akaian

P u s ke sm a s P e



KELAS TERAP I,N A MA G E NE R IK

ep i ne fr i n ( ad r ena l i n)

k lor f eni ramin

FORMULASI( B e n tu k S e d ia a n ,

K e ku a ta n , d a n K em as a n)

i n j s . k /i .m 0 , 1% ( s eb a g ai H C I/

b ita rt ra t) , k tk 1 00 a mp @ 1 m l

ta b 4 m g ( m al ea t) , b tl 1 00 0 t ab

i n j 5 m g /m l ( m a le a t) ,

k tk 1 00 am p @ 1 m l

4 . A N TI DO T d an O BA T L AIN u ntu k K ER AC UN AN

4 .1 K H US US

at ropin

k a l si um f o li na t

( I euk ov o r in , Ca l

na t ri um b i k a rbona t

na t ri um t i o su l fa t

4 .2 U MU Mk a rb o n a k ti f

m a g n es i um s u lf a t

i n j i . m /i .v /s .k 1 m g /m l ( su l fa t ),


ta b 1 m g, b tl 1 00 t ab

ta b 5 00 m g, b tl 1 00 0 ta b

inj i.v 2 5% , ktk 1 0 a mp @ 10 m l

s er b a kt if , k tg 0 ,5 k g

s er b, k tg 3 0 9

diazepam

5 . A N T IE P IL E PS I - A N TI KO N V UL S I

fenitoin

61

i n j i . m /i .v 5 m g / m l,

ktk 1 00 a mp @ 2 m l

l ar r ek ta l4 m g/ ml , tu be 2 ,5 m l

k ap s 3 0 m g ( ga ra m N a) ,

b tl 2 5 0 k ap s

k ap s 1 00 m g (g ar am N a) ,

b tl 2 5 0 k ap s

i nj 5 0 m g /m l ( ga ra m N a ),


RESTRIKSIKELAS TERAP I ,N A MA G E NE R IK

- T er pi li h u nt uk a na fil ak si s

- O os is 0 ,3 m g - 0,5 mg ,

b i s a d i u lang

fenobarbi t a l

6 . A N T II N F EK S I

6 .1 A N TE LM IN T I K- O a lam label perlu

d ic a nt um k an p e ri ng a ta n

"h an ya s eb ag ai a nti d ot"

( dos is bes a r ).

- P em akaian hanya d i

P u s ke sm a s P e ra w a ta n



ta b 3 0 m g, b tl 1 00 0 ta b

ta b 5 0 m g, b tl 1 00 0 ta b

ta b 1 00 m g, b tl 1 00 0 ta b

i nj i .m 5 0 m g /m l,

k tk 1 00 a mp @ 2 m l

inj i.v 5 0 m g /m l ( se b ag a i g a ra m

N a), k tk 10 0 a mp @ 2 m l

6 .1 . 1 A n te lm i n ti k I n te s ti na l

mebendazo l tab 1 00 m g, b tl 100 tab

s ir 1 00 m g/ 5 m l, b tl 3 0 m l

pi rante l

6 . 1 .2 A n t if i la r ia

diet i lkarbamazin

6 .2 A N T I B AK TE R I

6 .2 .1 B e ta l ak ta m

amok s i si l in t r ih i d ra t

ampis i l in

K h u su s t e ra p i l a nj u ta n p a s ie n

yang d iru ju k kem ba li ke

Puskesmas.

benza t in benz i lpen i s il i n

Daf tar Oba t Esens ia l Nas io na l 2 00 8Daftar Dbat Esensia l Nasional2008

t ab s co re d 2 5 0 m g ( se b ag a i

p a mo a t) , b tl 2 5 0 t ab s co re d

s us p 1 2 5 m g /5 m l ( se b ag a i

p a mo a t) , b tl 3 0 m l

t ab s co re d 1 0 0 m g ( si tr at ),

b tl 1 0 00 t ab


k tk 1 0 s tr @ 1 0 t ab s co re d

s ir k er in g 1 25 m g/ 5 m l, b tl 6 0 m l

s e rb i n j i . m /i .v 2 5 0 m g /v i al


k tk 1 0 v i a l

s e rb i n j i . m /i .v 5 0 0 m g /v i al


k tk 1 0 v i a l

i nj i .m 1 ,2 j ut a U I/ ml ,

k tk 2 5 v ia l @ 4 m l

i nj i .m 2 ,4 j ut a U I/ ml ,

k tk 2 5 v ia l @ 1 0 m l

RESTR

O is ed ia ka n u n

d a e ra h e n d em i s f





( B e n tu k S e d ia a n , RESTRIKSI ( B e n tu k S e d i aa n , RESTRN A M A G E NE RI K

K e ku a ta n , d a n K em as a n)N A M A G E NE RI K


b en zilp en is ilin k ris ta l in j i .m /i.v 1 0 ju ta U I/v ia l, su lfad ia z in tab 500 m g , bt l 100 tab

k tk 2 5 v ia ltrim e top rim tab scored 2 00 m g,

fenoks im etil p enis ilin tab 500 m g ( sebaga i ga ram K ), T idak un tuk in feks i bera t b tl 1 0 0 t a b s co re d

(penis ilin V ) bt l 1000 tab

ta b 2 50 m g ( se ba ga i g ar am K ), 6 . 2. 2 .4 M a k ro l id

k tk 1 0 s tr@ 1 0 t ab e ritrom is in kaps 2 50 m g ( sebaga i s tea rat),s ir k e ri ng 2 5 0 m g /5 m l ( se b ag a i b tl 1 0 0 k a ps

g ar am K ), b tl 6 0 m l s ir 2 0 0 m g /5 m l ( se b ag a i e ti l

p ro ka in b en zilp en is ilin s erb in j i .m 3 j uta U I/v ia l, s u ks in a t) , b tl 6 0 m l

k tk 1 0 0 v i a l6 .2 .2 .7 P e ng g un a an K h us u s

s e rb i nj i .m 1 j u ta U I/ vi al ,

k tk 1 0 0 v i a l m e tron idazo l tab 2 50 m g , b t l 1 00 /1 000 tab

ta b 5 00 m g , b t l 1 0 0/1 00 0 t ab

6 .2 . 2 A n ti ba k te ri L a in6 .3 A N TI IN F E KS I K H US U S

6 . 2 . 2. 1 Te t r a si k li n6 . 3 . 1 A n t i le p r a

oks ite tra s ik lin in j i.v 2 5 0 m g /3 m l ( H el ),dapson tab scored 1 00 m g,

k tk 1 0 a mp @ 3 m lb tl 1 0 00 t ab s co re d

inj i.v 5 0 m g /m l ( He l) ,

k tk 1 0 v ia l @ 10 m l k lo fa z im in , micronized k ap s d ala m m in ya k 1 00 m g ,

te tra s ik lin kaps 250 m g (He l),b tl 1 0 0 k a ps

b tl 1 0 00 k a ps6 . 3 . 2 A n t i tu b e r ku l os i sk a ps 5 0 0 m g ( He l) ,

k tk 1 0 s tr@ 1 0 k ap s e tam bu to l tab 250 m g (H el), b tl 100 tab

ta b 5 00 m g ( He l) , b tl 1 00 ta b

6 . 2 . 2. 2 K l o r am fen i k o lison ia z id tab 1 00 mg , bt l 1000 tab

k lo ram fen iko l kaps 2 50 m g , b tl 1 000 kaps ta b 3 00 m g , b t l 1 0 00 ta b

s u sp 1 2 5 m g /5 m l ( se b ag a ip ira z inam id tab 500 m g , bt l 1 00 tabp a lm it at ), b tl 6 0 m l

rifam p is in tab scored 3 00 m g, H a n ya u n tu k t ub

6 . 2 . 2. 3 S u l fa - T r ime t op r im ktk 10 str @ 10 tab lep ra.

kotrim oksazo l D OEN I tab , k tk 1 0 s tr@ 10 t abta b 4 5 0 m g, k tk 1 0 s tr @ 1 0 t ab

ta b 6 0 0 m g, k tk 1 0 s tr@ 1 0 t ab( de w as a ) k o mb in a si :

s u lf am e to k sa zo l4 0 0 m g strep tom is in se rb in j 1 000 m g/v ia l (sebaga i D engan kem as

trim e top rim 80 m g s u lf at ), k tk 1 0 0 v i a l

ko trim oksa zo l D OE N II ta b, b tl 1 00 ta bkombinas i :

rifam p is in kapl1 50 m g ; 7 5 m g Ben tuk sed ia( p e di a tr ik ) k om b in a s i :

ison ia z id tab 150 mg ; 50 mg p en gg un aa n s es u lf am e to k sa zo l1 0 0 m g

p ro g ra m T B p a rutrim e top rim 20 m g

63Daftar Dbat E sensial Nasional2008 Daftar Obat E sensial Nasional 2008




kombinas i :

ri fampisin

isoniazid

e tambuto l

kombinas i :

ri fampisin

isoniazid

p i raz i namid

kombinas i :

ri fampisin

isoniazid

p i raz i namid

e tambuto l



k ap l1 5 0 m g

ta b 1 50 m g

ta b 4 0 0 m g

k ap l1 50 m g; 7 5 m g; 4 50 m g

ta b 7 5 m g; 5 0 m g; 3 00 m g

ta b 4 0 0 m g; 1 50 m g; 5 00 m g

k ap l1 50 m g; 4 5 0 m g

ta b 7 5 m g; 3 00 m g

ta b 4 0 0 m g; 5 00 m g

ta b 2 7 5 m g; 2 50 m g; 5 00 m g

6 .3 .3 A n ti se p ti k S a lu r an K e m ih

ko trim oksazo l D OE N I ta b, k tk 10 s tr @ 10 t ab

( d ew a s a) k o m bi na s i :

s u lf am e t ok s az o l4 0 0 m g

trim etopr im 80 m g

nitrofurantoin

trimetoprim

6 .4 A N T IF U NG I


b tl 1 0 0 t a b s co r ed


b tl 1 0 0 t a b s co r ed

6.4.1 A n t if u n gi , S i s tem i k

griseofulv in, micron i zed t ab s co re d 2 50 m g ,

b t l 1 0 0 t a b s c o r ed

n is ta tin ta b sa lu t 500 .000 U l/tab ,

b tl 10 0 / 1 0 0 0 t ab

s us p 1 0 0. 00 0 U l/ ml , b tl 1 2 m l

6.4.2 A n t if u n gi , T o p ik a l

A n t if u ng i D OEN

kombinas i :

a sa m b e nz oa t 6 %


65

s al ep , p ot 3 0 9

RESTRIKSIKELAS TERAP I ,N A M A G E NE RI K

FORMULASI

( B e n tu k S e d i aa n ,


t a b v a g in a 1 0 0 .0 0 0 U l /t ab ,

k tk 1 0 s tr @ 1 0 t ab

nistatin

Bentuk sed ia an dan

p en gg u na an s es ua i d en ga n

p r og r am T B p a ru n a si on a l.6 .5 A N T IP ROTOZOA

Bentuk sed ia an dan


p r og r am T B p a ru n a si on a l.

6.5.1 A n t iam u b a d a n A n t ig i ar d ia s is

me tro n id azo l tab 2 50 m g, b tl 100 tab

t ab 5 00 m g , b t l 1 0 0 t ab

6.5.2 Ant imalar iaBentuk sed ia an dan


p r og r am T B p a ru n a si on a l.

6 .5 . 2. 1 U n tu k P e n ce g a ha n

klo ro ku in tab 1 50 m g (sebaga i f osfa t),

b tl 1 0 00 t a b

6 .5 . 2. 2 U n tu k P e n go b at a n

A n ti m al ar ia D OEN

kombinas i :

p irimetam in 25 mg tab , b tl 5 00 ta b

s ulfa do ks in 5 00 m g

arteme ther in j 80 m g / m l , ktk 6 am p @ 1 m l

artesuna t in j i . v l i .m 60 m g / m l ,

ktk 8 v ia l @ 1 m l

kombinas i :

a rte su na t ta b 5 0 m g k tk , 2 b ls @ 1 2 ta b ( ko mb ip ak)

a mo dia ku in ta b 2 00 m g k tk , 3 b ls @ 8 t ab

klo ro ku in tab 1 50 m g (sebaga i f osfa t),

b tl 1 0 00 t a b

s ir 5 0 m g / 5 m l , b tl 6 0 m l

ku in in tab 222 m g (b isu lfa t), b tl 1000 tab

inj i.v 2 5% ( s eb a ga i H e l) ,

ktk 1 00 a mp @ 2 m l

prim aku in tab 1 5 mg (se baga i f osfa t) ,

b t l 1 0 0 0 t ab


RESTR

U ntu k d ae ra h-d

t er da pa t r es is te

k lo ro ku in y an g

o leh D inas

Kabupaten .

- H an ya u ntu k

gawat .

P emaka ian

Pu s k e smas Pe





(Bentuk Sed iaan , RESTRIKSI (Bentuk Sed iaan , RESTRNAMA G E NERI K



7 . A N T IM I GREN 1 2 . D I AGNO S TI K

7 . 1 P RO F IL AKS IS 1 2.2 T ES F UN G SI

d ih id roe rgo tam in tab 2 ,5 m g ( sebaga i m es ila t), 12 . 2 .3 L a i n -l a in

k tk 1 0 s tr@ 1 0 ta b fluo rese in t is m a ta 1% (garam Na ), b t l 5 ml

t is m a ta 2 % ( ga ra m N a) , b t l 5 m l

7 .2 S ER A NG AN A K UT in j 1 0% , k tk 1 a m p 5 m l

e rgotam in tab 1 m g ( tartrat), b tl 1 00 tabin j 2 0% , k tk 1 a m p 5 m l

kom b inas i: tab, k tk 30 /1 00 t ab 1 2.3 T ES K UL IT

e rgo tam in 1 mg tuberku lin p ro te in in j i .k 1 :10 , k tk 1 v ia l 2 m lka fe in 50 mg p u r i fi e d de r iv a t iv e

9 . A N T IP ARK IN SO N1 3 . D I SI N F EK T AN d a n AN T IS E P TI K

An tipark in son OOE N tab, b tl 1 00 tab O iagnost ik park in son ism

kombinas i : h a r us d i pa s ti ka n d u lu . 1 3 .1 AN T IS E P TI K

b en se ra zid 2 5 m gh id ro ge n p erok sid a e aira n ko nsen tra t, b tl 10 00 m l - O is im p an d

lev od opa 1 00 m gdengan sum

O ia g no st ik p a rk in s on is mk ed ap u da ra ,

triheks ifen id il tab 2 m g ( H e l), bt l 250 t abd a ri e a h a ya

h a r us d i pa s ti ka n d u lu . - U ntuk d ie ne er

3% .

1 0 . D A RA H , O BA T y an g M E MP E NG A RU HI

pov idon iod ida la r 1 0% , b tl 1 000 m l

1 0 .1 AN T IANEM I

asam f ola t tab 1 mg , btl 1000 tab 1 3 .2 D I S IN F E K T AN

ta b 5 m g , b t l 1 0 00 t abe tano l70% la r, btl 100 m l /1000 m l

bes i (II ) s ulfa t 7 H 2O tab sa lu t 300 m g, bt l 1 000 tabka ls ium h ipok lorit se rb , k tg 20 9 P rog ram sam ija

s ir , b t l 6 0 m l P2-PL.t ts , b t l

k re so l t er sa po ni fi ka si 5 0% e air an , b tl 1 00 0 m ls ianokobalam in in j 500 m eg/m l,

(I isol)(v itam in B 12 ) k tk 1 00 am p @ 1 m l

1 0 .2 K O A GU L AS I, O B A T y a n g M E M P EN G A RU H Ipara fo rm a ldeh ida tab 1 g , b t l 1 00 t ab

l ar 5 % , b tl 1 00 0 m l

fito me na dio n (v ita min K 1) ta b s a lu t 1 0 m g , b tl 1 00 0 t ab

in j 1 0 m g/m l, k tk 1 00 a mp @ 1 m l

in j i .m 2 m g /m l, am p 1 m l - O os is un tuk bay i ba ru lahir

1 mg

- O os is u ntu k b ay i p re m atu r

0 ,5 m g





FORMULASI



1 4. G IG I d an M UL UT , O BA T d an B AH AN u n tu k

1 4.1 G /G I d an M U LU T, O B AT u nt uk

A ne ste tik lo ka l g ig i D O EN in j, k tk 2 0 / 5 0 / 1 0 0 am p @ 2 ml

kombinas i :

l id ok ai n H CI 2 %

ep ine frin 1 : 8 0.000

e t il k l o r ida

eugeno l

f luor

k a l s ium h i d r oks i da

k lo r fe n o l k am fe r m e n to l

(CHKM )

l idokain

nistat in

s e mp ro t 0 ,0 5 -0 ,2 m l , b t l 1 0 0 m l

e a ir an , b tl 1 0 m l

ta b 0 ,5 m g, b tl 1 00 t ab

p a st a, k tk 2 t ub e

e a ir an , b tl 1 0 m l

i nj 2 % ( HC I) , k t k 1 0 0 a m p @ 2 ml

p as ta 5 % ( HC I) , t u be 1 0 9

s em p ro t 1 5% ( HC I) , b t l 6 0 m l

s us p 1 00 .0 00 U l/m l, b tl 1 2 m l

1 4.2 G /G I d an M U LU T, B A HA N u nt uk

b a h a n t um pa t an

sementara

g la ss i on o me r A R T

(A t rauma t ic Res t or a t iv e

Treatment )

g u tt a p e rc h a p o in ts

k om p os i t r e si n

l ar d an s er b, b tl 1 00 9

s er b, b tl 1 0 9

l ar , b tl 6 9 ( 4, 8 m l )

c oc oa b ut te r 5 9

k tk 1 2 0 b a t an g

se t

p as ta p en gis i s al ur an a ka r p as ta , b tl

cubic les 1 x 1 x1 e m , k l g 5 0 b u ti rp o n s g e la t in

6 9

RESTRIKSIKELAS TERAP I ,

N A M A G E NE RI K

1 5 . D I URE TI K

f urosemida



ta b 4 0 m g , b tl 2 50 ta b

inj i . v l i .m 10 m g / m l ,

k tk 2 5 a mp @ 2 m l

1 6 . H O RM O N, O B AT E N DO K RI N L A IN d a n K O NT RA S EP TI K

1 6 .2 AN T ID I A B ET E SK em asa n h aru s ke dap

udara 1 6 .2 . 1 A n t id i ab e te s , O r al

gl ibenk lamida

U n tu k p u s ke sm a s d a e ra h

tertentumet formin

ta b 2 ,5 m g, b tl 1 00 t ab

ta b 5 m g, b tl 1 00 t ab

ta b 5 00 m g , b tl 1 00 ta b

RESTR

1 6.3 H O RM O N K EL AM IN d an O B AT y an g M E M PE NG AR U HI F ER TIL IT AS

S esua i d en gan

N as io na l y an g

BKKBN .6 . 3 .4 Kon t ra sep ti k

1 6 .3 .4 .1 K o n tr a se p ti k, O r al

kom b inas i : p il

l ev on o rg e st re l 1 5 0 m e g

e ti nil e st ra di ol 3 0 m e g

1 6 .3 .4 .2 K o n tr a se p ti k, P a r en t er a l

m ed roks i p roges teron in j d epo 150 m g

asetat

c op pe r T

1 6 .3 .4 .3 K o n tr a se p ti k, A KDR ( I UD )

se t 1 buah

l a ru t an l u go l

1 6. 4 H O R M ON T IR O ID d a n A N T IT IR O ID

b tl 3 0 m l

propi l t iouras i l


ta b s co re d 1 00 m g, b tl 1 00 0 ta b

P e m ak a ia n h a

dulu.




NAMA G E NERI K(Bentuk Sed iaan , RESTRIKSI

K e ku a ta n, d an K ema sa n )

16 . 5 KORT I KOSTERO ID

deksam e tason tab 0 ,5 m g, b t l 1 000 t ab

i nj 5 m g / m l ( s eb a g a i n a tr ium

fo sf at ), k tk 1 00 a mp @ 1 m l

h idroko rlison tab 1 0 mg,

s e rb i n j 1 0 0 m g l vi a l( N a s u k si n at )

k tk 1 00 v ia l @ 2 m l

p redn ison tab 5 mg , bt l 1000 tab S ebaga i a lte rnat if

dek s ame t as on .

KELAS TERAP I ,

NAMA G E NERI K

f urosemida

kaptopr i l

1 7. 7 S YO K, O BA T u ntu k

1 7 .7 .1 S y ok K a rd i og e ni k

ep i ne fr i n ( ad r ena li n )17 . KARDIOVASKULER ,OBAT

1 7 .1 AN T IANG INA

a tenolo l tab 50 mg, ktk 10 str@ 10 tab 17 . 8 ANT I H IP ERL I P IDEMIA

i s o s o rb i d d i n i tr a t s imvastat int ab s u bl in g ua l 5 m g ,b tl 60 t ab

FORMULASI

(Bentuk Sed iaan ,

K e k ua ta n , d a n Kemas a n )

ta b 4 0 m g, k tk 2 0 s tr @ 1 0 t ab

inj i . v l i .m 10 m g / m l ,

k tk 2 5 a mp @ 2 m l


k tk 1 0 s t r@ 1 0 t ab s co re d


k tk 1 0 s t r @ 1 0 t a b s c or ed

inj i.v 0 ,1 % ( se b ag a i H e ll

b ita rt ra t) , k tk 1 00 a m p @ 1 m l

ta b s co re d 1 0 m g , k tk 3 0 t a b

1 7 .2 AN T IAR I TM I A

p roprano lo l tab 1 0 m g (H e l), b tl 1 00 tab

inj i.v 1 m g / m l (Hel ) ,

k tk 1 0 a mp @ 1 ml

1 8. K U Ll T, O BA T T OP IK A L u n tu k

1 8 .2 AN T IB AK T ER I

A n ti b ak te r i D O E N

kombinas i :

17 . 3 ANT I H IP ERTENS I

hidrok lorot iaz ida

bas itra s in 500 U I/g

p o li mi ks in B 1 0 .0 0 0 U I/ g

ta b 2 5 m g, b tl 1 00 t ab

kaptopr i l

1 8 .3 AN T IF U NG I

A n ti fu n g i D O E N

kombinas i :

a sa m b en zo at 6 %



k tk 1 0 s tr @ 6 ta b s co re d


k tk 1 0 s tr @ 6 tab/10 tab

scored

- T idak bo leh digunakan

u n tu k w a n i t a h am il .

- D ap at t im bu l e fe k s am p in g

batuk .

na t r ium t i o su l fa t

1 7 .4 A N TI AG R EG A SI P L AT E LE T

s ale p, tu be 5 9

s ale p, p ot 3 0 9

1 8 .4 AN T II N FL AMAS I d a n AN T IP RU R IT IK

c air an 2 5% , b tl 3 0 m l

as am ase t il s a li s il a t

(asetosal )

ta b 8 0 m g, k tk 1 0 b ls @ 1 0 t abbe t ame t as on

1 7.6 G AG AL J AN TU N G, O BA T

d igoks in tab 0,0625 m g , btl 100 tab

ta b 0 ,2 5 m g , b t l 100/100 tab

i n j 0 , 2 5 m g / m l , k tk 1 a mp 2 m l

T ab le t 0,0625 m g un tuk

pediat r ikhidrokor t ison

71

s a le p 0 , 1% ( s eb a g a i v a le r at ),

tu be 5 9

k r im 0 , 1% ( s eb a g ai v a le r a t) ,

tu be 5 9

k ri m 2 ,5 % ( as et at ), t ub e 5 9

RESTR

- T idak boleh

u n tu k w a n it a h a

- D ap at tim bu l e

batuk .

U ntuk keadaan

kronis .

Daftar Dbat Esensial Nasional2008 Daftar Obat Esensial Nasional 2008






1 8 .5 AN T IS KAB IE S d a n AN T IP E D IK U L O SI S

S a le p 2 - 4, k o m bi na s i :

a sa m s alis ila t 2 %

b ele ra ng e nd ap 4 %

1 8 .6 KAU S TI K

pe ra k n i tr a t

s al ep , p ot 3 0 9

l ar 2 0 %, b tl 1 0 m l

a s am s a li s il a t

1 8. 7 K E RA T OL IT IK d a n K E RA T OP L AS T IK

c o a l t a r

podofi l in

sa lep 2% , p ot 30 9

sa lep 5% , p ot 30 9

s ale p 1 0% , p o t 3 0 9

la r 5 % , b t l 1 00 m l

t in g tu r 2 5 % , b t l 3 0 m l

1 8 .8 L A IN - LA I N

beda k sa lis il se rb 2% , ktk 10 0 9

liq uo r c a rb on is d et er ge ns s us p 2 % , b tl 3 0 m l

s us p 5 % , b tl 3 0 m l

liq uor fa ber i liquo r

7 3

RESTRIKSIKELAS TERAP I ,N A M A G E NE RI K



2 0. L AR UT AN E LE KT RO Ll T, N U TR IS I d an L AI N - LA IN

Un t u k l e s i h i p e r g ra n u l as i

2 0.1 O RA L

Ga ram o ra lit se rb , 10 0 ktg ,

kom binas i : t iap k tg un tu k 200 m l air

n at riu m k lo rid a 0 ,5 2 9

ka liu m klo rid a 0 ,3 0 9

t r in a t ri um s i tr a t

d ih id ra t 0 ,58g

g lu ko sa a n hi dr at 2 ,7 0 9

na tr ium b ikarbonat tab 5 00 m g, b tl 1 000 t ab

P erlu p en ga wa sa n kh usu s

karena :

- H aru s d ia plik as ika n o le h

dok te r

- 1 -4 ja m s ete la h p em ak aia n

h ar us d ib er sih ka n s up ay a

tidak ada obat yan g

tertinggal .

- P eng gun aan han ya p ada

pe neb alan yan g he bat,

k ar en a d ap a t m e ni mb ul ka n

b ah ay a a kib at a bs or bs i.

- T id ak b ole h d ig un ak an p ad a

w an ita h am il k are na e fe k

te ra togen i k .

- T id ak b ole h d ip ak ai s en dir i

o l e h p a s ie n

- T id ak b ole h d ib aw a p ula ng .

2 0 .2 P ARE NT E RAL

g lukosa la r in fu s 5% , btl 500 ml

l ar i nf us 1 0 %, b tl 5 0 0 m l

la r i nfu s 4 0 %, b tl 2 5 m l

na tr ium k lo rid a la r in fu s 0 ,9% , b tl 500 m l

la r in fu s 3 %, b tl 5 00 m l

i nj 1 5 %, v ia l 5 0 m l

rin ger la kta t la r in fu s, b tl 500 m l

2 0.3 LA IN - L AINa ir u ntu k i nje ks i k tk, a m p/via l @ 1 0 m l/20 m l

2 1. M AT A, O BA T u nt uk

2 1 .1 A N ES T ET IK L O KA L

te traka in tis m a ta 0 ,5% ( H CI), btl 5 ml

2 1 .2 AN T IM I KROBA

oksite tra sik lin sa lep m a ta 1% ( HCI), t ub e 3 ,5 g

su lfa se tam id a tis m ata 15% ( natrium ), b tl 5 m l

2 1 .4 M I D R IA T IK

atro p in tis m a ta 0,5% ( su lfa t), b tl 5 m l

t is m a ta 1 % ( su lf at ), b tl 5 m l


RESTR

D i m in um s e d ik i

2 - 3 t e gu k u n tu

muntah

P er lu d

pem erik sa an

nat r i um

P em aka ia n

P us ke sm a s

FORMULASI FORMULASI



KELAS TERAP I, KELAS TERAP I ,(Bentuk Sed iaan , RESTRIKSI (Bentuk Sed iaan , RESTR

NAMA G E NERI KK e ku a ta n, d an K ema sa n )

N AMA G E NERI KK e ku a ta n , d an K ema sa n )

2 1 .5 M IO T IK D A N A N TI GL A UK O M A k lorpromazin tab s alut 25 m g ( HCI),

p ilokarpin tis m ata 2% (HCl/nitrat), btl 5 m l b tl 1 00 0 t ab

t ts m at a 4 % ( HC l/ ni tr at ), b tl 5 m l t ab s al ut 1 00 m g ( HC I) ,

b tl 1 00 0 t ab

2 2. O KS IT OS IK d an R EL AK S AN U TE RU Si nj i .m 2 5 m g / m l (HCI),

k tk 100 am p @ 1 m l

2 2 .1 O KS IT O S IK2 5. S AL UR AN C ER NA , O BA T, u nt uk

metilergometrin tab salut 0,125 mg (maleat),

b tl 1 00 t ab 2 5 .1 A N TA S ID A d a n A N T IU L KU S

i n j 0 , 200 m g / m l ,Antas ida DOEN I tab kunyah, btl 1 000 tab

k tk 100 am p @ 1 m lkombinas i :

in j 1 0 U l/m l, k tk 1 00 a mp @ 1 m laluminium

oksitosinh id ro ks id a 2 00 m g

magnes ium

2 3 . P S IKO FARMAKA h id ro ks id a 2 00 m g

2 3 .1 A N TI AN S IE T AS d a n A N T II NS O M NI A Antas ida DOEN II susp, btl 60 m l

diazepam tab 2 mg, btl 1000 tabkombinas i :

a luminiumta b 5 m g, b tl 1 00 0 ta b

h id ro k si da 2 0 0 m g / 5 mlin j i .m 5 m g / m l ,

k tk 100 am p @ 2 m lmagnes ium

h id ro k si da 2 0 0 m g / 5 ml

2 3 .2 A N TI DE P RE S I d a n A N T IM A N IA 2 5 .2 AN T IE ME T IK

am itriptilin tab s alut 2 5 m g (HCI),d imenhidrinat tab 50 m g, btl 1000 t ab Penggunaan

k tk 1 0 b ls @ 1 0 t ab sebelum mak

m e nd ap at ka n

2 3 .3 A N TI Oa S ES I K O M PU L SI y an g l eb ih b ai k

k lom ipram in tab 2 5 m g ( HCI), btl 1 000 t abk lorpromazin tab s alut 25 m g ( HCI),

b tl 1 00 0 t ab

23 . 4 ANT I P S IKOS I Si nj i .m 2 5 m g / m l (HCI),

ktk 100 am p @ 1 m l

haloperidol tab 0,5 m g, btl 1 0 0 / 1 0 0 0 tab - Sebagai a lternatif in j i .m 5 m g / m l (HCI),

ta b 1 ,5 m g, b tl 10 0 / 1 000 tab klorpromazin. k tk 100 am p @ 2 m l

tab 2 m g, k tk 100 tab - Puskesmas yang terintegrasi

tab 5 m g, b tl 1 0 0 / 1 000 tab dengan kesehatan jiwa. 2 5 .3 AN T IH EMO RO ID

t ts 2 m g / m l , b tl 1 5 m l / 1 0 0 mlAntihemoroid DOEN sup, ktk 100 sup

in j i .m 2 m g / m l (HCI),kombinas i :

k tk 5 a mp @ 1 m lb ism ut su bg ala t 15 0 m g

in j i .m 5 m g / m l (HCI),heksaklorofen 2,5 mg

ktk 5 a mp @ 1 m llidokain 10 mg

i nj 5 0 m g / m l ( s ebaga i dek anoa t ),seng oksida 120 mg

ktk 5 a mp @ 1 m l ( l ong ac t in g )sup ad 2

9


FORMULASI FORMULASI



KELAS TERAP I, KELAS TERAP I ,

NAMA G E NERI K(Bentuk Sed iaan , RESTRIKSI (Bentuk Sed iaan , RESTR



2 5 .4 AN T IS P ASMOD I K kodein tab 10 mg , b tl 250 tab

atrop in tab 1 mg (sulfat), klg 1 00 tab

inj i . m / i . v l s . k 0,25 m g / m l (sulfat), 2 6 .3 E KS P EK T O RAN

ktk 1 00 am p @ 1 m l gliseril gua iakolat s ir 25 m g / 5 m l, b tl 6 0 m linj i . m / i . v l s . k 1 m g / m l (sulfat),

ktk 5 0 a mp @ 1 m lta b 1 00 m g, b tl 1 00 0 t ab

ekstra k beladon tab 1 0 m g, b tl 100/1000 tab oba t b atuk hitam (O BH ) caira n, btl 2 00 m l

c ai ra n k on se n tr at , b tl 1 00 0 m l

2 5. 5 D lA RE , O BA T u nt ukGaram ora lit serb, 1 00 ktg, D im in um s ed ik it d em i s ed ik it

2 7. S IS TE M I MU N , O BA T y an g M E MP EN G A RU HI

kombinasi: tia p k tg u ntuk 200 m l air 2-3 teguk un tuk mengh inciari 2 7. 1 S E RU M d a n I MU N O GL O BU L INna t ri um k l o ri da 0 ,5 2 9 muntah

k a l ium k l o ri da 0 ,3 0 9se rum anti b isa ular in j i . m . l i . v , ktk 1 0 v ia l @ 5 m l - Khusus daerah

t ri na tr i um s i tr a tA .B .U . I ( k hu su s u la r - D is im pa n p ad a

dih id rat 0 ,58gd a ri l u ar P a p ua )

g lu ko sa a n hi dr at 2 ,7 0 9A . B. U .I I ( kh u s us u l ar

d a ri P a p ua )

2 5 .6 KA T ARTI K

gliserin cairan, b tl 100 mls e r um an t id i ft e ri (AD.S ) i n j i . m 1 0 .0 0 0 U l lv i al , D is im p an p a d a s u


2 6. S AL UR AN N AP AS , O BA T u nt uki n j i . m 2 0 .0 0 0 U l lv i al ,

2 6 .1 AN T IA SMA

ktk 1 0 v ia l @ 1 0 m l

deksame tason tab 0 ,5 m g, b t l 1 000 t abse rum antirabies in j i.m 1 00 U l/m l, - D igunakan untu

inj i.v 5 m g / m l ( s ebaga i na t ri umktk 10 v ia l @ 20 m l an p o s t - e x p o s u r e

fo sta t) , k tk 1 00 a mp @ 1 m lrabies .

- D is im pa n p ad a

efed rin tab 25 m g (HCI), b tl 1000 tabs eru m a nti te ta nu s ( A.T .S ) U ntu k p en ce ga ha n : - D is im pa n p ad a s

epinefrin (adrenalin ) in j 0 ,1 % (sebagai HCl / b i t art rat ),i nj i .m 1 50 0 U l/ am p .

ktk 1 00 am p @ 1 m lktk 1 0 am p @ 1 m l

U n tu k p en g ob a ta n :

sa lbu tam ol tab 2 m g (sebaga i su lfa t),inj i . m . l i . v 1 0 .0 0 0 U l /am p ,

b tl 100/1 0 00 t abktk 1 0 am p @ 2 m l.

t ab 4 m g ( se b ag a i s ul fa t) ,inj i . m . l i . v 20 . 000 U l l vi a l,

b tl 100/1 0 00 t abktkl1 0 v ia l @ 4 m l

2 6 .2 AN T IT U S IF 2 7. 2 V A KS IN

deks trome torfan tab 15 m g ( HBr), b tl 1 000 tab vaks in B .C.G . in j i.k, k tk 5 am p @ 2 m l Ha rus d is impan p

s ir 1 0 m g / 5 m l ( H Br) , b tl 6 0 m l in j i .k, ktk 5 a mp @ 4 m l d ib aw ah 5 0 C .


FORMULASI FORMULASI



( Be n tu k S e d ia a n ,


in j s.k, O isimpan pad a suhu 2-8 0 C

k tk 1 0 v ia l ( 1 0 d o s is ) @ 5 ml


v a k s in e ampa k

v a ks in h e pa t it is B

rekombinan

RESTRIKSIKELAS TERAP I ,

N A M A G E NE RI K

t ia m in ( v it am i n B 1 )

in j 2 0 m e g /m l, k tk 1 v ia l 0 ,5 ; 1 m l O is im pa n p ad a s u hu 2 -8 0 Cv it am i n B k om pl ek s

v ak si n j e ra p d if te ri t et an us i nj i .m , k tk 1 0 v i al @ 5 ml

(OT )

v ak si n j e ra p d if te ri t et an u s i nj i .m , k tk 1 0 v i al @ 5 ml

p e r tu s i s (OTP )

vaks in j erap te ta nus in j i .m , ktk 1 v ia lS m l

( t e ta nus ads o r bed

toxoid)

vaks in po lio tts, k tk via l 1 0 /20 d osis

vaks in rab ies, un tuk serb in j s .k.li.k ,

m anus ia ktk 7 via l @ 1 do s is +

7 a m p p e la ru t @ 2 ml

Boos te r :

k tk 5 a mp @ 1 do s is +

5 a m p p e la ru t @ 4 ml

2 8. T EL IN G A, H ID UN G d an T EN G GO RO KA N, O BA T u ntu k

karbo g lise rin tts te linga 10 %, b tl 5 m l

2 9 . V IT AM IN d an M IN E RA L

a sa m a sk or ba t ( vit am in C ) ta b 5 0 m g , b t l 1 0 00 ta b

ka ls ium lakta t (ka lk ) ta b 5 00 m g, b tl 1 000 tab

p iridoks in (vitam in B 6) ta b 1 0 m g (HCI), b t l 1 0 0 0 t ab

ta b 2 5 m g (HCI), b t l 1 0 0 0 t ab

re tino l ( vitam in A ) ta b 5 .00 0 U I, b tl 1 000 t ab

k a ps l un a k 5 0 .0 0 0 U I ,


k a ps l un a k 1 0 0 .0 0 0 U I ,


k a ps l un a k 2 0 0 .0 0 0 U I ( s eb a ga i

p a lm i ta t) , b t l 5 0 k a ps l un a k

O i si m pa n p a d a s u h u 2 - 80 C



O i si m pa n p a d a s u h u - 2 00 C

- O is im p an p ad a s uh u 2 -80 C

- O igunakan untuk

pengobatan p re-exposure

da n p re-exposure di

d a e ra h ra b ie s .

( Be n tu k S e d ia a n ,


ta b 5 0 m g ( HC I) , b tl 1 00 0 t ab

RESTR

t ab , b t l 1 0 0 0 t a b

MENTERIKESEHATAN

Daftar Dbat Esensial Nasional2008 Daftar Obat Esensial Nasional 2008

DAFTAR OBAT DALAM DOEN 2005



YANG MENGALAMI PERUBAHAN

LAMPIRAN I

FORMULAS IPENAMB

P E NG U RANO NAM A GENERIK (Bentuk Sediaan, Kekuatan

P E RUS e d ia a n , K em as a n)

FORM

1 alprazolam tab 0,25 mg,

k tk 1 0 s tr@ 1 0 t ab

t ab 0 ,5 m g ,

k tk 1 0 s tr@ 1 0 t ab

2 ama lgam perak serb 6 5·75% , btl 1 oz

3 am foteris in*) in j. i.v., via l 50 m g

4 am ilorid tab 5 mg (l+Cl), btl 100 tab

5 am iodaron tab 2 00 mg, k tk 30 tab

i nj 1 50 m g /3 m l,

ktk 6 a mp @ 3 m l

6 artesunat in j i.v /i.m 60 mg /m l,

ktk 8 v ia l @ 1 m l

7 asam triklorasetat krista l, k tg

8 as e tazo lam i da ta b 2 50 m g, b tl 1 00 ta b P i ndahsub

s e rb i nj i .m / i. v. 5 0 0 m g /v ia l

( se b ag a i g a ram N a ),

k tk 1 0 v i al + 1 0 a m p a ir

u ntu k in je ks i @ 5 m l

9 atrakurium inj 25 m g/2,5 m l, amp 2 ,5 m l

10 benzilpenisilin salep mata 1000 U I/g, t ube 5 9

11 benzoil peroks ida je li 2 ,5%, t ube 5 9

je li 5 %, tu be 5 9

12 bes i ( II) sulfat 7 H20 tts, b tl 60 m l

13 betametason tts m ata 1mg/m l ( natrium ),

b tl 5 m l

DAFTAR OBAT DALAM DOEN 2005

YANG MENGALAMI PERUBAHAN

Daf tar Oba t Esens ia l Nas io na l 2 00 8

PENAMBAHAN (+) , PENAMB



FORMULAS I

NO NAMA GENER IK (Ben tuk S ediaan , KekuatanP EN G UR A NG A N ( .) ,

P ERUBAHANS e d ia a n , K em as a n)

FORMULAS I

14 bupivaka in in j in filtr 0 ,25% (l+Cl), -k tk 5 v ia l 2 0 m l

1 5 ca mp ura n in su lin regular : i nj 1 00 U l/m l, k tk 1 v i al 1 0 m l +

in t ermediate ( 30 : 7 0 )

16 c op pe r T se t 1 buah +

17 daunorubisin serb i n j 50 mg (He l) +

18 deks tran 70 lar infus 6% , btl 500 m l -

19 deks trose lar infus 5 %, btl 500 ml +

20 desmopres in semprot Perubahan bentuk

sediaan

21 dietilkarbamazin tab s cored 100 m g (sitrat), Perubahan kekuatan

btl 1000 tab sediaan

22 digoksin tab 0,0625 m g, btl 100 tab +

ta b 0 ,2 5 m g, b tl 1 00 ta b

i n j 0 , 25 m g /m l ,

k tk 1 a m p @ 2 ml

23 diloksanid tab 500 mg (furoat) +

24 dinatrium edetat tis m a ta 0 ,35% , bt l 5 ml -

25 dobutam in in j 50 mg/m l; via l 5 m l +

i nj 2 5 m g/ ml; v ia l 1 0 m l

26 edro fonium inj i.v. 10 mg/m l ( klorida), -k tk 1 0 v i al @ 1 0 m l

28 efavirens tab 200 m g , btl 90 tab Perubahan sub kelas

tab 6 00 m g, b tl 30 tab terapi dan bentuk

sediaan

29 enfluran cairan ih, btl 250 ml -

30 etakrid in (rivanol) lar 0,1 % , b tl 300 m l -s er b, b tl 1 00 9

FORMULAS I

NO NAM A GENERIK (Bentuk Sediaan, KekuatanP E NG U RA

P E RUS e d ia a n , K em as a n)

FORM

31 etil e ster dari o leum inj i .a.li.v .1 m l

papaveris teriodisas i mengandung 0,96 m l

(o leum iodatum ) (setara dengan 0,48 9

io diu m) , k tk 1 a m p 1 0 m l

32 etoksuks im id kaps 250 mg,

b tl 10 0 / 1 0 0 0 k ap s

s ir 2 5 0 m g / 5 m l, b tl 6 0 m l

33 etonogestre l im plan 1 rods (3 th)

34 fen ito in sirup 50 m g / 5 ml

35 fenobarbita l tab 50 mg

36 fenol cair btl 10 m l

37 fentanil in j i.m .li.v . 0 ,05 m g/m l ( sitrat), P erubahan

k tk 5 a mp @ 2 m l kemasan

39 fitom enadion (v itam in K1 ) in j. i .m . 2 mg/m l, am p 1 m l

40 fluoksetin kap/tab 10 mg, ktk 30 tab

k ap /t ab 2 0 m g , k t k 3 0 t ab

4 1 fr ak si p ro te in p la sm a ( te rm as u] b e nt uk s e

fibrinogen) kekuatan

dicantumk

42 fram isetin kasa s teril1 % ( sulfat),

k tk 1 0 I br

43 gam eksan krim 1% , btl 30 m l

44 Garam Oralit I serb, 100 k tg , tiap k tg untuk

1 00 0 m l a ir

45 gen tian v io let lar 1% , bt l 10 ml

46 haloperido l in j i.m . 2 mg/m l ( l+Cl), P erubahan

k tk 5 a mp @ 1 m l ga ram

i nj i .m . 5 m g /m l ( l+ C l) ,

k tk 5 a mp @ 1 ml

8 2Daftar Dbat E sensial Nasional2008 Daftar Obat E sensial Nasional 2008

FORMULAS IPENAMBAHAN (+) ,

FORMULAS IPENAMB



NO NAMA GENER IK (Ben tuk S ediaan , KekuatanP EN GU RA NG AN ( . ) ,

S e d ia a n , K em as a n)P E RU B A H A N

FORMULAS I

47 hidrok lortiaz id tab 2 5 m g, b tl 1000 t ab +

48 hidrokort ison tab10mg +

49 hidrokortison krim 1 % (aseta t), tube 5 9 -

50 hidrokortison ase tat tis m ata 1% , b tl 5 m l -

51 human t etanus in j i.m 500 U I, via l +imunoglobul in

52 insulin intermediate in j 40 U I/m l, ktk 1 v ia l 1 0 ml -

53 insulin regu lar in j 40 U I/m l, k tk 1 via l 1 0 m l -

54 iodium inj 480 mg/m l, ktk 1 amp 10 m l -

55 isofluran eairan ih, btl 250 ml +

56 isoprenalin in j 1mg /m l (HCI), -k tk 1 a mp 2 m l

57 karbamazepin s irup 1 00 mg/5 m l, +

b tl 1 20 m l

t ab 1 00 m g ( ku ny ah )

58 karbon a ktif serb ak tif, k tg 0,5 kg Perubahan nam a obat

59 ketoprofen sup 100 mg +

60 klom ifen tab 50 mg (s itrat), b t l 10 tab -

61 klom ipram in tab 1 0 mg (HCI), b tl 250 t ab -

62 klorambusil tab 2 mg +

63 kloram fenikol tis te linga 3 % , btl 5 ml -

64 klorheks id in lar 1 ,5 % ( glukonat), bt12,51 -l a r 4 , 0 % ( gl u ko n a t) , b t1 2 ,5 1

65 klorheks id in lar 0,2% (glukonat), btl 2,5 I +

NO NAM A GENERIK (Bentuk Sediaan, KekuatanP E NG U RA

S e d ia a n , K em as a n)P E RU

FORM

66 k lormetin se rb in j 10 mg/v ia l ( HCI),

k tk 1 v ia l

67 k lozapin *) ta b 2 5 m g, k tk 5 0 t a b

ta b 5 0 m g, k tk 5 0 t a b

68 kodein tab 1 0 mg (fos fat), btl250 tab P eru baha

s ed ia an

kemasan

69 kolkhis in tab 500 meg,

ktk 3 s tr@ 1 0 ta b

70 kombinas i: tab, ktk 30/100 t ab

e rg ota min 1 m g

kafein 50 m g

71 kombinas i: kapsul

ekst. apii herba 92mg

ek s l. o r to s i phon i s f o l ium 28 mg

72 kompos it r e sin set

73 kuin id in tab 200 mg (sulfat),

b tl 1 0 0/ 1 0 0 0 t ab

7 4 la r. n utris i : g lu ko sa 4 % + i nf us , b tl 5 00 m l

NaCI0,18%

75 laru tan nutris i DOEN I infus, botol 5 00 m l

76 laru tan nutris i DOEN II infus, botol 500 m l

77 laru tan nutris i D OEN III in fus, botol 50 0 m l

78 laru tan nutris i DOEN IV infus, botol 500 m l

79 laru tan nutris i DOEN V infus, botol 500 m l

80 levam iso l tab 50 mg (HCI),

ktk 4 b ls @ 9 ta b

84Daftar Dbat E sensial Nasional2008 Daftar Obat E sensial Nasional 2008

FORMULASIPENAMBAHAN ( + ) ,

FORMULASIPENAMB



NO NAMA G ENERIK (Bentuk Sediaan, KekuatanP EN G UR AN G AN ( .) ,

P E R U B A H A NS e d ia a n , K em as a n)

FORMULASI

81 levertran salep kulit 5% -

82 levonorgestre l p il75 meg , 150 m eg -

83 levonorgestre l implan 6 r ods ( 5 th) -

84 lidokain in j 5% + g lu ko sa 7 ,5 % , +

am p 2 m l

85 lidokain in j 1% (HCI) + e pin efr in 1 : -2 00 .0 00 , k tk 1 0 v ia l @ 3 0 m l

i nj 2 % ( HC I) + e pin ef ri n 1 :

2 00 .0 00 , k tk 1 0 v ia l @ 2 0 m l

86 liquor faberi liquo r d itambah men tol 0 ,1% -l iq u o r d i tam b ah m e n to l 0 , 5%

87 liquor veilli; laru tan +

kombinas i :

a sa m s al is il at 0 ,1 %

boraks 0,5 %

g liserin 10%

88 lis inopril tab 5 mg, ktk 3 s tr @ 10 tab -ta b 1 0 m g, k tk 3 str @ 1 0 ta b

ta b 2 0 m g, k tk 3 str @ 1 0 ta b

89 litium karbonat tab200 mg,k tk 10 s tr@ 10 tab Perubahan kekuatan

sediaan

90 lopinavir tab +

91 lotio k ummerfe ld i eairan, kemasan sesuai -kebutuhan

92 manito l lar infus 20% , btl 500 m l -

93 melfa lan tab 2 mg +

94 metampiron in j i.m 250 mg/m l, -k tk 2 5 v ia l @ 1 0 m l

k tk 100 am p @ 2 m l

NO NAMA GENERIK (Bentuk Sediaan, KekuatanP EN G UR A

PERUS e d ia a n , K em as a n)

FORM

9 5 ( dl ) m e ti lfe nid at *) t ab r eg ul ar r el ea se 1 0 m g

k ap s e xte nd ed r ele as e 2 0 m g

96 m etil p rednisolon tab 4 m g, b tl 100 tab

97 met i lse lu losa,diubah menjadi la r 2 % , b tl 5 m l P er ub ah an

met i lse lu losa, kombinas i : t e ra p i d a n

hidroks ipropi lmet i lse lu losa5 mg o b at d it ul

deks t ran(70) 1 mg

gliserin 2 mgbenza lk on iumk l o r ida 0 , 01% b/v

98 m etoklopram id sir 5 mg/5 m l, b tl 5 0 m l

t is 0 ,1 m g /t ls , b tl 1 0 m l

99 m idazolam inj i.v . 1 mg/m l

i n j i . v. 5 m g /m l

100 natrium b ikarbonat in j 1 ,4 % isoton ik

101 na trium fus ida t krim 2 0 m g/g, t ube 5 9

102 natrium n itroprusid in j, via l

103 neom is in tab 500 mg, bt l 100 kaps

104 n iko tinam id tab 100 mg

105 norep inefrin in j 4 mg/m l, amp 2 m l

106 Obat t e linga DOEN tis t e linga, btl 5 m l

kombinas i :

n e om is in s ul fa t 5 00 m g

p o li m ik s in B s u lf at

1 j u t a U I /1 0 0 m l

107 pankuronium in j i.v . 2 mg/m l (brom ida),

ktk 1 0 am p @ 2 m l

108 pa rasetamol sup 120 mg

su p 2 4 0 m g

1 09 p as ta d ev ita lis as i (n on a rse n) p as ta , b tl


FORMULASIPENAMBAHAN ( + ) ,

FORMULASIPENAMB



NO NAMA GENERIK (Bentuk Sediaan , KekuatanP EN G UR AN G AN ( -) ,

PERUBAHANSe d ia an , Kemasan )

FORMULASI

110 pasta iodo form pasta -

111 patent b lue V inj s.k. 2,5% , k tk 1 amp 2 ml -

112 perak nitrat lar 40% , btl 10 ml -

113 perfenazin tab 4 mg (l+Cl), -b tl 10 0 / 1 0 00 t ab

t ab 1 6 m g ( l+ C l) ,b tl 10 0 / 1 0 00 t ab

114 permetrin krim 5% , tube +

115 piridos tigm in tab 1 0 mg (b rom ida), -k t k 1 0 s t r/ b ls @ 1 0 t ab

11 6 po l ik r e su l en ( k ondensasi c a ir a n, b tl 1 0 m il 50 ml P i nd a h k e la s t er a pim e ta k re s ol s u lf on a t d a n

metanal )

1 17 prednisolon tis ma ta 0,5% , b tl 5 ml -s ale p m at a 1 %, tu be 3 ,5 9

118 preparat sulfa cones, btl 100 b utir -

119 prokainam ida in j 100 m g/m l ( Hel) -

120 propanolo l tab 40 mg +

121 prop iliodon in j dalam m inyak 5 00-600 -m g/m l, k tk 1 a m p 2 0 ml

12 2 prop iltiourasil tab 1 00 m g , b tl 1 000 t ab Perubahan kekua tan

sediaan

123 propranolo l tab 10 mg, ktk 100 tab -ta b 4 0 m g, k tk 1 00 ta b

124 reserpin tab 0,10 m g, btl 1000 tab -t ab 0 ,2 5 m g , b t l 1 00 0 t ab

NO NAMA GENERIK (Bentuk Sed iaan, KekuatanP EN G UR A

P E R USe d ia an , Kemasan )

FORM

125 retinol (vitam in A ) tab 5 000 U I, b tl 50 t ab

k ap s l un ak 1 0 0. 00 0 U I, b tl 5 0

k a ps l u na k

126 retinol (vitam in A ) in j 1 00.000 UII amp,

ktk 1 00 a mp 1 ml

i n j d a lam m i ny a k 1 0 0 .0 0 0 U l /am p

( s ebaga i pa lm it a t) ,

k tk 1 0 0 a m p @ 2 ml

127 rokuronium inj i.v 10 m g / m l , v ia l 5 m l

128 sefazolin in j 1 gr, via l, ktk 2 via l

129 seftriakson in j 1 gr, via l, k tk 2 via l

130 semen seng f os fat se rb d an c airan,

se t 3 0 9 b tl 1 s et

131 s irop tim i m ajemuk cairan, btl 1 00 m l

132 spons g elatin lem bar 5 x 7 x 1 cm

13 3 stavud in tab 30 mg, btl 60 tab P erubahan

tab 4 0 m g, btl 60 tab terapi d

sediaan

134 sufentanil in j 50 m c g / m l (sitrat),

k tk 5 v ia l @ 5 ml

135 suksametonium serb in j iv /i.m 500 m g/v ia l

( kl o ri d a) , k tk 1 0 v ia l

13 6 s uk s in i l k o l in s e rb i nj i v/ i. m 5 0 0 m g /v ia l P e ru b ah an

( kl o ri d a) , k tk 1 0 v ia l

137 sulp irid kap 50 mg , ktk 10 s tr @ 1 0 k ap

ta b 2 0 0 m g , ktk 2 s tr @ 1 0 t ab

138 tiam in (vitam in B 1) in j 100 m g / m l ,

ktk 1 00 a mp 1 m l


FORMULASIP EN A MB A HA N ( +) ,

P EN G UR AN G AN ( .) ,



NO NAMA GENER IK (Benluk Sediaan, KekualanP E RU B A H AN

S e di a an , K em as a n)FORMULASI

139 tiopental serb i n j i.v . 1000 m g/amp -( g ar am N a ) ( un tu k d il ar u tk a n

d a lam 2 0 m l a ir i nj e ks i) ,

k tk 2 5 a mp

140 tropikam ida tis mata 1 %, btl 5 m l -

1 41 tu be rk uli n p ro te in purif ied i nj i .k . 1 :1 0, k tk 1 v ia l 2 5 m l -derivat ive

142 vaks in meningokokus serb in j, k tk 10 v ia l @ 1 0 d o si s -polisakarida A + C + 1 0 amp pelarut @ 5 ml

14 3 valproat t ab 2 50 m g ( ga ra m N a ), b tl 5 0 t ab P e ru b ah a n b e nl uk d a n

t ab 5 00 m g ( ga ra m N a ), b tl 5 0 t ab k ekuat an s ed iaans ir 2 50 m g /5 m l ( g ar am N a ),

b tl 1 20 m l

144 vankom is in serb in j. 500 mg/via l, +

k tk 1 v i al

145 vekuronium serb in j 1 0 mg/vial (brom ida), -k tk 2 0 v ia l

146 warfarin tab 2 mg (garam K), btl 100 tab P er ub ah an k ek ua ta n

sediaan

14 7 zidovudin tab 100 mg, btl 100 tab P er ub ah an s ub k el as

terapi dan bentuk

sediaan

LAMPIRANII

KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDNOMOR : 239/MENKES/SKlIII/2008

TENTANG

PEMBENTUKAN KOMITE NASIONAL REVISDAN PENYUSUNAN

DAFTAR OBAT ESENSIAL NASIONAL(KOMNAS REVISI DOEN) 2008

90Daftar Dbat Esensia l Nasional2008



Men imbang

MENTER IKESEHATAN

R E PU BL IK I ND O NE S IA

K E PU TU S AN M E NT ER I K ES EH A TA N R E PU B LI K I ND O NE SI A

NOMOR : 2 3 9 /MENKE S /S K l II I /2 0 0 8

TENTANG

P E MB EN T UK AN K O MI TE N A SI ON A L R E VI SI D A N P EN Y US UN A N

D AF TA R O BA T E SE NS IA L N AS IO NA L ( KO MN AS R EV IS I D OE N) 2 00 8

MENTER IKESEHATAN

R EP U BL IK I ND O NE SI A

MEMUT US KAN :

M enetapkan KEPU TUSAN MENTER I KES EHATAN TENTANG PEMBENTUK

N AS IO NA L R EV IS I D AN P EN YU SU NA N D AF TA R O BA T E SE NS

( KO M NA S DO E N 2 00 8) .

P erta ma M em ben tuk K om ite N as ional R ev is i d an P enyusuna n D aftar O bat E

2 00 8 ( Ko m Na s D O E N ) d e ng a n s u su n an p er so na li a s eb a ga im a na t e

l a m p i r an k e pu t us a n i n i.

M E NT ER I K ES EH A TA N R EP U BL IK I ND O NE SI AKedua Tugas K omNas DOEN sebagai be rikut:

a . P en ga ra h

P en ga ra h b er tu ga s m em be rik an p en ga ra ha n d ala m ra ng

p e ny us un a n D O E N 2 00 8 s e su a i d en g an p er at ur an y an g b e rl ak u;

b . T im Ah li

T im A hli b er tu ga s m el ak uk an e va lu as i o ba t d ala m D O EN 2 0

u su la n o ba t y an g a ka n d im a su kk a n d a n/ at au d ik el ua rk a n d a ri l

2 008;

c . K on su lt an

K o n su l ta n b e r tu g as m em b er ik a n m a s uk a n t e kn i s I i lm i a h y a n g d i

d . T im A hli d an K on su lt an b er sa ma -s am a m em be rik an d uk un ga

k ep a da D e pa rt em e n K e se ha ta n m e la lu i D ir ek to ra t J en d er al B

d a n A l a t K e se h at an d a la m p e ne ra p an D O E N s ec ar a n as io na l

D i re kt or at B in a P e ng gu n aa n O b at R a si on a l d al am p en e ra pa n k

e . A ng go ta

A n g go t a b e rt u ga s m em b er ik a n m a s uk a n y a n g d i pe r lu k an d a la m

D O E N 2 0 05 d a n u s u la n o b at y a ng a ka n d im a su kk a n dania t a u d i

DOEN2008;

f. Pelaksana

P e la ks a na b er tu g as m e ng in ve nt ar is as i d a ta , m e mp er si ap ka n

p ed om an p ela ks an aa n, m em pe rs ia pk an u su la n r an ca ng an

m ela ks an ak an ra pa t- ra pa t te kn is d an s id an g p le no ,

p e n do k ume n ta s ia n , f in a li sa s i DOEN 2 0 0 8 d a n p e ny e b ar lu a s an n y

a . b ah wa d al am u pa ya p en in gk at an m ut u p el ay an an k es eh at an , k et er se di aa n

o ba t e se n si al y a ng a m an , b e rm a nf aa t s er ta b e rm u tu d a la m j um la h d a n j en is

y an g c uk up m er up ak an t an gg un g j aw ab p em er in ta h s ep er ti d i a ma na tk an

d al am K e bi ja ka n O b at N a si on a l ( K ON A S );

b . b ah wa s es ua i h al t er se bu t p ad a h ur uf ( a) p er lu d id uk un g d en ga n p em bin aa n

p e n gg u n aa n o b a ty a n g r a si o na l ;

c . b ah w a s es ua i d e ng a n p e rk em b an ga n i lm u p e ng e ta h ua n d an t ek no lo gi d ib id an g

o ba t d a n k ed o kt er an , p o la p e ny ak it , p ro gr am k es eh a ta n s er ta p er ba ik an s ta tu s

k es eh a ta n m a sy a ra ka t s eb a ga i h as il d ar i p e mb a ng un a n d ib id an g k es eh a ta n

D a f ta r Oba t E s e ns ia l N a s io n al ( DOEN ) p e rl u d i re v is i ;

d . b ah wa d ala m r an gk a r ev is i D af ta r O ba t E se ns ia l N as io na l ( DO E N) 2 00 8, p er lu

d ib en tu k K om ite N as io na l R ev is i d an P en yu su na n D OE N 2 00 8 d en ga n

K e p ut u sa n Me n te r i K e s eh a ta n .

Mengingat 1.

2.

3.

4.

5.

6.

7.

91

U n da ng -U n da n g N o mo r 2 3 T a hu n 1 9 9 2 t e n ta n g K e se ha ta n ( Le m ba ra n N e ga ra

T a hu n 1 9 9 2 N o m o r 1 0 0, t a m ba h an L e mb a ra n N e ga ra N o mo r 4 4 31 ) ;

P er at ur an P em er in ta h N o. 7 2 t ah un 1 9 98 t en ta ng P en ga ma na n S ed ia an

F a rm a si d a n A l at K e se h at an ( L em b ar an N e ga ra T a hu n 1 9 9 8 N o .1 3 8, t am b ah an

L e mb ar an N e ga ra R I N o . 3 7 8 1 );

P er at ur an P em er in ta h N om or 3 8 T ah un 2 00 7 t en ta ng P em ba gi an U ru sa n

P e me ri nt ah an D a er ah K a bu pa te n/ Ko ta ( L em b ar an N e ga ra R e pu b li k I nd o ne si a

t ah u n 2 0 07 N o mo r 8 2 , t a m ba ha n L e mb a ra n N e ga ra R e pu b li k I nd on e si a N o m or

4737) ;

P er atu ra n P re sid en R ep ub lik In do ne sia N om or 9 T ah un 2 00 5 te nta ng

K e du d uk an , T u ga s, F u ng si , S u su n an O r ga n is as i, d a n T a ta K e rj a K e me nt er ia n

N e g ar a R I ;

P e ra tu ra n P r es id e n R I N o m o r 1 0 T a hu n 2 0 05 t en ta n g U n it O r ga n is as i d a n T u g as

E s el on I K e m en te ri an N e ga ra R I ;

P e ra tu ra n M e nt er i K e se h ta n R I N o m or : 1 5 75 /M e nk es /P e ri X I / 2 0 0 5 tentang

O r ga ni sa si d an T a ta K e rj a D e pa rt em e n K e se h at an R I ;

K e pu tu sa n M e nt er i K e se ha ta n R I N o m or : 1 8 9 /M E N K ES /S K lI II /2 00 6 t en ta n g

K e b ij a ka n Ob a t N a s io n a l.

M a sa t ug as K om N as D O EN t er hi tu ng m ula i t an gg al d it et ap ka nn ya

s a mp ai d e ng a n a kh ir ta h un 2 0 08 .

Ket ig a R ev is i D OEN 2005 d ilaksanakan selam a tahun 2008 .

Keempa t D alam m elakukan tugasnya KomNas Rev is i DOEN be rta nggung

Me n t er i K e s eh a ta n m e la l ui D i re k tu r J e nd e r al B i na K e fa r m as ia n d a n

s e rt a m e l ap o rk a n h a s il k e gi a ta n n ya 1 ( s a t u) b u la n s e te l ah b e ra k hi r ma

Kel ima

Daftar Dbat E sensial Nasional2008 Daftar Obat E sensial Nasional 2008



MENTER I K ESEHATAN

R E PU B LI K I ND O NE S IA

Keenam B iaya penyusunan KomN as DOEN dan se lu ruh kegia tan revisi dan penyusunan

D O EN 2 00 8 d ib eb an ka n p ad a D IP A D ir ek to ra t B in a P e ng gu na an O ba t R a si on al

T a h u n 2 0 0 8 .

Ke tu juh Kepu tusan in i m ula i be rlaku sejak tangga l d ite tapkannya dengan ca tatan bahwa

a k an d ia d ak a n p e ni nj au a n k e mb a li a ta u p e ru b ah a n s e ba g ai m an a m e st in y a a p ab il at e rd a p a t k e k ur a n g an a t a u k e k e l ir u a n d a lam p e n e ta p a n ny a .

Pengarah :

MENTERIKESEHATAN

R E PU B LI K I ND O NE S IA

LAMPIRAN :

K EP U TU S AN M E NT E RI K E SE H AT A N

N O MO R : 2 39 IM E NK E S/ SK Jl I1 I2 00

T AN GG AL : 5 M AR ET 20 08

K O MI TE N A SI ON A L R E VI SI D A N P E NY U SU N AN

D A FT A R O B AT E S EN S IA L N A SI ON A L ( KO M NA S D O EN ) 2 00 8

1 . D i re k tu r J e nd e ra l B in a K e fa r ma s ia n d a n A l a t K e se h al an

2 . K ep al a B ad an P e ng aw as O b al d an M a ka na n

3 . D i re k tu r J e nd e ra l B in a P e la y an a n M e d ik

4 . D i re k tu r J e nd e ra l P e ng e nd a li an P e ny a ki t d a n P e ny e ha ta n L in g ku n ga n

5 . D e pu ti I B a d an P en ga wa s O ba l d an M a ka na nD ite tapkan d i J A K ART A

P ad a tangga l 5 M A RE T 2008

TimAhl i :

P e na n gg u ng J a wa b : D i re k tu r J e nd e ra l B i na K e fa rm a s ia n d a n A l a i K e se h at an

Ke tua

Wak i l

Anggo ta

S a li na n K e pu tu s an i ni d is a mp a ik a n k e pa d a:

1 . M e nt e ri K o or d in a to r B i da n g K e se ja h te ra a n R a k ya t

2 . M en te ri D a la m N eg er i

3 . K ep ala B AP PE NA S

4 . K ep al a B a d an P e ng aw as Ob at da n M a ka na n

5 . P a ra E s el on I d i l in g ku n ga n D e pa r te m e n K e se h at an

6 . K e pa la D i na s K e se h at an P r ov in s i d i s e lu r uh I nd o ne s ia

7 . D i re k tu r R u m ah S a ki t P e n d id ik a n d a n V e rt ik a l D e pa r te m e n K e se h at an

8 . K e pa la D i na s K e se h at an K a bu p at e n/ K ot a d i s e lu r uh I n do n es ia

9 . Y a ng b e rs a ng k ut an u n tu k di la k sa n ak a n s e ba g ai m an a m e st in y a

Konsultan

93

I w a nDa rma n s ja h (Do k te r umum )

R i a nt o S e t ia b u d y (Do k te r umum )

1 . A bd ul M u th ali b ( Do kt er s pe si al is )

2 . A s ri l A m i n ul la h ( D ok te r s p es ia li s)

3 . B am b an g S u da rm a nt o ( Do kt er s pe si al is )

4 . D e de G u na wa n ( D ok le r s pe si al is )

5 . D ja ka ri a ( Do kt er s pe si al is )

6 . G un aw an ( Do kl er s pe si al is )7 . H a n af i T r is n oh a di ( D ok te r s p es ia li s)

8 . In ge S ula nlo ( Do kle r u mu m)

9 . N ug ro ho K am p on o ( Do kt er s pe si al is )

1 0 . O m o A b du l M a d ji d ( D ok te r s p es ia li s)

1 1 . R o b er t R e ve r ge r ( D ok le r s p es ia li s)

1 2 . S a rw o no W a s pa d ji ( D ok le r s p es ia li s)

1 3 . S il vi a D e s ir ee F a di el ( D ok te r g ig i)

1 4 . S r i R e z e ki S . H a d in e go r o ( D ok le r s p es ia li s)

1 . A ri ni S et ia wa ti ( Ap ot ek er )

2 . A tie W . S o ek an da r ( Do kle r u mu m)

3 . E n gk o S o si al in e ( Ap ot ek er )

4 . l ra wa n M a ng un al ma ja ( Do kl er s pe si al is )

5 . I wa n D w ip ra ha sto ( Do kte r u mu m)

6 . K ar to no M uh am m ad ( Do kt er u mu m)

7 . N an i S u k as ed ia ti ( Ap ot ek er )

8 . P inky F. R i aw a n ( D ok te r u m u m)

9 . S ri S u ry aw at i ( Ap ot ek er )




Pelaksana :

Ke tua

Sekretar is

S e k re t ar is I

Anggo t a

Sekretar ia t

9 5

MENTER IKESEHATAN

R E PU BL IK I N DO NES I A

D i re k tu r B i n a P e n g g u n aa n Ob a t R a s io n a l

Z o r ni F a d ia ( D o kt e ru m um )

D i t a Nov i a n ti (Apo t e ke r )

LAMPIRAN III

DAFTAR PESERTA PEMBAHASAN TEKNIS

RAPAT KONSULTASI DOEN 2008

1 . S e kr e ta ri s D i re k to ra t J e nd e ra l B in a K e fa rm a si an d a nA la t K e se ha ta n

2 . D ir ek tu r B in a O b a t P u bl ik d an P e rb e ka la n K e se h at an

3 . D ir ek tu r B in a K e se ha ta n I bu

4 . D ir ek tu r B in a K e se ha ta n A na k

5 . D ir ek tu r P e ng e nd a li an P e ny a ki t M e n ul ar L a ng su n g

6 . D ir ek tu r P e m be ra n ta s an P e ny ak it B e rs u mb e r B in a ta n g

7 . D ir ek tu r P e ng e nd a li an P e ny a ki tT id a k M e n ul ar

8 . D ir ek tu r S u rv ei la ns E p id em i ol og i, I m un is as i d a n K e s eh a ta n M a tr a

9 . K a su bd it St an d ar di sa s i d a n B i m bi ng a n T e kn is P e ng g un a an O b at R a si on a l

1 0 . K a su bd it P r om o si P e ng g un a an O b a t R a s io n al

1 . E ri e G u sn el ly an ti

2 . L iz a F e tr is ia ni

3 . P ri ha di M u ly on o

4 . A nw a rW a hy ud i

5 . N ofiy an ti

6 . M ulyati

D ite tap kan di J A K ART A

P ad a tan 99a l 5 M ARET 2008


DAFTAR PESERTA PEMBAHASAN TEKNIS DAN

RAPAT KONSULTASI DOEN 2008

4 7 K e pa la D in a s K e se h at an P r o p in si J a w a B a ra t

4 8 K e pa la D in a s K e se h at an P r o p in si J a w a T e ng a h

4 9 K e pa la D in a s K e se h at an P r o p in si J a w a T im u r



5 0 K e p a la D i na s K e s e h at a n P r o p in s i K a li m a nt a n B a r a t

5 1 K e p a la D i na s K e s e h at a n P r o p in s i K a li m a nt a n T e n ga h

5 2 K e p a la D i na s K e s e h at a n P r o p in s i N u s a T e n g ga r a B a r at

5 3 K e p a la D i na s K e s e h at a n P r o p in s i N u s a T e n g ga r a T im u r

5 4 K e pa la D in a s K e se h at an P r o p in si P a p ua

5 5 K e p a la D i na s K e s e h at a n P r o p in s i S u la w e s i T e ng a h

5 6 K e p a la D i na s K e s e h at a n P r o p in s i S u la w e s i U t ar a

5 7 K e p a la D i na s K e s e h at a n P r o p in s i S um a te r a B a r a t

5 8 K e p a la D i na s K e s e h at a n P r o p in s i S um a te r a U t a r a

5 9 K e pa la D in a s K e se h at an K a b u pa te n K a ra n g A ny ar

6 0 K e pa la D in a s K e se h at an K a b u pa te n S le m a n

6 1 K e p a la D i na s K e s e h at a n K a b u pa t en S u r a k a rt a

6 2 K e pa la P u sk es m as P a j an g , S ur ak a rt a6 3 K e p a la P u s ke s m a s K e cam a ta n T e b e t, J a k ar t a

6 4 K e tu a P u s at I k a ta n D o k te r I n do n es ia

6 5 K e tu a P e n g ur us P u s a t I ka ta n B i da n I n d on e si a

6 6 K e tu a P e r s a tu a n A h li F a rm ak o lo g i I n d on e si a

6 7 K e tu a P e r s a tu a n P e r a w a t N a s io n a l I n do n e si a

6 8 K e tu a I k at an S a r ja n a F a rm a si I n do n es ia

6 9 K e tu a P e r s a tu a n I k a t an D o k t e r S p e s ia li s A n e st e si d a n R e a n im a s i I n d on e s ia

7 0 P r of . d r. I w a n D a rm a ns ja h , S pF K .

7 1 P r of . d r. R i a nt o S e ti ab u dy , S pF K .

7 2 P r of . d r. A b du l M u t ha li b, S p P D ( K ) .

7 3 P r of . d r. D j a ka ri a, S p R a d ( K ).

7 4 P r of . d r. N u g ro h o K a mp o no , S p O G .

7 5 P r o f. D r . d r . H a n a f i T r is n o ha d i, S p K J ( K)

7 6 P ro f. D r . dr . In ge S u ta nto

7 7 P r of . D r . dr . S a rw o no W a sp a dj i, S p P D ( K )

7 8 P r of . D r . dr . S ri R e z e ki S . H a di ne g or o, S p A ( K )

7 9 P r of . D r .A r in i S e ti aw a ti , P h D .

8 0 P r of . d r. I w a n D w ip ra h as to , M . M ed S c, P h D .8 1 P r of . d r. A s ri l A m in u ll ah , S p A ( K )

8 2 d r. O m o A b du l M a djid , S pO G .

8 3 d r. B a m ba ng S u da rm a nt o, S p A

8 4 d r. D e de G u na w an , S pS ( K)

8 5 d r. R o b e rt R e v er ge r, S p K J ( K)

8 6 d r. G u n a wa n D a r ma n sj ah , S p A n.

8 7 d r. I r a wa n M a n gu n at m ad ja , S pA ( K )

8 8 d rg . S i lv ia D e si re e , S pK G A

8 9 D R . Atie W . Soe k anda r , SpFK .

9 0 D R. S ri S ur ya wa ti

9 1 d r. K a rt on o M u ha mm a d

9 2 d r. P in ky F . Ria wa n

9 3 O r a. E n g ko S o s ia li ne , M . B io m e d

9 4 d r. Z orn i Fa dia

9 5 d r. A bd ulla h A kh m ad , M A R S

9 6 O r a. D e tt ie Y u li at i, A p t, M S i

9 7 D it a N o v ia n ti , S .S i, A p t, M M

1 D ir ek tu r J e nd e ra l B i na K e f ar m as ia n d a n A IK e s

2 K ep ala B a d an P e n ga wa s O ba t d an M a ka na n

3 D ir ek tu r J e nd e ra l B i na P e l ay a na n M e d ik

4 D i re k tu r J e n d er a l P e n a n gg u la n g an P e n y a k it d a n P e n y eh a ta n L i n g ku n g an

5 D e pu ti I B a da n P e ng aw a s Ob at d a n M a ka na n

6 S e k re t ar is D i re k tu r J e n d e ra l B i n a K e f a rm a s ia n d a n A l a t K e s eh a ta n

7 D ir ek tu r B i na P e n g gu n aa n O b a t R a si on a l

8 D ir ek tu r B in a O ba t P u blik & Pe rb e k a la n K e s eha ta n

9 D ir ek tu r B in a K es eh at an I b u

1 0 D ir ek tu r B i na K e s e ha ta n A n ak

1 1 D i re k tu r P e n g e n d al ia n P e n y a k it M e n u l a r L a n gs u n g1 2 D i re k tu r P e n g e n d al ia n P e n y a k it T i d a k M e n u la r

1 3 D i re k tu r P em b e r a nt a sa n P e n y a ki t B e r s um b e r B i n a ta n g

1 4 D i re k tu r S u r v e il an s E p i d e m io lo g i, I m u n i sa s i& Kes eha t an Ma t r a

1 5 D ir ek tu r B i na G i z i M a sy ar ak a t

1 6 D i re k tu r B i n a P e l a y an a n K e s e h at a n J iw a

1 7 D ir ek tu r B i na P e l ay a na n M e d ik D a s a r

1 8 D i re k tu r B i n a P e l a y an a nMe d i k S p e s ia l is ti k

1 9 D ir ek tu r R S U D r M Y un us B e ng ku lu

2 0 D ir ek tu r R S U D R . M . D ja mil P a da ng

2 1 D ir ek tu r R S U U li n B a n ja rm a sin

2 2 D ir ek tu r R S U P N C i pt o M a n g un ku su m o

2 3 D ir ek tu r R S U P H a s a n S a di ki n B a n du n g

2 4 D ir ek tu r R S U P M u h . H u s se in P a l em b an g

2 5 D ir ek tu r R S d r. M o e w a rd i, S o lo

2 6 D ir ek tu r R S d r. S a r dj it o, Y o g ya ka rt a

2 7 D i re k tu r R SU P W a h id in S u d i r oh u s od o , M a k a s ar

2 8 D ir ek tu r R S U D r . K ar ya d i, S e m a ra n g

2 9 D ir ek tu r R S J an tu ng & Pembu l u hDa ra h Ha ra p anK i t a3 0 D ir ek tu r R S . Jiw a C im a hi

3 1 D i re k tu r R SU D W a h id in S u d i r oh u s od oM o jo k e rt o -J a ti m

3 2 D ir ek tu r R S U d r .S o et om o , S ur ab a ya

3 3 D ir ek tu r R S U K a b. T a n ge ra n g

3 4 D ir ek tu r R S U D A r if in A c h m ad , P e k an b ar u

3 5 D ir ek tu r R S U P S a n gl ah - D e n p as ar

3 6 D ir ek tu r R S . S i lo a m K a ra w ac i, B a n te n

3 7 D it re k tu r R S S u m be r W a ra s , Ja ka rt a

3 8 D it re k tu r R S U H u sa d a, J a ka rt a

3 9 D it re k tu r R S U Y o s S u d ar so , P a d an g

4 0 D ir ek tu r U t am a P T . I n do fa rm a

4 1 D ir ek tu r U t am a P T . K i mi a F a rm a

4 2 D ir ek tu r U ta m a P T .P h ap ro s

4 3 D ir ek to ra t K e se h at an T N I -P O L R I

4 4 K e p a la D i na s K e s e h a ta n P r o p i ns i N a n g ro e A c e h D a r u s a la m

4 5 K e p a la D i na s K e s e h a ta n P r o p i ns i S u la w e s i S e la t an

4 6 K e pa la D in a s K e se h at an P r o p in si D K I J a ka rt a


9 8 E r ie G u sn e ll ya n ti , S .S i, A p t.

9 9 d r. O j e nt ot F i bi ha n in d yo P u t ro

1 0 0 O r a. O a r a A me li a, A p t.



1 0 1 O r a. E m a V i az a , A pt .

1 0 2 R o h a ya t i R a h a fa t , S . S i, A p t .

1 03 D rs . S uh at a

1 0 4 A w a n Y u ri an to

1 0 5 S u pr ih a nd o yo

1 0 6 P r ih a di M u l yo n o

1 07 A n wa r W a hy ud i

1 0 8 N o fi ya n ti

1 09 M u ly at i

LAMPIRANIV

PERNYATAAN KESEDIAAN

MENJADI KETUAIWAKIL KETUAIANGGO

TIM AHLI/ANGGOTA KONSULTAN *)


PERNYATAAN KESEDIAAN

MENJADI KETUA / WAKIL KETUA / ANGGOTA



TIM AHLI / ANGGOTA KONSULTAN *)

S a ya y an g b e rt an d at an ga n d i b a w ah i ni ,

N ama

A lamat

LAMPlRANV

SURAT PERNYATAAN

KONFLIK KEPENTINGAND e ng a n i ni m e n ya ta ka n :

1 . B er se dia m en ja di K etu a / W ak li K etu a / A ng go ta T im A hli / A ng go ta K on su lt an *) d al am

K O MN A S D O EN .

2 . B e rs ed ia m e ng h ad ir i r ap at -r ap a t p e mb a ha sa n t ek ni s r ev is i D O EN .

3 . B e rs e di a m e n a nd a ta n g an i S u ra t P e rn y at a an K o n fl ik K e p en t in g a n t er lam p ir .

Jakarta, .

* ) C o r et y a n g t i d a k p e rl u


SURAT PERNYATAAN

KONFLIK KEPENTINGAN

6 . A n gg ol a K om N as l id ak m e ny am p ai ka n i nf or m as i y an g d ih as il ka n d ar i p er te

k e gi al an r e vi si d e ng a n c a ra a p ap u n d a n a la s an a p ap u n l an p a p e rs e lu ju a n

T im A h li d an a ng go la K o mN a s y an g l ai n.



D a la m r a ng k a R e vi si D a ft ar O b a l E s en s ia l N a si on a l ( D OEN) d ip e rl uk a n a d an y a j am i na n b a hw a l id a k

a ka n a da k on fl ik k ep en lin ga n a ng go la K om il e N a si on al D O E N ( di si ng ka l : K om N as D O E N) y an g

d ap al m e ng ga ng gu k ep ul us an y an g d ib ua t. U n lu k i lu p er lu a da ny a k es ed ia an s el ur uh a ng go la

K omN as D OEN u n lu k m em pe la ja r i d a n m e n an d al an g an i d o kum e n p e rn y al aa n b e ri ku l a p ab il a s u da h

menyelujuinya.

1 . T id ak a da k el ua rg a d ar i a ng go la K om N as y an g m e mi lik i, m e nj al an ka n, m e ng en da li ka n,

m e mil ik i k ep en lin ga n a la u b ek er ja p ad a p er us ah aa n a la u f as il ila s l ai n y an g b er ad a d i

b a w ah p e ng a wa s an a n gg o la K omNa s .

S a ya y a ng b e rl an d a l an g an d i b a w a h i ni :

Nama

Jaba lan Ke lua /Wak i l Ke lua l Anggo la T imAh li I Konsultan' '

K omNasDOEN

D e n ga n i ni m e n y al ak a n b a hw a s a ya :

M em a ham i d a n a k a n m em a lu h i p e rn y al aa n y a ng l er te r a d i a l as .

2 . A ng go la K om Na s lid ak m em in la a la u m en er im a u an g a la u a pa pu n y an g b er nila i d ar i

s es eo ra ng a la u o rg an is as i b ai k s ec ar a l an gs un g a la u l id ak l an gs un g d al am ju m la h

s e dem ik i an y a ng mung k in d a pa l mempengaru h i s u b ye k li v il a s r e v is i a l a u h a s il p e n il a ia n .

3 . A nggo la K om Nas lidak berlindak sebaga i w akil resm i dari sualu badan un luk

m em p re s en la s ik a n b a ik b e ru p a l ul is a n, l is a n, p e ra g aa n a la u m e n am p il ka n s e su a lu y a ng

mung k in d a pa l mengun lu n g k an s e c ara f in a n s ia l /ma l e ri a l b a g i d i r in y a .

Anggo la KomNas Tangga l

4 . A n gg ola K om N as d ip er bo le hk an u nl uk le rl ib al s eb ag ai p el ug as a la u a ng go la b ad an d ar i

o r ga n is a si s o si al , o r ga n is a si k e ag am aa n d im a n a i a l i da k m e n er im a k om pe n sa s i a p ap u n

a la u s e pa n ja n g o r ga n is a si l er se b ul l id a k m em pe n ga r uh i p a nd a ng a nn y a s e ba g ai a n gg o la

KomNas .

*) Co re l y a n g l id a k p e r lu

5 . J ik a d a la m m e la ks an ak an l ug as s eb ag ai a ng go la K om N as m e mp un ya i k on fl ik a la u r es ik o

k o nf li k k e pe n li ng a n, m a k a y a ng b e rs a ng k ul an h a ru s m em be r il ah u ka n k e pa d a K e lu a T im

A h li a la u D i re k lu r B i na P e n gg u na a n Ob a l R a s io n al s e be lu m s e li ap k e gi al an r e vi si d a n l i da k

i k ul s e r la d a lam pe l ak s a naan pengamb i la n k e pu lu s a n .


LAMPI RAN VI



FORMAT KAJIAN

USULANPENAMBAHAN/PENGURANGAN

OBAT PADA DOEN 2008

LAMPIRANVI

0 KETERANGAN

1 R in gkasan

2 A lasan P enar ikan

3 H ub un ga n d en ga n m asa la h m as ya ra ka t

4 P e rb a nd in ga n d en ga n o ba t y an g s ej en is d al am D O E N

5 S i f at f a rmak o l og i

6 Buk t i e fek t i vi tas

7 B u k ti k e am a n an

8 R a si o m a nf aa t t er ha d ap b ia ya

9 Formu las i

1 0 P en gg un aa n o ba t in i d a la m p ed om an in te rn as io na l

1 1 P era tu ra n y an g m en du ku ng p en gu ra ng an o ba t in i

12 R ekom endas i

13 D afta r P us taka

FORMAT KAJIAN

USULANPENAMBAHAN/PENGURANGAN

OBAT PADA DOEN 2008


REKAPITULASI USULAN REVISI DOEN 2008

Us u l a n dar i



N ama I n st a n si

A l am a t l e ng k a p

N o T e lp / Fa x

B E N T U K P E R U B A H A N B U K T I

N OK E L A S N A M A S E D I A A N

K E M A S A NI L M I A H

T E R A P I O B A T D A NP EN AM - P EN GU -

P E N D U K U N G

K E K U A T A NBA HA N R AN GA N

*J

INDEKS

Keterangan:

*) Berdasarkan l iteratur / acuan / pus taka terpercaya

*) Dilampirkan l iteratur / acuan / pus taka terka it

. .. .. .. ... .. .. .. .. .. .. 2 00 . .

Cap Dinas / tanda tangan

Nama terang

NIP.


INDEKS

atropin, 2 3 , 2 4 , 50 , 54 , 60 , 6 1, 7 4, 7 7

d e fe r ok s am i n, 2 4

deksametason, 2 3, 4 3, 5 5, 60, 7 1, 7 7

deks t rometor f an, 5 5, 7 7

d e ks tr a n , 50

fenobarbital, 2 5, 6 2

f e noks ime ti l p en is i li n , 2 7

f e n tan i l, 2 1

f i t omenadion, 3 6, 6 7



AAB .U / , 5 6, 7 8

AB .U. I I , 5 6, 7 8

A.D .S , 5 6, 7 8

A . IS , 5 6,7 8

adrenal in , 2 4, 4 4, 4 5, 5 5, 6 1, 7 2, 7 7

a ir s te ri l b eb a s p ir og en , 3 7

a i r u n t uk i n je k s i, 49 , 5 0, 7 4

a lb e n da z ol , 2 6

alopurinol, 2 2 , 5 9

a l um in i um h i d ro k s id a , 5 3, 7 6

amfoterisin, 3 1 , 4 9

am in o fi li n, 5 5

am io d a ro n , 4 3

amitript ilin, 5 1, 7 5

am o di a ku i n t ab , 33 , 66

amok s is i li n t r ih i d ra t , 2 6, 6 2

ampisilin, 2 6, 6 2

a ne st et ik l ok al g ig i D O EN , 4 0, 6 9

a nt as id a D O EN I , 5 3, 7 6

a nt as id a D O EN I I, 5 3, 7 6

a n ti b ak te r i D O E N , 4 6, 7 2

a n ti fu n g i D O E N , 3 2, 4 6, 6 5, 7 2

a n ti h em o ro id D O E N , 5 4, 7 6

a n ti m al ar ia D O E N , 32 , 66

a n ti p ar ki ns o n D O E N , 3 6, 6 7

a p om o rf in , 2 5

ar t emether , 32 , 66

artesunat, 3 2, 3 3, 6 6asam aset i lsa l is i la t , 2 1, 4 2, 5 9, 7 1

as am as k o rba t , 5 8, 7 9

a s am b e nz o at , 3 2, 4 6, 6 5, 7 2

a s am f ol a t, 3 6, 6 7

a sa m r et in oa t, 4 6

as am sa l is i la t , 3 2, 4 6, 4 7, 6 5, 7 2, 7 3

a s et a zo l am i da , 5 0

as e to s a l , l i ha t a s am as e ti l sa l is i la t

a s i kl o v ir , 3 3

a s pa r ag i na s e, 3 4

atenolol, 4 3, 4 4, 7 1

a tr a ku r iu m , 5 2

a t rauma t ic r e s to r a ti v e t r ea tment , 4 1 , 6 9

10 7

a z at io p ri n , 3 4 d e ks tr o se , 4 8

d e sm o p re s in , 4 1

D G a na l ih a t d a rr ow g lu ko sa a na

d ia li sa p er it on ea l D O EN , 4 8

diazepam, 2 3 , 2 5 , 5 1 , 60, 6 1, 7 5

diet i lkarbamaz in, 2 6, 6 2

di f enhidramin, 23 , 60

digoks in, 4 3, 4 5, 7 1

dih idroergotamin, 3 4, 6 7

d i k lo k s asi l in , 2 7

d i lo k sa n id , 3 2

d i lt ia z em HC I , 4 3

dimenhidr inat , 5 3, 7 6

d i so p ir a mi da , 4 4

d o b ut am i n, 4 5

dok s is i kl i n, 2 8

d o ks o ru b is in , 3 5

dopamin,45

DT , 57,79

DTP , 57,79

ga r am o r a li t , 4 8, 7 4, 7 7gentamis in , 2 9, 4 9

g la ss i on om e r a rt , l ih at

r e s to r a ti v e t r ea tmen t

g l ibenk lamida, 41 , 70

g l ip i z id , 4 1

gl iser il guaiakolat , 5 6, 7

gliserin, 46 , 50 , 5 4, 7 7

glukosa, 2 2, 4 8, 4 9, 7 4

g l u kos a anh id r a t, 4 8, 5 4

g r is eo fu l v in , m i c ron i zed ,

g u tt a p e rc h a p o in ts , 4 1,

Bf lu fe n az in , 5 1

f l uo k s e ti n , 5 1

f lu o r, 4 0 , 6 9

f luoresein, 3 9, 6 8

f l uo r ou ra s i l, 3 5

f ra k si p r ot ei n p la s m a, 3 7

furosemida, 4 1 , 4 5 , 7 0 ,

b ah an k on tra s m ed ia D OE N, 3 8

b ah an t um p at an s em e n t ar a, 4 1, 6 9

b a ri um s u lf at , 3 8

basitrasin, 4 6, 7 2

bedak s a l is i l, 4 7, 7 3

b e le ra n g e n d ap , 4 7, 7 3

benseraz id , 3 6, 6 7

b e nz a lk o ni um k lo r id a , 5 0

b e nz a ti n b e n zi lp e ni si li n , 2 7

benz il p en is i li n k r is t a l, 2 7, 6 3

b e si ( II ) s u l fa t 7 H20, 3 6, 6 7

betametason, 46 , 5 0, 7 2

b i ru m e ti le n , 2 4

b i sa k od il , 5 4

b i smut s ubga la t , 5 4, 7 6

bleomis in ,34

boraks ,46

b u de s on i d, 5 5

bup ivakain, 2 2 , 4 9

b u su lf an , 3 4

G

E

e fa v ir e ns , 3 3

efedrin, 4 5, 5 5, 7 7

ek s tr a k be l adon , 54 , 77

ep i nef r in , l i ha t ad r ena l in

e r goka l s if e ro l , 5 8ergotamin, 3 4, 6 7

erit romisin, 2 9, 6 4

e s tr o ge n t er ko n ju g as i, 4 2

e tam b ut ol , 3 0 , 3 1, 6 4, 6 5

e ta n ol 7 0% , 4 0, 6 8

et i l k lor ida, 22 , 4 0, 6 0, 6 9

e t in i le s tr a d io l , 4 2

e to p o si d , 3 5

e ug e no l, 4 0 , 6 9

H

c haloper ido l , 5 2, 7 5

halotan,23

heksak lorofen, 5 4, 7 6

h ek sa m in m a nd el at , 3 1

h em o di al is a D O EN , 4 8

h ep a ri n, N a , 3 7

h i d rogen p e r o ks i da, 3 9,

h i d ro k l o rt i az i d a, 41

hidrokort ison, 7 1, 7 2, 4 3

h i dr o ks ip r op il m e ti ls e lu l os

h i dr o ks i p r og e st er o n, 4 2

h om at ro p in , 5 0

h um a n t et an us i mm u no g

h yd ro xy e th yl s ta rc h, 3 7

C HK M, 4 0, 6 9

c a ir a n i nt ra l ip i d, 4 8

c o al t ar , 4 7, 7 3

c op pe r T , 42 , 70

D

d a ka r ba z in , 3 4

d a kt in om is in , 3 5

dapson, 2 9, 6 4

d ar ro w g lu ko sa a na , 4 8

d ar ro w g lu ko sa h al f s tr en gt h, 4 8

d a un o ru b is in , 3 5

F

f ak to r V I II , 3 7

f ak to r I X k o m pl ek s, 3 7

f en i lb u ta s on , 2 1

fenitoin, 2 5, 6 1

I

Ibup rofen, 2 1, 5 9

Daftar Obat Esensial Nasional 2008aftar Dbat Esensial Nasional2008

i d ok s ur id i n, 4 9 k ot ri mo ks az ol D O EN I , 28 , 6 3 m id a zo la m , 2 3

i n su l in i n te r m ed i at e , 4 2

p e rm e tr in , 4 6

i ns ul in r eg u la r, 4 2

k ot ri mo ks az ol D O EN I I, 2 8, 6 3 mikonazol , 3 2, 4 6 pet idin, 2 1 , 5 9

k otr im ok sa zo l D O EN I II , 2 8 mor f in , 2 1, 2 3, 3 6, 6 0

iod ium, 3 8, 5 8 k r es o l, t er sa p o ni fi k as i, 4 0 , 6 8

p il o ka r pi n , 5 0 , 7 5

pirantel, 2 6, 6 2



i o fe n d il a t, 3 8 kuin in , 3 3, 6 6

i o he k so l , 3 8N p ir a zi n am i d , 3 0 , 3 1, 6 4, 6

i o pam id o l, 3 8 L

piridoksin, 5 8, 7 9

i s of /u r an , 2 3n a lo k so n , 2 4

p ir id o st ig m in , 5 3

i s on i az id , 3 0 , 3 1, 6 4, 6 5lam ivudin,

n a tr iu m am i no h ip u ra t , 3 9 p i r imetamin, 3 2, 6 6

i s o s or b id d i n it r at , 4 3, 7 133 na t ri um b i k a rbona t, 2 4, 3 8, 4 8, 4 9, 6 1, 7 4 podof ilin, 4 7, 7 3

l a r ut an l ugo l, 4 3, 7 0 n a tr iu m b r om s u /f ta le i n, 3 9 p o li g el in , 3 7

Jl ar ut an n ut ri si , 4 9 na t ri um d i k lo f enak, 2 2, 5 9 p o li kr e su le n , 3 9

l a ru ta n n u tr is i D O E N , 49 n a tr iu m h i po k lo r it , 4 0 polimiksin B , 4 6, 7 2

l e uk o vo r in , C a , l ih a t k a ls iu m f ol in a t n a tr iu m i o po d a t, 3 8 p ov id o n i od id a , 4 0, 6 8

l ev od o pa , 6 7 na t ri um k l o ri d a , 4 8, 4 9, 5 4, 7 4, 7 7 p r az ik u an t el , 2 6

levonorges t re l , 4 2, 4 3, 7 0 n a tr iu m k r om o g li ka t, 5 0 p rednisone, 4 3, 7 1

Kl idokain, 22 , 40 , 4 4 , 5 4 , 5 7 , 60 , 6 9, 7 6 n a tr iu m n i tr o pu s id , 4 4 p r imakuin, 3 3, 6 6

l iq u o r c a rb o n is d e te r ge n s, 4 7, 7 3 na t ri um t i os u l fa t , 3 2, 4 6, 7 2 p robenes id, 2 2, 5 9

kafe in , 3 4, 6 7l iquorfaberi, 4 7, 7 3 n a tr iu m t ir o ks in , 4 3 p r o k ai n benz il p en is i li n , 2 7

k a l ium k l o ri d a , 3 7, 4 8, 5 4, 7 4, 7 7l iq u o r v e il li , 4 6 neos t igmin,53 p r ok a rb a zi n , 3 5

kalk , 58,79l i si n op ri l , 4 4 n e vi ra p in , 3 3 propilt iourasil, 4 3, 7 0

kals ium,37l i so l , l i ha t k r e so l t e rs ap on if i ka s i n i fe d ip i n, 4 4 p r op o fo l , 2 3

k a l s ium f o li n a t, 2 4, 3 5, 6 1l it iu m k a rb o n at , 5 1 n i ko ti n am i d, 5 8 p rop ranolo l , 4 4, 7 1

k a l s ium g l u k ona t , 2 4, 4 8, 5 8l op in av ir , 3 3 nistat in, 3 1 , 3 2 , 40 , 6 5, 6 6, 6 9 p r o tam i n s u l fa t , 2 4 , 3 7

k al si um h id ro ks id a, 4 0 , 6 9 Mnitrofurantoin, 3 1, 6 5

k a ls iu m h i po k lo r it , 4 0 , 6 8n i tr o ge n o k si da , 2 3 Q

k a ls iu m l a kt a t, l ih a t k a lkn i tr o g li s e ri n , 4 3

kaptopril, 4 4, 4 5, 7 1, 7 2 magnes ium h i d ro k s i da , 5 3, 7 6n o re p in e fr in , 4 5

k a rb am a ze p in , 2 5 m a g n es ium s u lf at , 2 5, 5 1, 6 1n o re t is te r on , 4 2

k a r bon ak t if , 2 5, 6 1 mani t o l , 41,49 R

karbogl iser in , 5 7, 7 9 mebendazol , 2 6, 6 2 0

ketamin, 2 3, 6 0

m e d ro k si p r og e s te r on a s et at , 42 , 34,70

k e to k on a zo l , 3 1 m e gl um in a m id o tr iz oa t, 3 8 OBH , 56,78 r a n it id i n , 5 3

k e to p ro fe n , 2 1 meg l um in na t ri um am ido tr i zoa t , 3 8 , 3 9 o b at b a tu k h it am , l ih a t O B Hret inol, 5 8, 7 9

k li nd a mi si n, 2 9 m e lf al an , 35 oks igen, 2 3, 6 0r if am p i si n , 3 0 , 3 1, 6 4, 6 5

k l of az i mi n , m i cr o ni ze d , 3 0 , 6 4 m e r ka p to p u ri n , 3 5 o k si m et a zo l in , 5 7r i nge r l a k ta t , 4 9, 7 4

k lomip ramin, 5 1, 7 5 m e ta k re s ol s u lf o na t , 3 9 oksitetrasiklin, 2 8, 4 9, 6 3, 7 4r is p er id o n , 5 2

k l on i di n , 4 4 metamp iron, 2 2, 5 9 oksitosin, 5 1, 7 5r o ku r on i um , 5 2

k l or amb u s il , 3 5 m eta na l, 3 9

k loramfeniko l , 2 8, 6 3 m e te n am in m a n de l at , l ih a t h e ks am in p S

k lor f en i ramin, 2 4, 6 1 mandelat

k l or fe n o l k am fe r m e n to l , l ih a t C H K M mei f orm in, 4 2, 7 0 p a ra f or m a ld e h id a , 4 0 , 6 8salbutamol , 5 5, 7 7

k lorheks id in , 3 9, 4 0 m e ti l t io n in k lo r id a , l ih a t b i ru m e ti le nsalep 2 -4 , 4 7, 7 3

k lorokuin, 3 2, 6 6 m e ti ld o pa , 4 4parasetamol , 2 2 , 5 9 s e ng o k si d a, 5 4, 7 6

k l or p rom a zi n , 3 3 met i lergomet r in , 5 1, 7 5p a st a p e n gi s i s a lu r an a k ar , 4 1, 6 9 s e fa z ol in , 2 7

k lo za pi n, 5 2 ( d l) m e ti lf e ni d at , 5 2p e ng g an ti p la sm a D O EN , 3 7 s e fi ri a ks o n, 2 7

kodein, 2 1, 5 6, 7 7 m e to kl op ra m id , 5 4penisilin V , l i ha t f e noks ime ti l p en i si l in s en ya w a k lo r, 4 0

k om po s it r e si n , 4 1, 6 9 m e to t re k sa t , 3 5p e r a k n i tr a t , 4 7, 7 3 s er um a nt i b is a u la r, l ih at

met ron idazol , 2 9, 3 2, 6 4, 6 6p e ra k s u lf ad i az i n, 4 6 s e rum a n ti d if ie r i, l ih a t A.D


s e r um an t ir a b ie s , 5 6, 7 8

s e rum a n ti te t an u s , l ih a t A . T S

s er um i mu n og lo b ul in , 5 6

s ianokobalamin, 3 6, 6 7

v

vaks in 8 .C .G ., 5 6, 7 7

v a ks i n c am pa k , 5 6, 7 7



s ik l of o sf am id , 3 5

s ik l os p o ri n , 3 4

s imet ikon,38

s imvas tat in , 4 5, 7 2

s i p ro f /o k s as in , 2 9

s is p la t in , 3 5

s it a ra b in , 3 6

s o l u ti o s a l ic y l ic a c i d 0 , 1 % , l ih a t l iq u o r v e il li

s p ir o no l ak t on , 4 1

s p ons ge l a ti n , 4 1, 6 9

s ta v u di n , 3 3s tr e pt o ki n as e , 4 5

s tr e pt om is i n, 3 0 , 6 4

s u fe n ta n il , 2 1

s uk s in i lk o l in , 5 3

sul f ad iaz in , 2 8, 6 4

sul f adoks in, 3 2, 6 6

sul f ametoksazol , 2 8, 3 1, 6 3, 6 5

sul f asa laz in , 2 9 , 5 5

s u lf a se tam i da , 5 0 , 7 4

s ur gi ca l g in g gi va l p a ck , 4 1

v ak s in hep a t it is 8rekombinan, 5 6, 7 8

v a ks i n j e r ap d i ft e ri t e ta n u s p e rt u si s, l ih a t

O T P

v ak si n j e ra p d if te ri t et an u s, l ih a t 0 T

v a ks i n j e r ap t e ta n u s 5 7, 7 9

v ak s in p o l io , 5 7, 7 9

v a ks i n r a bi e s, u n tu k m a n u si a , 5 7, 7 9

v a lp r oa t , 2 5

v a n kom is i n, 2 9

v a so p re s si n , 4 1

v e ra p am il , 4 4v i nb la s t in , 36

v i n k ri s ti n , 36

v it a m in A , l ih a t r e ti n ol

v i t amin 8komp leks , 5 8, 7 9

v i t amin 81 , l i ha t t i am in

v i t amin 812, l i ha t s i a nokoba l am in

v i t amin 86 , l ihat p i r idoks in

v i t amin C, l ih a t a s am a s k or b at

v it a m in 0 3 , l ih a t e r go k a ls if e ro l

v it a m in K 1 , l ih a t f it o m en a d io n

T w

t a m ok s if e n, 3 4

tes tos teron, 3 4, 4 2

t e ta n u s a d s or b ed t o xo i d, 5 7, 7 9

t e t rakain, 4 9, 7 4tetrasiklin, 2 8, 6 3

t iamin, 5 8, 7 9

t imolo l , 50

t iopenta l , 2 3, 6 0

t r iheksifenidil, 3 6, 6 7

t r imetop r im, 2 8, 2 9, 3 1, 6 3, 6 4, 6 5

t r in a t ri um s i tr a t d i h id r a t , 4 8, 5 4, 7 4, 7 7

t u be rk u l in p r o t ei n p u r if i e d de r i va t i ve , 3 9, 6 8

w a r fa r in , 3 7

x

y

z

z id o v ud i n, 3 3

uurea, 47

1 1 1Daftar Dbat Esensial Nasional2008

Documents

Plugin-Home DOEN 2008